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Summary 
Hematopoietic stem cells (HSCs) sustain the life-long production of blood and maintain the 
integrity of the hematopoietic system. Therefore, they possess self-renewal capacity and are able to 
differentiate into all the mature blood cell lineages. These are finely tuned processes, which 
constantly involve dynamic HSC fate decisions and an imbalance may result in misregulation 
associated with cellular transformation or other types of diseases.  
In the hematopoietic disorder Fanconi Anemia (FA), such an imbalance in the HSC pool results in 
bone marrow failure, a collapse of the entire hematopoietic system. In addition, FA patients are 
susceptible to developing hematologic malignancies such as acute myeloid leukemia (AML) or 
myelodysplastic syndrome (MDS). This is the result of a loss of function in the FA DNA repair 
machinery, which renders HSCs genetically unstable as they are unable to repair certain forms of 
DNA damage. Murine knockout models for individual FA pathway members fully recapitulate the 
FA HSC DNA repair defect seen in patients and demonstrate a severe engraftment defect in 
competitive transplantation experiments. We could recently show, that in response to proliferative 
stress, such as during transplantation and reconstitution, FA HSCs accumulate DNA damage and are 
quickly lost due to apoptotic cell death, which is a key driver of bone marrow failure. FA HSCs are 
also subject to cellular transformation, which may result in the outgrowth of a leukemic founder 
clone. The identification of novel therapeutic targets would likely provide insight into the underlying 
mechanism of the FA HSC defect and the associated pathology of FA. In this respect, forward 
genetic screens using insertional mutagenesis have proven to be a powerful screening method for the 
identification of genes with the potential to influence stem cell kinetics when upregulated or 
disrupted. 
We have employed retroviral insertional mutagenesis in the context of FA HSC biology using a 
murine transplantation model in order to try and identify novel factors with the potential to rescue 
the inherent FA HSC transplantation defect. In this respect, we show that retroviral vector 
integrations trigger the expansion of nonmalignant dominant FA clones in transplanted mice and 
allow the retrospective identification of nearby genes whose deregulation had caused clonal expansion 
in the face of genomic instability. We identified four candidate drivers of clonal dominance in the FA 
HSCs: Osgin1, Evi1, Taf1b and Grhl1, which we further characterized in the context of HSC 
biology under homeostatic and stress conditions as well as during development. In this respect, we 
identified the oxidative stress-induced growth inhibitor (Osgin1) as a promising candidate target 
gene, which is expressed in FA and WT HSCs under homeostatic conditions as well as in hemogenic 
endothelium/HSPCs during developmental specification from normal embryonic stem cells. 
Furthermore, we provide insight into the hematopoietic role of Osgin1, which displays differential 
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expression levels during the individual steps of HSC commitment and their response to physiologic 
stress. We conclude that Osgin1 is an essential factor for hematopoiesis and we will further 
characterize Osgin1 using the tools and assays that we have developed to assess whether it impacts on 
FA HSC fate decisions in vitro and during hematopoietic reconstitution in vivo. Furthermore, we 
provide some insight into how the FA HSCs may become a dominant clone and suggest likely 
candidate mechanisms with the potential to compensate the inherent FA HSC defect. According to 
our hypothesis, the identified candidate target genes may either prevent the acquisition of DNA 
damage or repair it or, alternatively, block the apoptotic cell death, which is a likely cell fate outcome 
for FA HSCs. Our findings hold great potential for HSC research with implications for normal as 
well as FA HSC biology. 
 Z U S AMM EN F A S S UNG  
VIII 
Zusammenfassung 
Blutstammzellen bilden die Basis des blutbildenden Systems und gewährleisten dessen Integrität. Zu 
diesem Zweck besitzen Blutstammzellen zum einen Selbsterneuerungspotenzial und können sich 
darüber hinaus in alle reifen Blutzellen entwickeln. Diese schicksalhaften Entscheidungen zwischen 
Selbsterneuerung und Differenzierung sind stark regulierte Prozesse, deren Ungleichgewicht 
schließlich die Transformation betroffener Zellen begünstigt und zu Krankheiten des Blutsystems 
führen kann. 
In der Fanconi Anämie (FA), einer hämatopoetischen Funktionsstörung, führt solch ein 
Ungleichgewicht zum Versagen des kompletten Blutsystems. Außerdem sind FA Patienten anfällig 
für Tumore des blutbildenden Systems, wie zum Beispiel der akuten myeloischen Leukämie (AML) 
und des myelodysplastischen Syndroms (MDS). Dies ist auf einen Funktionsverlust des FA DNA-
Reparaturmechanismus zurückzuführen, welcher verhindert, dass FA Blutstammzellen DNA-
Schäden reparieren können und dadurch eine genetische Instabilität hervorruft. FA Mausmodelle, 
die einzelne Komponenten des FA Signalweges ausgeschaltet haben, weisen ebenfalls diesen FA 
Stammzelldefekt auf. Dieser kommt vor allem bei Transplantationsversuchen zum Tragen, in denen 
die FA Stammzellen deutlich schlechter anwachsen, als dies beispielsweise bei WT Stammzellen der 
Fall ist. Wir konnten kürzlich zeigen, dass Stammzellen durch den Proliferationsstress, dem sie 
während der Transplantation ausgesetzt sind, Schäden in ihrem Erbgut akkumulieren, was 
schließlich den programmierten Zelltod zur Folge hat. Dieser spielt eine Schlüsselrolle in der 
Pathologie dieser Bluterkrankung. FA Stammzellen fallen außerdem der zellulären Transformation 
zum Opfer, welche die Entstehung einer leukämischen Stammzelle begünstigen kann. Die 
Erforschung neuartiger Therapeutika verspricht bisher unbekannte Einblicke in die Mechanismen, 
die dem FA Stammzelldefekt unterliegen und mit der Pathologie der FA verbunden sind. In diesem 
Zusammenhang haben sich genetische Screens, die das Konzept der retroviralen 
Insertionsmutagenese nutzen, als überaus hilfreiche Methode erwiesen, welche die Identifikation 
stammzellrelevanter Gene ermöglicht. 
Im Rahmen dieser Arbeit haben wir einen retroviralen Insertionsmutagenese-Screen mit FA 
Stammzellen durchgeführt, bei dem wir ein murines Transplantationsmodell verwenden, um 
neuartige Faktoren mit dem Potential den angeborenen FA Stammzelldefekt zu kompensieren, 
ausfindig zu machen. In diesem Zusammenhang konnten wir zeigen, dass retrovirale 
Vektorintegrationen im Erbgut der FA Stammzellen die Expansion gutartiger dominanter FA 
Stammzellklone in transplantierten Mäusen fördern. Dies erlaubt die Identifikation der durch die 
Integrationsstelle deregulierten Gene, welche trotz der genetischen Instabilität der FA Stammzelle die 
Expansion der Klone begünstigen konnten. Zusammenfassend konnten wir vier Faktoren ausfindig 
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machen, die sehr wahrscheinlich einen Einfluss auf die klonale Dominanz der FA Stammzellen 
haben: Osgin1, Evi1, Taf1b und Grhl1. Diese haben wir im Hinblick auf ihre Rolle während der 
Hämatopoese sowohl unter homöostatischen als auch unter Stressbedingungen näher betrachtet. In 
diesem Zusammenhang konnten wir den oxidativen Stress-induzierten Wachstumsinhibitor Osgin1 
als einen vielversprechenden Kandidaten identifizieren, welcher nicht nur in FA, sondern auch in 
normalen Blutstammzellen und während der Spezifikation embryonaler Stammzellen in vitro 
exprimiert ist. Während der einzelnen Differenzierungsschritte von Stammzellen zu Vorläuferzellen, 
aber auch unter physiologischen Stressbedingungen, weist Osgin1 differentielle Expressionsmuster 
auf, woraus wir folgern, dass Osgin1 ein essentieller Faktor für die Hämatopoese ist. Ausblickend 
werden wir Osgin1 anhand bereits etablierter Methoden genauer charakterisieren um zu verstehen, 
ob Osgin1 tatsächlich Einfluss auf die Schicksalsentscheidungen der FA Blutstammzelle nimmt und 
darüber hinaus das Anwachsen transplantierter FA Stammzellen begünstigen kann. Weiterhin 
gewähren wir Einblicke in die Mechanismen, die es der FA Stammzelle erlauben, den angeborenen 
Defekt zu überwinden und im Rahmen der genetischen Instabilität  zu einem dominanten Klon zu 
werden. Unserer Hypothese zu Folge könnten die identifizierten Zielgene entweder das Auftreten des 
DNA-Schadens verhindern, dessen Reparatur veranlassen oder den programmierten Zelltod 
blockieren, welcher ein sehr wahrscheinliches Schicksal für die FA Stammzelle darstellt. Unsere 
Erkenntnisse beinhalten großes Potential für die Stammzellforschung und könnten möglicherweise 
Auswirkung auf die normale als auch auf die Biologie der FA Stammzelle haben. 
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1 Introduction 
1.1 Hematopoiesis and the hematopoietic system 
Hematopoiesis is the formation of the cellular blood components, which are hierarchically organized 
according to their state of maturation in the hematopoietic system. Hematopoiesis occurs in the bone 
marrow and the lymphatic system in order to generate the mature blood cells, such as red blood cells 
(erythrocytes), white blood cells (leukocytes) and platelets (thrombocytes), which elicit vital functions 
in order to control and maintain the integrity of the hematopoietic system. In this process, 
erythrocytes mediate the exchange of respiratory oxygen and carbon dioxide across all tissues, the 
primary function of leukocytes is to protect against infections and thrombocytes facilitate coagulation 
and wound repair. Some leukocytes are also involved in tissue and bone remodeling and the removal 
of dead cells. Many blood cells are short-lived and, due to their high turnover rates, need to be 
constantly replenished. The average human requires approximately one hundred billion new blood 
cells each day. Therefore, specialized multipotent cells at the top of the hierarchy, known as 
hematopoietic stem cells (HSCs), allow for the continued production of so called transit amplifying 
or progenitor cells, which then further differentiate into all the mature blood cell lineages. Since these 
cells represent only a small fraction of all bone marrow cells, amplification steps at the progenitor 
level allows for the production of sufficient numbers of mature effector cells (Reya et al., 2001). 
1.1.1 Hematopoietic stem cells 
HSCs comprise the top of the hematopoietic system hierarchy and are responsible for the life-long 
production of all mature blood cells as well as for the maintenance of the HSC pool in blood and 
bone marrow. In order to fulfill these functions, HSCs have the capacity to self-renew and give rise to 
differentiated cells (Morrison et al., 1997; Till and McCulloch, 1980; Weissman, 2000a). Self-
renewal describes the ability of HSCs to produce daughter cells that have the same stem cell 
properties as the parent cell, which is essential for the maintenance and expansion of HSC numbers. 
During differentiation, HSCs successively lose their self-renewal capacity, but gain increased 
proliferation potential while going through multiple progenitor stages towards committed precursors 
(Osawa M, 1996). 
The first hint towards the existence of a common precursor of the various blood cell types arose 
shortly after the atomic bombings of Hiroshima and Nagasaki in 1945, with victims exposed to 
radiation subsequently suffering from hematopoietic failure and the inability to regenerate sufficient 
amounts of mature blood cells in order to fulfill vital functions. Later studies provided definitive 
evidence for the presence of the HSC when irradiated mice could be rescued from otherwise fatal 
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hematopoietic failure by bone marrow transplantation, as the injected bone marrow cells directly 
regenerated the hematopoietic system (Ford et al., 1956; Lorenz et al., 1951; Nowell et al., 1956). 
This led to the development of bone marrow transplantation as a curative therapy for hematopoietic 
failure following whole body irradiation, which uses bone marrow transplantation in order to transfer 
HSCs that possess regenerative capacity to the host organism (Kondo et al., 2003; Weissman, 
2000b). In 1990, E. Donnall Thomas received the Nobel Prize for Medicine for these pioneering 
discoveries, which initially set the basis for the cure of leukemias and other fatal blood diseases. When 
physicians started to evaluate the irradiation sensitivity of normal mouse bone marrow cells in order 
to formulate an irradiation therapy against cancer in the 1960s, researchers could demonstrate that 
transplanted cells were able to develop colonies in mouse spleens, which directly correlated to the 
number of initially injected bone marrow cells (Till and McCulloch, 1961; Till et al., 1964). Such 
colonies were derived from a single precursor cell, which was able to reconstitute the hematopoietic 
system of irradiated secondary recipients by both self-renewal and multilineage differentiation 
(Becker et al., 1963; Wu et al., 1968). These findings shaped the definition of the multipotent and 
self-renewing HSC and provided the basis for a lot of speculation and prediction of HSC biology. 
Later on, however, it was demonstrated that these spleen colonies were rather primitive progenitors 
than bona fide HSCs as they could only give rise to cells of the myeloid lineage. Definite proof for 
the existence of a stem cell, which was able to generate cells of the myeloid and the lymphoid lineage, 
was provided another decade later (Abramson et al., 1977). 
These initial experiments set the stage for modern HSC research, which focuses on the prospective 
isolation of HSCs in order to characterize their function and evaluate potential applications for the 
development of novel cell-based therapies. HSCs hold great potential for regenerative medicine due 
to their proliferation and differentiation capacities (Daley et al., 2003; Keller, 2005). However, the 
dysregulation of stem cell properties may also be the cause of certain types of diseases and cancer 
(Dalerba et al., 2007; Reya et al., 2001). 
1.1.1.1 Functional hematopoietic stem cell assay 
In order to formally address stem cell function, a plethora of in vitro and in vivo assays have been 
developed. However, the only method that fully allows assessing the capacity of HSCs to be able to 
differentiate into all mature lineages while also being capable of self-renewal is bone marrow 
transplantation, which serves as the “gold standard” test for functional stem cells. In this context, the 
mouse transplant system is well established and by far the most frequently used model system to 
study mammalian hematology. 
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When HSCs are transplanted into irradiated mice intravenously, the cells set out to find their way 
from the peripheral blood to their bone marrow niches in a process called homing. During this 
process, HSCs rely on a variety of chemokines, cytokines and adhesion molecules in order to roll and 
tether to the blood vessel walls and extravasate through the bone marrow endothelium. After the 
HSCs have reached the perivascular region of the bone marrow, they start to repopulate the blood 
system. (Lapidot et al., 2005). Ideally, this assay is carried out with at least one serial step of 
transplantation into a secondary recipient. The ability of the transplant to repopulate a secondary 
recipient and give rise to all the mature blood cell lineages formally proves its self-renewal and long-
term reconstitution potential. 
However, recent studies have cast some doubt on whether the classically defined transplantable HSCs 
are really responsible for the long-term maintenance of the hematopoietic system under homeostatic 
conditions (Busch et al., 2015; Sun et al., 2014). Nonetheless, the transplantation assay remains the 
most well characterized experimental procedure for HSC function that is widely available. 
1.1.1.2 Purification of hematopoietic stem and progenitor cells from the bone marrow 
The basis for all stem cell assays is to prospectively enrich and isolate hematopoietic stem and 
progenitor cells from the bone marrow. This requires cell surface markers that uniquely define HSCs 
and their progenitor cells. Since the initial identification of HSCs in the 1960s, it took several 
decades until the first immunophenotypic marker set of murine HSCs and their committed progeny 
could be established. In this quest, the development of fluorescence-activated cell sorting (FACS) 
(Hulett et al., 1969) and monoclonal antibodies (Kohler and Milstein, 1975) has been crucial. In 
addition, transplantation assays were used to evaluate correlations between marker expression and the 
functional HSC potential in hematopoiesis. 
The first attempt towards enriching HSCs demonstrated that they reside in a fraction of the bone 
marrow, which was depleted for the expression of markers that are expressed on the surface of mature 
lineage committed cells: so called “lineage markers” (Muller-Sieburg et al., 1988; Muller-Sieburg et 
al., 1986). Addition of the markers stem cell antigen 1 (Sca-1) and c-Kit, the receptor for stem cell 
factor/steel factor, further refined this population to the so-called lineage- (lin-), Sca-1+, c-Kit+ (LSK) 
population (Ikuta and Weissman, 1992; Ogawa et al., 1991; Spangrude et al., 1988), which is highly 
enriched for stem cells but also contains multi-potent and lineage biased progenitor cells that possess 
more restricted self-renewal properties than the HSC compartment. Although the LSK population is 
commonly used as the basis for stem cell transplantation assays, other assays often require a much 
higher purity. Therefore, the signaling lymphocytic activation molecule (SLAM) marker set, defined 
according to the cluster of differentiation (CD) marker set CD150+ and CD48-, can be exploited in 
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order to further enrich HSCs within the LSK population to almost 50% purity (Kiel et al., 2005). 
Gain of CD48 with differentiation can be used to identify the LSK progenitor compartment. Within 
this population the stepwise loss of CD150 and the gain of CD135 allows for the distinction of the 
individual multipotent progenitor populations MPP2 (CD34+ CD48+ CD150+ CD135-), MPP3 
(CD34+ CD48+ CD150- CD135-) and MPP4 (CD34+ CD48+ CD150- CD135+). 
HSCs can be further distinguished into long-term (LT-) and short-term HSCs (ST-HSCs) based on 
their CD34 expression, two HSC populations which possess different reconstituting capacity 
(Wilson et al., 2008). While long-term reconstituting LT-HSCs are negative for CD34, the ST-
HSCs have limited self-renewal capacity and are CD34+. 
1.1.1.3 Investigating HSC fate decisions 
The generation of mature blood cells during hematopoiesis is a finely tuned process, which 
constantly involves HSC fate decisions in order to decide for self-renewal, differentiation, 
proliferation, quiescence, survival or apoptosis. These fates are tightly regulated by a complex 
interplay between cell intrinsic and extrinsic mechanisms in order to maintain blood homeostasis 
(Zhu and Emerson, 2002). Among the intrinsic mechanisms, transcription factors such as Runx1, 
Lmo2, Bmi1, Gata1 and Gata1 play a role (Orkin and Zon, 2008). Extrinsic mechanisms influence 
the fate of stem cells via cytokines such as stem cell factor (SCF), thrombopoietin (Tpo), 
erythropoietin (Epo) and interleukins as well as cell-cell contacts or extracellular matrix contacts in 
the bone marrow niche (Metcalf, 2008; Trumpp et al., 2010). An imbalance in these highly 
controlled cellular programs can result in cellular transformation of HSCs into disease-initiating 
leukemic stem cells. Since similar signaling pathways may regulate self-renewal in both normal and 
deregulated HSCs, a further understanding of these regulatory mechanisms holds the potential to 
identify novel therapeutic targets for the treatment of diseases such as hematologic malignancies. 
(Reya et al., 2001). Therefore, investigating HSC fate decisions can reveal novel insights into HSC 
biology as well as its implications for processes such as ageing, disease and leukemic transformation. 
However, the identity of single cells in culture experiments is quickly lost and their morphology does 
not allow distinguishing developmental stages. Therefore, the analysis of HSCs in heterogeneous 
populations requires innovative single cell analysis tools in order to elucidate stem cell behavior. 
Michael Rieger and Tim Schroeder have developed video time-lapse microscopy in order to observe 
hematopoiesis in cell culture and follow the fate decisions of hundreds of cells individually (Rieger 
and Schroeder, 2008). With this methodology, fate decisions of cells and their progeny can be 
investigated and displayed in pedigrees representing the exact history of the merging colonies. Using 
this methodology, the group of Michael Rieger could recently identify a novel instructor of HSC 
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differentiation, which is inducible by cytokine signals (Thalheimer et al., 2014). Furthermore, single 
cell transplantation studies demonstrated the potential to revise established models of the 
hematopoietic hierarchy and reveal novel insights into the largely heterogeneous stem cell population 
(Babovic and Eaves, 2014; Yamamoto et al., 2013). 
1.2 The hematopoietic disorder Fanconi Anemia (FA) 
As discussed above, HSC self-renewal and differentiation are tightly regulated processes, which cause 
disease in humans if deregulated. For example, unrestricted self-renewal is a feature of leukemic 
transformation while insufficient self-renewal would lead to a depletion of HSC reserves and may 
cause bone marrow failure: a collapse of the entire hematopoietic system. 
Fanconi anemia (FA) is a hereditary disorder and the most common inherited bone marrow failure 
syndrome, which impacts upon the production of all hematopoietic lineages. While FA patients 
usually display normal blood cell counts at birth, the hematologic complications arise later on, 
mainly within the first decade of life. Initially, this manifests as abnormally low platelet counts in the 
peripheral blood (thrombocytopenia) followed by low neutrophil counts (neutropenia) before 
eventually developing into aplastic anemia, the insufficient production of red blood cells, leukocytes 
and platelets in the bone marrow. In addition, FA patients possess severely compromised 
hematopoietic progenitor compartments (Bagnara et al., 1992; Daneshbod-Skibba et al., 1980). 
Unless treated, the hematologic manifestations of FA remain the primary cause of morbidity and 
mortality, with patients suffering from a markedly increased risk of myelodysplastic syndrome 
(MDS) and acute myeloid leukemia (AML). Approximately half of all FA patients present with MDS 
and/or AML before they are 40 years old (Auerbach and Allen, 1991; Butturini et al., 1994; Kutler et 
al., 2003). 
In addition to the hematologic abnormalities, FA patients suffer to varying degrees from a range of 
congenital developmental defects, such as skin pigmentation abnormalities, short stature, 
microphthalmia or thumb abnormalities. Other organ systems involved include the cardiac, renal 
and auditory systems (Auerbach, 2009). In addition, FA patients are susceptible to various forms of 
solid tumors such as squamous cell carcinoma of the head, neck and gynecologic area as well as 
esophageal carcinoma and tumors of the liver, brain, skin and kidney (Alter, 2003; Kutler et al., 
2003). 
From the genetic point of view, FA is a heterogeneous disorder caused by inactivating mutations in 
16 different genes, which have been identified to date: FANCA, FANCB, FANCC (Strathdee et al., 
1992), FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1, 
FANCL/PHF9/POG, FANCM, FANCN/PALB2, FANCO/Rad51C (Vaz et al., 2010), 
  I N T RODUC T I ON  
6 
FANCP/SLX4/BTBD12 (Crossan et al., 2011; Kim et al., 2011; Stoepker et al., 2011) and 
FANCQ/XPF (Bogliolo et al., 2013; Kashiyama et al., 2013). These genes are thought to function in 
an epistatic signaling pathway, a common biochemical ubiquitin-phosphorylation network, which is 
involved in controlling multiple functions related to deoxyribonucleic acid (DNA) repair and the 
cellular response to stress (Figure 1) (Garcia-Higuera et al., 2001). 
1.2.1 The FA signaling pathway mediates DNA damage repair 
Intensive research has been conducted in order to reveal the molecular function of the FA signaling 
pathway and its individual members. In summary, several findings demonstrated that all 16 FA 
proteins are critical for the repair of cross-linked DNA in order to maintain genomic stability. 
 
Figure 1: Schematic representation of the FA signaling pathway. FA proteins function in an epistatic 
signaling pathway and assemble to form the FA core complex and the ID complex, which bind to DNA and 
interact with classical downstream effectors to contribute to DNA damage repair. (Provided by Amelie Lier 
and Michael Milsom) 
Upon DNA damage, FA proteins are recruited to the site of damage and assemble to form a large 
nuclear complex termed the FA core complex (Figure 1). This nuclear multi-protein complex 
consisting of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM 
functions as an E3 ubiquitin ligase and, via FANCL, mediates the activation of a heterodimer 
composed of FANCD2 and FANCI termed the ID complex (Alpi et al., 2008; Bogliolo et al., 2013; 
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Garcia-Higuera et al., 2001; Howlett et al., 2002; Kashiyama et al., 2013; Kennedy and D'Andrea, 
2005; Kim et al., 2011). Once mono-ubiquitinated, the ID complex can bind to single- and double-
stranded DNA structures in order to repair DNA interstrand cross-links (Joo et al., 2011). This task 
is fulfilled by components of the excision nuclease machinery such as FANCP/SLX4/BTBD12 and 
FANCQ/XPF, which are activated in order to excise the cross-link (Crossan et al., 2011; Kim et al., 
2011; Stoepker et al., 2011). Furthermore, the ID complex interacts with classical tumor suppressors 
downstream of the FA pathway including FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1 and 
FANCO/Rad51C thereby contributing to DNA double-strand break repair via homologous 
recombination (HR) (Hirano et al., 2005; Kee and D'Andrea, 2010; Niedzwiedz et al., 2004). Loss 
of function of any of the FA family members results in inefficient repair of DNA damage and 
deregulation of signaling pathways controlling cell proliferation and apoptosis. 
1.2.2 Defective DNA repair causes genomic instability in FA 
Fanconi anemia is a genomic instability syndrome caused by defects in the DNA repair machinery, 
which would usually resolve DNA interstrand cross-links, the most deleterious type of DNA lesions, 
which cause replication arrest and lead to DNA double strand breaks. DNA interstrand cross-links 
originate from endogenous sources such as nitrous acid and aldehydes or can be caused by exogenous 
agents such as cisplatin and its derivates. The individual FA pathway members are critical for the 
repair of these cross-linked DNA in order to protect the human genome from DNA damage and 
maintain genomic stability (Kee and D'Andrea, 2010). Therefore, the FA pathway is an essential 
tumor-suppressive pathway, which prevents the development of cancer. In FA patients, the mutation 
in a single FA gene results in the inactivation of the whole FA signaling pathway and, ultimately, in 
defective DNA repair in every cell of the patients’ body. For this reason, FA patients are unable to 
resolve certain forms of DNA damage and as a consequence of genetic instability, they are 
predisposed towards the development of cancer. In the hematopoietic system, genetic instability may 
promote malignant transformation of hematopoietic stem and/or progenitor cells and the outgrowth 
of an abnormal clone leading to blood malignancies with gross chromosomal changes such as MDS 
and/or AML (Welch et al., 2012). 
FA is often referred to as a chromosome instability syndrome since FA patients display increased 
chromosomal aberrations, particularly radial chromosomes, at the cellular level. These aberrations 
can be explained by the fact that FA cells are hypersensitive to DNA interstrand cross-linking agents 
such as mitomycin C, cisplatin, diepoxybutane, and melphalan (Auerbach, 1993; Cervenka et al., 
1981; Chen et al., 2007; Kondo et al., 2011; Sasaki and Tonomura, 1973). While mitomycin C 
causes radial chromosomes, diepoxybutane mainly functions as a bifunctional cross-linking agent 
inducing chromosomal breakage or rearrangements (Auerbach, 1993; Cervenka et al., 1981). The 
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increased susceptibility of FA cells to these compounds results in an exaggerated arrest in the G2/M 
phase of the cell cycle and apoptosis (Kaiser et al., 1982; Kubbies et al., 1985). 
The genomic instability phenotype of FA cells is further promoted by the sensitivity to the inhibitory 
action of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interferon gamma 
(IFN-γ), and macrophage inflammatory protein-1 alpha (MIP-1α) (Haneline et al., 1998; Rathbun 
et al., 1997). Both TNF-α and IFN-γ are produced at abnormally high levels in the serum and bone 
marrow of FA patients and have been implicated in the pathogenesis of hematopoietic failure as FA 
cells are prone to apoptosis when exposed to these cytokines (Dufour et al., 2003; Rosselli et al., 
1994; Wang et al., 1998). For several years, it was not clear whether the abnormal response to 
cytokines was a cause or consequence of the bone marrow failure in FA and whether this could be 
linked to the DNA damage phenotype at all. However, recent findings have provided evidence for a 
direct link between proinflammatory cytokines and the defective DNA damage response seen in FA 
cells. In response to treatment with TNF-α, murine bone marrow cells defective in the FA DNA 
damage response demonstrated an excessive production of reactive oxygen species (Li et al., 2007). 
Reactive oxygen species are highly reactive and readily cause oxidative modifications to biomolecules 
like DNA, proteins, and lipids. Our group has recently demonstrated, that these reactive oxygen 
species are a metabolic byproduct of activating stem cells out of their homeostatic quiescent status 
into cell cycle such as in response to hematopoietic stress and comprise a physiologic source of DNA 
damage in HSCs (Walter et al., 2015). In addition, these findings can explain the highly penetrant 
bone marrow failure seen in FA patients since the inability to repair DNA damage results in 
accelerated cellular depletion in response to physiologic stress and leads to a collapse of the entire 
hematopoietic system. In normal individuals, this damage can be repaired to some extent by the 
coordinated action of the DNA repair machinery. 
1.2.3 Bone marrow failure arises from a defect in the FA HSC 
In addition to the various hematologic complications that start to arise early on, virtually all FA 
patients develop bone marrow failure within their first decade of life. As a result, all hematopoietic 
lineages are severely compromised, which strongly implies that FA patients have a defect at the level 
of the stem cell. Indeed, FA patients demonstrate a significant decrease in the CD34+ compartment, 
which is comprised of HSCs and progenitor cells, even well before the onset of bone marrow failure 
(Kelly et al., 2007). Importantly, this correlates with the fact that reduced stem and progenitor 
numbers can be found in umbilical cord blood taken from newborn FA patients (Auerbach et al., 
1990). Thus, the depletion of hematopoietic stem and progenitor cells appears to precede the 
decreased production of mature hematopoietic cells and may hint towards a prenatal origin of the 
stem cell defect. 
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Moreover, bone marrow transplantation studies, in which a transplanted normal donor HSC is able 
to permanently reconstitute the failing hematopoietic system of a FA patient, provide evidence that 
the hematologic problems associated with the pathology of FA are driven by a defect at the level of 
the stem cell (Farzin et al., 2007; Tan et al., 2006). In addition, successful correction of the FA defect 
with a single functionally normal HSC was also demonstrated by the phenomenon of reverse 
mosaicism, which occurs as a consequence of the correction of one of the patient’s nonfunctional FA 
alleles within a somatic cell clone either as a result of genetic recombination of two heterozygote 
mutations in a FA gene or from spontaneous point or frame shift mutations that restore the function 
of the inactivated gene. These rare genetic events have been found in several individual patients, in 
which a single corrected hematopoietic clone had been able to expand to sufficient numbers in order 
to support the hematopoietic function and survival of the patient. Importantly, cells within other 
somatic tissues did not contain the correcting mutations and patients presented with nonhematologic 
symptoms of FA (Gross et al., 2002; Mankad et al., 2006; Waisfisz et al., 1999). 
1.2.4 FA knockout mouse models to study FA HSC biology 
In order to study the etiology of bone marrow failure in FA, a number of murine knockout models 
for the components of the FA core complex (FANCA, FANCC, FANCG, FANCF, and FANCM), 
FANCD2, and the downstream effectors FANCD1 and FANCP have been developed (Bakker et al., 
2009; Bakker et al., 2012; Crossan et al., 2011; Friedberg and Meira, 2006). Since all of these mice 
lack a functional FA DNA repair pathway and are unable to impact upon the acquisition of DNA 
damage, these models provide a platform for studying FA HSC biology in the context of genome 
instability. In addition they can serve as alternative transplant models in order to circumvent the 
problems associated with the lack of patient material due to low cell numbers (Parmar et al., 2009). 
In FA patients, the FA core complex genes Fanca, Fancc and Fancg are most commonly mutated with 
approximately 80% of all patients presenting with this mutations. Therefore Fanca, Fancc and Fancg 
knockouts for FA core complex loss of function are the most commonly used in FA HSC research. 
These mouse models exhibit some but not all of the developmental and hematologic manifestations 
of human FA patients. However, the phenotype common to all of these models includes the defective 
regulation of cell cycle and apoptosis, spontaneous genomic instability including chromosome 
breakage and radial chromosomes and increased sensitivity towards DNA interstrand crosslinking 
agents such as diepoxybutane, mitomycin C, and cisplatin (Neveling et al., 2009). In addition to 
these common features of FA, the mice display some mild hematologic defects, however not all of 
them can be recapitulated in each individual model. While young Fanca-/- mice present with signs of 
mild thrombocytopenia and impaired proliferation rates of bone marrow-derived megakaryocyte 
progenitors, the peripheral blood cell counts in Fancc-/- and Fancg-/- mice appear normal (Hadjur et 
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al., 2001). However, hematopoietic progenitor cells isolated from adult Fancc-/- mice have impaired 
function in vitro (Whitney et al., 1996). Most interestingly, HSCs isolated from the bone marrow of 
these mouse models reveal a severe defect, which becomes evident in both, in vitro and in vivo 
studies. Under growth stimulatory culture conditions, Fanca-/- and Fancc-/- HSCs demonstrate 
reduced proliferation rates due to apoptosis and dramatically reduced repopulation ability in 
subsequent transplantation assays (Habi et al., 2005; Li et al., 2005). The in vitro culture provides a 
certain stress situation to the cells as they are forced to proliferate. Therefore, the above-mentioned 
findings may indicate impaired HSC maintenance during stress. Although Murine models of FA 
have the same overall number of immunophenotypically defined HSCs, all three mouse lines 
demonstrate lower frequencies of functionally defined HSCs compared to wild-type (WT) HSCs. In 
competitive transplantation experiments, Fanca-/- and Fancc-/- HSCs largely failed to engraft irradiated 
recipient mice, which illustrates their severe engraftment defect (Geiselhart et al., 2012). 
Despite the fact that murine models of FA demonstrate a functional HSC defect during bone 
marrow transplantation assays, none of the FA mouse models spontaneously develops the highly 
penetrant bone marrow failure phenotype seen in FA patients. In addition, most of them have 
relatively normal hematologic function. However, these mice serve as a great model to interrogate FA 
pathogenesis as anemia can be elicited experimentally by in vivo exposure to crosslinking agents, 
endogenous aldehydes or conditions that model physiologic stress (Carreau et al., 1998; Hadjur et 
al., 2001; Langevin et al., 2011; Walter et al., 2015). Therefore, these mice allow investigating the 
drivers of the inherent FA HSC defect and provide a platform for the identification of potential 
mechanisms that may rescue it, thereby highlighting novel targets for therapeutic intervention. 
Furthermore, FA HSCs can serve as a model system to interrogate the biology of normal HSCs and 
can potentially impact upon our knowledge of more common disorders such as leukemias, 
myeloproliferative disorders and other bone marrow failure syndromes such as aplastic anemia. 
1.2.5 HSC transplantation and gene therapy for FA patients 
In light of the recent insights gained from FA mouse models, HSC transplantation currently remains 
the only curative treatment option for the hematologic disorders in FA patients (MacMillan et al., 
2011). In fact, FA was the first disease that was successfully treated by HSC transplantation using 
cord blood from an unaffected human-leukocyte-antigen (HLA)-identical sibling as a starting 
material (Gluckman et al., 1990). Nowadays, HSCs are derived from the bone marrow, mobilized 
peripheral blood or umbilical cord blood of a HLA-matched donor and transplanted in order to 
prevent the hematological disease and malignancies, which are the most common cause of death in 
FA (Auerbach, 2009). However there are some major limitations to successful transplantation of FA 
patients such as that patients are hypersensitive to cytotoxic agents and radiotherapy used to 
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condition the host for bone marrow engraftment as well as the lack of availability of an HLA-
matched disease-free donor (Auerbach et al., 1983; Farzin et al., 2007; Gluckman et al., 1984). 
One attractive novel therapeutic modality is the genetic correction of autologous patient HSCs as it 
prevents the immunologic rejection of the graft as well as a source of transplantable HSCs. In this 
context, FA appears to be an ideal candidate for treatment via gene therapy since individual corrected 
HSCs, which experienced a random genetic event of reverse mocaisism, have already been 
demonstrated to result in sustained reversal of bone marrow failure (Mankad et al., 2006). In 
addition, this would suggest that host bone marrow ablation with its associated toxicity may not be 
necessary in FA or at least could be reduced. Initially, the feasibility of gene therapy in the context of 
FA had been demonstrated in FA mouse models, in which the replacement of the defective FA gene 
by the respective human copy DNA (cDNA) was sufficient to correct the hypersensitivity of the FA 
HSCs to crosslink damage and their ex vivo proliferation defect (Rio et al., 2002). Recent major 
advances have been made in the field of gene therapy, which have allowed the correction of a range of 
different inherited genetic disorders with a hematologic basis using a delivery system such as a 
retroviral vector to deliver the correcting cDNAs into patient HSCs (Aiuti et al., 2013; Biffi et al., 
2013; Kohn, 2010; Watts et al., 2011). 
However, besides all of the advantages that gene therapy would bring for FA patients, it is also 
associated with some limitations such as the requirement for a sufficient cell number for gene 
modification. While these input numbers are routinely achieved in other patient groups subjected to 
gene therapy, CD34+ cells isolated from FA patients are limited in number and are also extremely 
sensitive to ex vivo culture conditions necessary for expansion (Kelly et al., 2007; Li et al., 2005). To 
date, the clinical gene therapy trials for FA have all failed to achieve robust engraftment of corrected 
patient HSCs, although advances have been made in the ability of clinicians to transduce FA CD34+ 
cells with retroviral vectors (Kelly et al., 2007; Liu et al., 1999; Walsh et al., 1994). Fortunately, 
some of the model systems that have been developed for FA have been able to assist in the 
formulation of new strategies that may help to overcome the barriers to effective gene therapy of FA. 
For example, novel protocols such as the “rapid” lentiviral-mediated transduction of Fanca-/- mouse 
hematopoietic stem cells have recently demonstrated to minimize ex vivo manipulation of cells and 
result in engraftment levels equivalent to WT cells (Muller et al., 2008). In addition to the 
minimized in vitro manipulation period, lentiviral and foamy retroviral vectors hold the distinct 
advantage over γ-retroviral vectors in that they are able to efficiently transduce nondividing HSCs. 
(Muller et al., 2008; Si et al., 2008). In addition, alternate mobilization protocols using specific Rac 
GTPase small molecule inhibitors (NSC23766) or CXCR4 antagonists (AMD3100) were able to 
overcome the FA HSC mobilization defect towards granulocyte colony stimulating factor (G-CSF) 
(Milsom et al., 2009; Pulliam et al., 2008). 
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All these advances highlight the therapeutic benefit of gene therapy for FA patients. In addition, they 
reveal novel targets for therapeutic intervention and provide proof of principle for the hypothesis that 
the FA HSC defect can be rescued or at least compensated. In this respect, novel therapeutic targets 
as well as biological insight in the FA HSC defect might be obtained by looking at genes with the 
potential to impact on the FA HSC biology. In this setting, a forward genetic screen might be 
employed to identify such genes. 
1.3 Retroviral insertional mutagenesis 
Retroviral insertional mutagenesis is referred to as the deregulation of gene expression resulting from 
proviral integration into the host genome during viral replication. In this context, the integration of 
the retrovirus genome in the vicinity of proto-oncogenes or within tumor suppressor genes may result 
in the deregulated expression of these genes, thereby eliciting cellular transformation. Retroviruses 
can induce cellular transformation in two ways. In contrast to acute transforming retroviruses, which 
contain viral versions of normal cellular proto-oncogenes such as Myc and Src and are able to rapidly 
induce cellular transformation (Beug et al., 1979; Gonda et al., 1982; Roussel et al., 1979), 
retroviruses that cause mutations by proviral integration do not carry oncogenes and cause 
transformation with a longer latency. These viruses contain very strong promoter/enhancer elements 
in their genome that drive and regulate viral transcription and are able to alter the expression of 
cellular genes proximal to the integration site upon insertion (Figure 2 A+B). In addition, retroviral 
integration may also result in the disruption of cellular gene expression (Figure 2 C). One example of 
a retrovirus with a semi-random integration profile is the murine leukemia virus, which preferentially 
targets the promoter regions of actively transcribed genes (Wu et al., 2003). 
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Figure 2: Mechanism of retroviral insertional mutagenesis. (A) Schematic representation of the integrated 
form of a recombinant retroviral vector. The long terminal repeats (LTRs), flanking the viral genome, consist 
of the U3 region, which contains the transcriptional enhancer/promoter (E/P) element, the R region 
containing a polyadenylation signal and the U5 region. These features may contribute towards insertional 
mutagenesis. (B) Potential mechanisms through which the integrated provirus may promote the deregulation 
of genes proximal to the integration site. (C) Integration within a cellular gene resulting in disrupted gene 
expression. (Modified from Mueller, 2011) 
1.3.1 Insertional mutagenesis in gene therapy clinical trials 
Besides the integration effects that occur naturally during viral infection, insertional mutagenesis has 
been observed as an adverse side effect in gene therapy clinical trials (Baum et al., 2003). Although 
replication-deficient retrovirus-based vectors have been used successfully to deliver correcting genes 
for the treatment of several genetic diseases including severe combined immunodeficiencies (Aiuti et 
al., 2002; Boztug et al., 2010; Cavazzana-Calvo et al., 2000; Gaspar et al., 2004), chronic 
granulomatous disease (CGD) (Ott et al., 2006) and adrenoleukodystrophy (ALD) (Cartier et al., 
2009) follow up clinical studies have revealed adverse events associated with clonal genotoxicity 
resulting in the development of leukemia (Braun et al., 2014; Hacein-Bey-Abina et al., 2003a; Howe 
et al., 2008; Ott et al., 2006). Interestingly, transplanted gene-modified HSCs that had led to the 
leukemic development in these trials often had very similar integration sites in the genome suggesting 
that the nearby genes were able to promote the expansion of malignant clones. Indeed, subsequent 
analyses revealed several genes that are usually involved in normal hematopoiesis such as LMO2 and 
EVI1/MDS1 and PRDM16 but had been deregulated as a result of the retroviral integration (Aguilo 
et al., 2011; Chuikov et al., 2010; Deichmann et al., 2011; Gratzinger et al., 2009; Oram et al., 
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2010; Ott et al., 2006). These studies have not only revealed several key players of leukemogenesis 
but have also led to advances in the design of viral vectors in order to improve their safety features for 
the successful use in gene therapy (Aiuti et al., 2013; Biffi et al., 2013; Coci et al., 2015; Suerth et al., 
2014). 
1.3.2 Insertional mutagenesis as a powerful screening method 
The unwanted side effect of insertional mutagenesis observed in gene therapy clinical trials has been 
employed in genetic screens in order to identify mutations contributing to tumor formation. 
Retroviral vectors able to induce multiple mutations in the same cell have been associated with 
leukemic complications and revealed proto-oncogenes that contributed to tumorigenesis in model 
organisms such as the mouse. Therefore, retroviral vectors allow for the investigation of oncogenic 
candidate genes as well as signaling pathways that collaborate in cancer (Akagi et al., 2004; Mikkers 
and Berns, 2003; Uren et al., 2005). These studies have led to the identification of several key 
regulators of oncogenesis (Akagi et al., 2004). Probably the most prominent example is the ecotropic 
viral integration site 1 (Evi1) proto-oncogene, a transcription factor with a role in both self-renewal 
and transformation of HSCs, as it has been found repeatedly deregulated in different insertional 
mutagenesis screens (Buonamici et al., 2004; Li et al., 2002). However, the oncogenic potential of 
vector integrations is largely dependent on a high vector dose and involves the selection of clones 
with combinatorial hits near proto-oncogenes or other signaling genes (Du et al., 2005; Fehse et al., 
2004; Modlich et al., 2005). Therefore, most of the screens for oncogenes have used replication 
competent viruses to increase the likelihood of a single cell acquiring the combinatorial hits required 
for transformation and to identify cooperating cancer mutations (Du et al., 2005). 
Moreover, Kustikova and colleagues could demonstrate that retroviral vector integrations can also 
trigger the expansion of nonmalignant clones in murine long-term hematopoiesis (Kustikova et al., 
2005). In these dominant clones, the vast majority of genes whose deregulation had caused clonal 
expansion were retrospectively identified as genes that are already expressed in hematopoietic stem 
and progenitor cells (Kustikova et al., 2007). Therefore, insertional mutagenesis screens may also be 
used in the absence of adverse events in order to gain insight into genes and processes underlying 
normal hematopoiesis such as stem cell engraftment. HSCs that harbor proviral integrations next to 
genes involved in stem cell self-renewal or expansion may possess an engraftment advantage upon 
transplantation. A very prominent example is HOXB4, a homeodomain transcription factor that 
promotes HSC expansion without malignant transformation (Antonchuk et al., 2002). Altogether, 
these studies have demonstrated, that insertional mutagenesis is a powerful genetic screening method 
that can be applied in an in vivo setting to identify genes with the potential to influence stem cell 
kinetics when upregulated or disrupted, which is of great interest for regenerative medicine. 
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1.3.3 Identification of retroviral integration sites and nearby deregulated genes 
In order to identify the genes near proviral integration sites in the genome of individuals that have 
received gene-modified stem cells, it is necessary to recover the integration sites from the highly 
complex DNA background of the peripheral blood cell or bone marrow sample. For this purpose, 
southern blotting with the flanking sequences of proviral insertions as probes was originally used. To 
date, this laborious approach, which requires extensive input material has been substituted by much 
more sensitive polymerase chain reaction (PCR)-based technologies, which combine long terminal 
repeat (LTR)-chromosome junction amplification with next-generation sequencing and 
bioinformatics. 
The amplification of provirus LTR-chromosome junctions in the genomic DNA is commonly 
conducted using ligation-mediated (LM)-PCR (Schmidt et al., 2001) or the more sensitive linear-
amplification-mediated (LAM)-PCR (Schmidt et al., 2007; Schmidt et al., 2002). LM-PCR allows 
for the direct genomic sequencing of multiple unknown DNA flanking sequences at LTR-
chromosome junctions by restriction digest of the genomic DNA and PCR-based extension of 
primers specific to the LTRs of the virus. As these primers are biotinylated, primer extension 
products can be enriched and ligated to an oligo linker cassette in a solid-phase LM-PCR in order to 
amplify the DNA by two exponential seminested PCR steps. Amplification products can then be 
sequenced in order to identify the genomic integration sequence. LM-PCR has been demonstrated to 
generate reliable and reproducible results for the investigation of clonal samples in vivo and in vitro 
and has the potential to recover a single dominant clone within a cellular population of 1000 other 
cells (Kustikova et al., 2007; Schmidt et al., 2001). Therefore, LM-PCR is very well suited for the 
identification of genes in the vicinity of vector integration with the potential to influence competitive 
fitness. 
In contrast, LAM-PCR has mainly been used for high throughput analysis of viral integration sites in 
preclinical and clinical settings (Biasco et al., 2011; Boztug et al., 2010; Cartier et al., 2009; Gabriel 
et al., 2009; Hacein-Bey-Abina et al., 2003b; Montini et al., 2006; Ott et al., 2006; Paruzynski et al., 
2010), in which the greater sensitivity of the method allowed for detecting and sequencing of 
unknown DNA flanking sequences down to a single event (Schmidt et al., 2002). LAM-PCR 
employs linear amplification of LTR-chromosome junctions followed by double-stranded DNA 
synthesis. The double-stranded DNA sequences are then digested with restriction enzymes, followed 
by linker ligation to the sequence and nested PCR. An advancement of this technology, 
nonrestrictive linear-amplification-mediated (nrLAM)-PCR, avoids the often-criticized restriction 
bias of the recovered integration sites, allowing for a comprehensive approach for unbiased restriction 
site retrieval independent of amplification efficiency during the PCR step (Gabriel et al., 2009; 
Paruzynski et al., 2010). nrLAM-PCR has been successfully coupled with next generation 
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pyrosequencing allowing for high-throughput analysis of the LTR-chromosome junctions in 
preclinical and clinical settings. 
To reveal the specific genomic sites of integration and allow for the identification of nearby genes 
and other genomic features of the amplified products, bioinformatical data mining is used to align 
the sequence reads to their respective genomes using the UCSC basic local alignment search tool 
(BLAST)-like alignment tool (BLAT). In addition, bioinformatics analyses have identified clusters of 
insertion sites across different insertional mutagenesis studies in mice as well as in clinical gene 
therapy trials and summarized in a publicly available database (Akagi et al., 2004). These so called 
common insertion sites (CIS) reveal areas of the same genomic location in different individuals, in 
which the proviral insertions had clustered more frequently than it would be expected by chance and 
can therefore assist in identifying insertions with a selective advantage for the cell. 
Altogether, these methods provide a valuable toolbox for the isolation of vector integrations and the 
identification of genes that might have been deregulated in response to proviral integration. Since 
each individual method is associated with different advantages and disadvantages, their applicability 
for the insertion site retrieval may vary depending on the context and the purpose of the 
experimental setting. 
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2 Aim of the thesis 
Effective hematopoiesis is reliant upon dynamic HSC fate decisions in order to maintain blood 
homeostasis. These cell fate decisions are tightly regulated and an imbalance may result in cellular 
transformation or other types of diseases. In the hematopoietic disorder FA, a loss of function in the 
FA DNA repair machinery renders HSCs genetically unstable as they are unable to cope with certain 
forms of DNA damage. In response to stress, FA HSCs are either lost due to apoptosis or subject to 
transformation. As a result, most of the FA patients develop bone marrow failure, a collapse of the 
entire hematopoietic system, and have an increased likelihood of developing hematologic 
malignancies such as AML or MDS. But what actually determines the decision between apoptosis 
and transformation in individual FA HSCs? As the cancer stem cell must have evolved mechanisms 
to evade apoptosis in order to propagate itself, this phenomenon provides a first hint towards the 
potential rescue of FA HSCs despite the DNA repair defect. We are interested in the identification of 
these rescue mechanisms that have the potential to compensate the inherent FA HSC defect and 
prevent stem cell loss in the face of genome instability. For this purpose, the FA mouse model serves 
as an important research tool. FA HSCs isolated from the FA knockout mouse models fully 
recapitulate the inherent FA HSC DNA repair defect seen in patients and demonstrate reduced 
proliferation rates in vitro as well as a profound engraftment defect in competitive transplantation 
experiments. However, the drivers of the defect remain to be investigated since no FA knockout 
mouse model spontaneously develops the severe aplastic anemia that is observed in almost all FA 
patients. We have recently demonstrated that proliferative stress is a key driver of bone marrow 
failure in FA mice, leading to increased DNA damage in FA HSCs, depletion of functional FA HSCs 
and if FA HSCs are chronically induced into cycle, eventual collapse of the hematopoietic system 
leading to severe aplastic anemia. Importantly, this probably relates to the FA HSC engraftment 
defect since donor HSCs are subject to prolonged replicative stress during transplantation. 
Here, we aim to rescue the inherent FA HSC transplantation defect in order to identify novel factors 
and mechanisms with the potential to prevent HSC loss in the face of genomic instability. 
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Specific aims: 
Specific aim 1: 
To conduct a retroviral insertional mutagenesis screen using FA and WT HSCs in a murine 
transplantation model. 
Specific aim 2: 
To perform a molecular analysis on dominant FA HSC clones that are able to overcome the inherent 
FA HSC transplantation defect. 
2.1: The identification of the retroviral integrations sites in the genome of the genetically 
modified FA HSCs. 
2.2: The analysis of whether normal gene expression is disrupted in the vicinity of the 
proviral integration site. 
Specific aim 3: 
To characterize the candidate target genes that were identified in the screen. 
3.1: The development of assays to assess whether candidate genes impact on FA and WT 
HSC biology. 
3.2: The evaluation of target gene expression and epigenetic status in HSCs under 
homeostatic and stress conditions as well as during development, in order to determine 
whether these genes may play a role in normal hematopoiesis. 
3.3: The assessment of the biological impact of target gene overexpression in WT and FA 
HSCs during hematopoietic reconstitution following transplantation. 
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3 Results 
3.1 Retroviral insertional mutagenesis screen 
In order to identify genes that might be able to compensate for the inherent FA stem cell defect when 
upregulated or disrupted, we have set up a gain-of-function screen using retroviral insertional 
mutagenesis in the FA mouse model. Proof of concept for the experimental approach has already 
been demonstrated in murine WT cells, in which retroviral-marked HSCs were selectively expanded 
upon proviral integration when the selective pressure of bone marrow transplantation was applied 
(Geiger et al., 2012; Kustikova et al., 2005). In addition, Hartmut Geiger and colleagues have used 
insertional mutagenesis in the context of identifying target genes that are sufficient to confer a 
competitive selection advantage to HSCs in mice following irradiation (Geiger et al., 2012). 
For the insertional mutagenesis screen in the FA mouse model, we have adopted the experimental 
design from Kustikova and colleagues (Kustikova et al., 2007) using the SF91 recombinant retroviral 
vector backbone, which is based on the murine leukemia virus. This replication-deficient virus 
preferentially integrates into the promoter regions of actively transcribed genes (Wu et al., 2003) and 
contains strong enhancer-promoters in the LTRs capable of mutating the expression of genes 
proximal to the integration site. In addition, it also includes the fluorescent protein Venus, which 
allows tracking of transduced cells upon transplantation. 
 
Figure 3: Experimental design of the retroviral insertional mutagenesis screen. LSK cells isolated from 
either FA or WT mice (CD45.1+ donors) were transduced with the S91 retroviral vector expressing the 
fluorescent marker Venus and transplanted into lethally irradiated WT mice (CD45.2+ primary recipients) at 
3 x 105 cells per mouse. After 24 weeks, peripheral blood and bone marrow cells were isolated and 3 x 106 
whole bone marrow cells were transplanted into myeloablated secondary recipients (CD45.2+). After 12 weeks, 
mice were sacrificed and peripheral blood and bone marrow cells were analyzed by FACS. 
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Figure 3 depicts a scheme of the retroviral insertional mutagenesis screening procedure. Murine bone 
marrow cells were isolated from either FA knockout mouse models (Fanca-/-, Fancc-/-, Fancg-/-) or WT 
mice. Mature lineage-committed cells were depleted and FACS-isolated for the LSK fraction, which 
is enriched for stem cells and multipotent progenitors. All leukocytes isolated from these mice, 
including stem and progenitor cells, express the CD45.1 version of the common leukocyte antigen. 
This means that donor leukocytes in the peripheral blood, bone marrow and spleen can additionally 
be distinguished from recipient cells by antibody staining as well as Venus-fluorescence, since 
recipient mice express the CD45.2 epitope. These LSK cells were then transduced with the SF91 
replication-deficient retroviral vector at a multiplicity of infection (MOI) in the range of 1 to 15, 
resulting in an average transduction frequency of 40.35% and an estimated average copy number of 
one to two proviral integrants per transduced cell. Irradiated WT recipient mice were subsequently 
transplanted with 3x105 unsorted retroviral-marked LSK cells per recipient. 24 weeks after the 
primary transplant, recipient mice were sacrificed and the hematologic parameters were assessed 
including the percentage of Venus-positive cells in the blood and bone marrow of the mice. 3x106 
whole bone marrow cells were then transplanted into lethally irradiated secondary recipient mice in 
order to create a selection pressure for dominant stem cell clones. In this scenario a dominant stem 
cell clone would transplant and engraft again in the secondary recipient in order to give rise to 
differentiated cells, whereas all progenitor cells would be lost independent of whether they had gained 
a growth advantage upon retroviral integration. Therefore, we ensured the selection for stem-cell 
relevant genes in our analysis. 12 weeks after the secondary transplant all secondary recipient mice 
were sacrificed and analyzed by flow cytometry. 
Primary as well as secondary recipient mice were thoroughly analyzed for the expansion of dominant 
stem cell clones by flow cytometry. In this context we looked at the percentage of transduced cells in 
bone marrow and peripheral blood as well as at the ratio of B, T and myeloid cells. The surface 
marker CD45.1/2 was used to distinguish donor cells from host cells in order to exclude cells that 
repopulated the recipient due to inefficient irradiation. Primary material, comprising cells from bone 
marrow and peripheral blood, was collected and stored for downstream analyses such as DNA 
sequencing and expression analyses. In addition, hematologic parameters such as cell counts and 
organ size of spleen and thymus were monitored in order to be able to distinguish malignant from 
non-malignant clonal expansion retrospectively. 
3.2 Analysis of insertion sites in transduced FA and WT HSCs 
To date, different methods to recover insertion sites from the highly complex DNA background of 
retroviral transduced cells have been used with constant development leading to increased sensitivity 
of detection. We initially performed a global analysis of the retroviral integrations present in clones 
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dominating in serially transplanted recipients using LM-PCR, which introduces a bias for dominant 
clones while neglecting integrations derived from minor clones (Schmidt et al., 2001). The reliability 
of this method results from enrichment of target DNA via magnetic extension primer tag selection, 
in which a reverse primer specific for the LTR U3 region of the virus is extended in a PCR step and 
subsequently coupled to magnetic beads (see Figure 38 in 5.9.1). This is followed by a solid-phase 
LM-PCR, in which two exponential PCR steps amplify the target DNA. The amplification products 
corresponding to dominant clones recovered from the peripheral blood of transplanted primary and 
secondary mice were separated on an agarose gel and the prevalent bands were extracted from the gel, 
ignoring weak bands that might reflect insertion sites in minor clones (see Figure 5 in 3.4). The 
DNA was then sequenced and blasted against the mouse genome in order to identify the genomic 
integration sites of the retroviral integrations. 
An overview of the insertion sites that were recovered from the primary and secondary recipient mice 
can be seen in Table 1. In total, 174 primary recipient mice have been analyzed, of which 134 were 
FA (47 Fanca-/-, 62 Fancc-/-, 25 Fancg-/-) and 40 were WT transplanted mice. From these primary 
recipients, a total of 395 insertion sites were recovered, 96 corresponding to Fanca-/-, 130 to Fancc-/-, 
59 to Fancg-/- and 110 to WT transplants. In the second transplantation round, 20 mice were lost due 
to graft failure and were therefore excluded from the analysis. In total, we could analyze 154 
secondary recipient mice, of which 117 were FA (37 Fanca-/-, 56 Fancc-/-, 24 Fancg-/-) and 37 were 
WT transplanted recipient mice. From these secondary recipient mice, we were able to recover 205 
insertion sites with 43 corresponding to Fanca-/-, 71 to Fancc-/-, 24 to Fancg-/- and 67 to WT 
transplants. These numbers demonstrate the reduction in the total amount of integration sites from 
395 integrations in the primary to 205 insertion sites in the secondary recipient during an additional 
round of transplantation. 
Table 1: Total number of insertion sites recovered from primary and secondary recipient mice  
experimental 
group 
1° recipient mice 2° recipient mice total n° of 
insertion sites n° of mice n° of insertion sites n° of mice n° of insertion sites  
Fanca-/- 47 96 37 43 139 
Fancc-/- 62 130 56 71 201 
Fancg-/- 25 59 24 24 83 
WT 40 110 37 67 177 
total 174 395 154 205 600 
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Initially, we wished to analyze this data by interrogation of all of the integration sites in FA HSCs in 
order to identify common insertion sites (CIS). However, CIS could not be detected with this 
approach since, despite the large number of experimental mice in each cohort, not enough 
integration sites could be recovered to analyze patterns of commonly targeted regions of the genome. 
We therefore sought another route of data analysis that would allow us to meaningfully compare the 
relatively low number of integrations sites recovered in this study. 
3.3 Engraftment rate of transduced FA and WT HSCs 
To find an alternative way of analyzing the data, we defined a selection strategy based on a 
phenomenon initially observed in human clinical gene therapy trials using retroviral vectors for the 
correction of certain gene-defects. These studies have provided clear evidence that, in individual 
patients, dominant clones can arise and take over the hematopoietic system of that patient (Braun et 
al., 2014; Cavazzana-Calvo and Fischer, 2007; Ott et al., 2006). Informed by these studies, we 
decided to next focus our analysis on individual mice with clear evidence of clonal dominance in 
order to select for clones in which the proviral integrant had likely impacted upon HSC biology. 
For this purpose, we followed the engraftment rate of transduced cells over the time course of serial 
transplantations using flow cytometry (Figure 4 A). By plotting CD45.1 versus Venus, we could 
identify the total contribution of the gene-modified graft to hematopoiesis in the secondary recipient. 
In some cases it was clear that the donor graft was almost completely depleted over the course of two 
rounds of transplantations (Figure 4 B). In contrast, in some mice the donor cells were responsible 
for the product of almost all peripheral blood cells in the secondary recipients (Figure 4 C). Such an 
expansion might be the result of an individual clone having a selection advantage over the residual 
recipient cells due to insertionally deregulated growth-promoting genes. 
If we analyzed all mice and first looked at the contribution of original donor cells to the 
hematopoietic system in the secondary recipients (Figure 4 D), we saw that in the majority of mice 
receiving FA donor cells, the transplanted CD45.1+ cells had been depleted. This phenotype was 
especially pronounced for the Fanca-/- and Fancg-/- group, in which only a few mice revealed a high 
CD45.1 chimerism. In contrast, mice of the Fancc-/- group revealed an engraftment rate of CD45.1 
cells almost comparable to WT. This finding correlates with the milder HSC defect that has been 
previously observed in this knockout mouse strain (Geiselhart et al., 2012). On average, WT donor 
cells were able to reconstitute secondary recipients better than FA. 
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Figure 4: Engraftment rate of transduced FA and WT HSCs. (A) Schematic outline of the analysis of 
secondary recipient mice for the percentage of Venus-positive cells. The input frequency of SF91-transduced 
Venus-positive bone marrow cells was compared to the output frequency of Venus-positive bone marrow cells 
after serial transplantation. Transduced cells were either lost (depletion) or have expanded (expansion). 
(B) Representative FACS plot of a FA bone marrow sample with no engraftment (0.2%) of the transplanted 
(CD45.1+) and transduced (Venus+) cells. (C) Representative FACS plot of a FA bone marrow sample with 
strong engraftment (95.5%) of the transplanted (CD45.1+) and transduced (Venus+) cells. (D) Percentage of 
original donor cells (CD45.1+) in each individual Fanca-/- (red), Fancc-/- (green), Fancg-/- (blue) and WT control 
(black) mouse. (E) Percentage of transduced (Venus+) original donor cells (CD45.1+) in each individual Fanca-
/- (red), Fancc-/- (green), Fancg-/- (blue) and WT control (black) mouse. (F) Relationship between donor 
chimerism (CD45.1+) and gene-marked chimerism (CD45.1+/Venus+) of the graft. (G) Change in percentage 
of transduced original donor cells (Venus+ CD45.1+) after two rounds of transplantation with individual mice 
that demonstrated a clear expansion of the gene-modified graft (#). 
Next, we wanted to see how gene modification with the virus impacted on clonal dominance, so we 
looked at the percentage of CD45.1 cells that were expressing Venus (Figure 4 E). While the 
majority of mice in the WT group revealed a gene-marked chimerism between 50 - 100%, the 
average frequency of Venus-positive donor cells was much lower in the FA groups with around 30% 
for the Fanca-/- and the Fancc-/-. Although the Fancc-/- group demonstrated higher transduction rates 
on average, only half of the mice had Venus-levels that were comparable to WT.  However, some FA 
mice that had high level of chimerism were gene-modified, which suggests that the vector had 
integrated into the genome of the cells conferring an engraftment advantage. 
Finally, we analyzed the relationship between the donor chimerism and the gene-marked chimerism 
of the graft. If we plotted these two variables together, we could observe a low level of chimerism for 
most of the FA mice. Especially in the Fanca-/- and the Fancg-/- groups, the majority of original 
CD45.1+ donor cells were depleted and very few mice displayed high Venus-positivity (Figure 4 F). 
Therefore it seems likely that in some mice, the integration of the retrovirus was able to impact upon 
FA HSC biology and a high gene-marked chimerism would therefore be a sign for cells that have 
expanded due to the insertional deregulation of growth-promoting genes. 
Taken together, we could identify individual mice with high chimerism, in which retroviral-
transduced Venus-positive cells have expanded and clearly dominated over the non-transduced FA 
cells and the residual recipient hematopoiesis. Even though we initially transplanted the same 
number of input cells, this phenomenon could have been an artifact relating to varying transduction 
efficiencies. In order to account for this, we looked at the change in percentage of gene-marked cells 
over two rounds of transplantation compared to the input transduction efficiency. We therefore 
subtracted the percentage of Venus-positive donor cells that were initially transplanted into recipient 
mice (input frequency) away from the final percentage of Venus-positive donor cells (output 
frequency) that were identified in the secondary recipient. We considered an increase in the 
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percentage of transduced cells over the course of serial transplantation to comprise evidence of clonal 
expansion, while mice in which there was no difference in the percentage of Venus-positive cells or a 
depletion of the transduced cells were eliminated from further analysis. The results obtained from 
this analysis are summarized in Figure 4 G. In the control group, which was composed of WT mice 
that were transplanted with retroviral-transduced WT cells, 56% of all mice displayed an increase in 
the number of transduced cells, which could be indicative of clonal dominance. In the Fancc-/- group, 
which was composed of mice that had received retroviral-transduced Fancc-/- cells, the situation was 
slightly different as more mice appeared in the negative area of the graph. Only 37% of all mice 
showed an expansion of transduced cells. In the Fanca-/- and Fancg-/- group, which was composed of 
WT mice that had received retroviral-transduced Fanca-/- and Fancg-/- cells respectively, we only found 
an expansion of transduced cells in 6% of the Fanca-/- and 1% of the Fancg-/- mice. 
Overall, it appears that the majority of mice that had received transduced FA cells, demonstrated a 
severe depletion of the transplanted gene modified cells suggesting that the selection pressure for 
dominant clones is higher in the Fanconi model than in WT cells. Therefore, the expansion of the 
gene-modified graft in some of the mice suggests deregulated expression of genes that allow the HSC 
to overcome the FA-specific selection pressure and to become a dominant stem cell clone. As these 
mice would reveal interesting target genes with the potential to alter the stem cell kinetics in the 
context of FA HSC biology, the mice with the strongest change in graft were selected in each 
experimental group. In the Fancc-/- group, mice #C1 (60.94%), #C2 (53.84%), #C3 (48.8%), #C4 
(42.3%), #C5 (42.14%) and #C6 (34.9%) were selected. In Fanca-/- and Fancg-/- HSCs, it seems that 
the selection pressure for dominant clones was extremely high as only three of the mice in these 
groups, termed #A1 (51.6%), #A2 (25.8%) and #G1 (43.2%), demonstrated such signs of clonal 
dominance. 
Moreover, we also considered the group of mice receiving WT transduced HSCs, as some individuals 
demonstrated a strong expansion of the gene-modified graft, which outnumbered the expansion rates 
in all FA groups. This was the case for mouse #WT1, which had a change in graft of 81.2%. 
Although this is probably due to a comparably low selection pressure for dominant clones in the WT 
setting, the analysis of retroviral integrations in the dominant clones would still provide some insight 
into how these cells mediated clonal dominance in a competitive setting with normally engrafting 
stem cells. In addition, this would allow us to reveal some aspects of normal HSC biology. Therefore 
we have selected three of the top WT candidate mice in order to characterize the retroviral 
integrations. In addition to mouse #WT1 (81.2%) we have selected mice #WT2 and #WT3 with a 
change in graft of 49.5 and 48.1 respectively. 
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3.4 Clonal dominance of transduced FA and WT HSCs 
To further analyze the individual mice that had dominated in the retroviral insertional mutagenesis 
screen, we determined the clonal composition of their hematopoietic tissues. For this purpose LM-
PCR analysis was performed on bone marrow samples from the secondary and corresponding 
primary recipients (Figure 5). The analytical LM-PCR gels show the insertions recovered from the 
mice after analysis with two distinct restriction enzymes (Tsp509I and MseI), which increases the 
likelihood of recovering all insertions. In addition, the restriction digest generated a vector-specific 
internal control band, which indicates a successful analysis. For the SF91 retroviral vector used in this 
study, the control band corresponded to 217 bp for Tsp509I and to 544 bp for MseI restriction as 
indicated by the arrows. These vector-specific internal control bands could be detected in almost all 
of the analyzed mice, however absence of the control in some of the mice could be the result of 
problems during primer annealing due to secondary stem loop structures. In addition, sequences with 
a high GC-content or a larger DNA fragment could have led to problems during the denaturation or 
the amplification step respectively. 
All other individual bands depicted retroviral insertions corresponding to dominant clones. Primary 
recipients revealed polyclonal hematopoiesis, which was a result of multiple cells carrying retroviral 
insertions as represented by a smear or several distinct bands. After an additional round of 
transplantation, secondary recipients only revealed one or two dominant clones (marked by an 
asterisk), which are indicative of mono or biclonal hematopoiesis in these animals. This demonstrates 
a dramatic reduction in the complexity of integration sites in the secondary recipient despite the 
increase in the gene marked chimerism, which was observed in the analysis of Venus-positive cells 
(see Figure 4 in 3.3). 
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Figure 5: Clonality of FA and WT bone marrow samples. LM-PCR gels showing insertions recovered 
from bone marrow of primary (1°) and secondary (2°) recipients after MseI and Tsp509I restriction digest. 
(A) Analysis of Fanca-/- (#A1, #A2) and Fancg-/- bone marrow (#G1) (B)+(C) Analysis of Fancc-/- bone marrow 
(#C1, #C2, #C3, #C4, #C5, #C6) (D) WT bone marrow #WT1, #WT2 and #WT3. Arrows indicate internal 
vector control bands for MseI (544 bp) and Tsp509I (217 bp); asterisks indicate retroviral insertions 
corresponding to dominant clones. 
Altogether these data suggest the selective expansion of one or two dominant clones after two rounds 
of transplantation demonstrating the dominance of some of the retroviral-transduced FA HSC 
clones.  These mice revealed dominant stem cell clones that had gained a growth advantage as a result 
of the genomic integration of the retroviral vector. In addition, we could demonstrate non-malignant 
clonal expansion of the dominant stem cell clones as we could not observe any signs of 
leukemogenesis (splenomegaly and increased peripheral blood cell counts) in these mice. Although 
we could detect abnormal hematopoiesis in clone #A1, which demonstrated a profound myeloid 
differentiation bias (Figure 6 A+B), we could exclude the existence of increased blasts or 
myelodysplasia as assessed by analysis of cellular morphology in peripheral blood smears (Figure 6 C) 
and bone marrow cytospins (Figure 6 D). 
 
Figure 6: Abnormal hematopoiesis in mouse #A1 with a profound myeloid differentiation bias. 
(A) FACS analysis of the peripheral blood in mouse #A1 demonstrating an overrepresentation of Mac1+/Gr1+ 
myeloid cells (88%). (B) FACS analysis of the lymphoid lineage revealing decreased numbers of B (B220+; 
0.8%) and T (CD3+; 0.8%) cells. (C) Peripheral blood smear revealing normal blood morphology. (D) Bone 
marrow cytospin representing all stages of differentiating myeloid cells. 
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3.5 Identification of retroviral integration sites in dominant FA and WT HSC 
clones 
Since the peripheral blood samples of serially transplanted mice had demonstrated dominance of one 
or two hematopoietic FA HSC clones, we next analyzing the retroviral vector integration sites present 
in these clones. For this purpose we have used nrLAM-PCR (Gabriel et al., 2009; Paruzynski et al., 
2010) in collaboration with the group of Manfred Schmidt at the National Center for Tumor 
Diseases in Heidelberg. Genomic DNA was isolated from the bone marrow of these mice in our 
laboratory and the samples were handed over to Cynthia Bartholomä, who performed the nrLAM-
PCR analysis together with the technical support of Stefanie Laier. 
The nrLAM-PCR is an advanced form of integration site analysis, which has been used in more 
recent studies as it has proven to be the most comprehensive technology available for the recovery of 
the genomic location of proviral integrants (Schmidt et al., 2007). The nrLAM-PCR exhibits lower 
sensitivity due to the less efficient ligation reaction of single stranded DNA but circumvents the 
often-criticized restriction bias introduced by LM-PCR, as it allows for the identification of vector 
integrations independent of restriction enzymes (see Figure 39 in 5.9.2). 
The results from the unbiased insertion site characterization of primary bone marrow samples 
recovered from mice that have dominated in serial transplantations are depicted in Figure 7. Each bar 
displays the retrieval frequencies of the most prominent integration sites in each sample illustrating 
the relative contribution of each individual integration site to the whole genome in each mouse 
(Figure 7 A). In mice #A1, #G1, C2, #C5 and #WT3, we only found one dominant integration site, 
in which the integration of the retrovirus had led to a growth advantage in a single HSC clone. 
However, in mouse #A2 we identified two dominant integration sites, which equally contributed to 
hematopoiesis. This could correspond to a single dominant HSC clone that harbored two 
independent proviral integration sites or two dominant clones, each with a single integration site and 
each contributing an approximately equal amount to ongoing hematopoiesis. In contrast, all other 
mice revealed oligoclonal hematopoietic reconstitution. Altogether, this analysis clearly demonstrates 
a mono- to oligoclonal hematopoietic reconstitution in mice, fully recapitulating what was already 
observed in the LM-PCR analysis (see Figure 5 in 3.4). 
Deep-sequencing analysis allowed for the identification of the unknown genomic sequences flanking 
the integrated vector DNA and revealed the closest gene for each integration site as shown in 
Figure 7 B. While this revealed up to 15 and 14 vector integrations in mice #C6 and #WT2 
respectively, we could only detect a single integration in mouse #C5 with all the others ranging from 
three to ten. However, most of these integrations corresponded to minor clones as confirmed by the 
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analytical LM-PCR gels (see Figure 5 in 3.4). The integration sites on top of the list are the genes 
proximal to the integration site in the dominant clones. 
 
Figure 7: Insertion site characterization of FA and WT HSCs. (A) Retrieval frequencies of the most 
prominent integration sites in the bone marrow sample of selected mice (#) as analyzed by nrLAM-PCR. 
(B) Table listing the closest gene to each integration site in each mouse. 
Although one could interrogate all of these mice we decided to focus our subsequent analysis on the 
FA clones termed #A1, #A2 and #G1, which demonstrated an extremely strong selection pressure. 
We hypothesized that the expansion of the gene-modified graft in these mice was due to the 
deregulated expression of genes that allowed the HSC to overcome the FA-specific selection pressure 
in order to become a dominant stem cell clone. Therefore the characterization of these dominant 
stem cell clones is of major interest as they would reveal target genes with the potential to compensate 
for the inherent FA HSC defect. 
3.6 Genomic location of the retroviral integrations in mice #A1, #A2 and #G1 
To further characterize the dominant FA HSC clones of mice #A1, #A2 and #G1, which 
demonstrated an extremely strong selection pressure, and to identify the genes proximal to the 
retroviral vector integrations, we next investigated their genomic locations. Figure 8 depicts an 
overview of the genomic location of the retroviral integrations in each individual clone, 
demonstrating the complexity of the surroundings of the retroviral integrations. Since some of the 
integrations have occurred in gene-dense regions and retroviral enhancers can elicit their effects over 
large distances, we considered windows of 300 kb for the analysis of genes that are proximal to the 
integration site. 
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Figure 8: Genomic location of the retroviral vector integration in each individual stem cell clone. 
Integrated version of the retroviral vector with flanking genes 150 kb downstream and upstream of the vector 
integration for the dominant stem cell clones #A1, #G1, #A2 I and II. 
In clone #A1, nrLAM-PCR revealed an integration of the retrovirus into chromosome 12, upstream 
of the TATA box binding protein-associated factor, ribonucleic acid (RNA) polymerase I, B (Taf1b) 
and the grainyhead-like 1 (Grhl1), a gene named after the “grainyhead-like” drosophila mutant. In 
clone #G1, the retroviral vector had integrated into the Evi1/MDS complex locus (Mecom), which is 
located on chromosome 3. In the two clones of mouse #A2, we found a total of 12 potential drivers 
of clonal dominance upstream and downstream of the two retroviral integration sites. One 
integration had occurred on chromosome 8, into a gene locus with eight genes in the window of 300 
kb and the other was identified on the X-chromosome with four additional genes in the surroundings 
of the provirus. All genes, which were found proximal to the retroviral integration, are summarized in 
Table 2. 
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Table 2: Potential candidate target genes 
Clone ID Candidate target gene 
#A1 Taf1b TATA box binding protein (Tbp) associated factor, RNA polymerase I, B 
#A1 Grhl1 grainyhead-like 1 
#A2 Cdh13 cadherin 13 
#A2 Hsdp1 heat shock factor binding protein 1 
#A2 Mlycd malonyl-CoA decarboxylase 
#A2 Osgin1 oxidative stress induced growth inhibitor 1 
#A2 Necab2 N-terminal EF-hand calcium binding protein 2 
#A2 Slc38a8 solute carrier family 38, member 8 
#A2 Mbtps1 membrane-bound transcription factor peptidase, site 1 
#A2 Hsdl1 hydroxysteroid dehydrogenase like 1 
#A2 Gm8817 predicted gene 8817 
#A2 Tmsb4x thymosin, beta 4, X chromosome 
#A2 Tlr8 toll-like recptor 8 
#A2 Tlr7 toll-like recptor 7 
#G1 Mecom MDS /Evi1 complex locus 
3.7 Identification of genes that drive clonal dominance 
To identify genes with the potential to alter FA stem cell kinetics and drive clonal dominance among 
the genes located 150 kb upstream and downstream of the retroviral integration as depicted in Table 
2, we sought to identify genes that demonstrated deregulated expression in whole bone marrow 
samples from the individual mice termed #G1 and #A2 using quantitative RT-PCR. The results 
from this analysis are depicted in Figure 15 and Figure 20 and described in more detail in the 
subsequent chapters (refer to 3.9 and 3.10). For mouse #A1, we were not able to analyze the 
expression profiles as we did not have backup cell pellets available for RNA isolation. Fortunately, 
only two candidate genes, Taf1b and Grhl1, were located downstream of the integration site in 
mouse #A1 and therefore were immediately selected for further functional characterization. 
3.8 Characterization of genes proximal to the integration site in mouse #A1 
In mouse #A1 we have identified two genes, Taf1b and Grhl1, downstream of the retroviral 
integration on chromosome 12. Due to the lack of sufficient material to perform expression analysis, 
both genes were further characterized and are described in more detail in the subsequent chapters. 
3.8.1 TATA box binding protein (TBP)-associated factor, RNA polymerase I, B (Taf1b) 
In bone marrow of mouse #A1, we found Taf1b, the TATA box binding protein-associated factor, 
RNA polymerase I, B in close proximity to the retroviral vector integration on chromosome 12. 
  R E S U L T S  
33 
Taf1b is a component of the transcription machinery for RNA polymerase I, which initiates 
ribosome biogenesis and regulates eukaryotic cell growth and proliferation (Laferte et al., 2006). 
Among the three types of eukaryotic nuclear RNA polymerases that transcribe DNA into different 
forms of RNA, Polymerase I is responsible for the synthesis of most ribosomal RNAs. For the 
formation of the pre-initiation complex at the promoter, RNA polymerase I requires general 
transcription factors that assist in positioning of the RNA polymerase I to ribosomal DNA in order 
to initiate transcription: the upstream binding factor (UBF) and the promoter selectivity factor SL1 
in humans and TIF-IB in mice (Grummt, 2003). TIF-IB/SL1 is a complex that consists of the 
TATA binding protein (TBP) and five TATA binding protein-associated factors (Taf1s), of which 
one is the 68kDa protein Taf1b (also termed Taf1-68) in mice. In general, Taf1 proteins play an 
integral role in the assembly of the transcription complex by mediating the recruitment of polymerase 
I to ribosomal DNA thereby contributing to promoter specificity and gene regulation (Heix et al., 
1997; Zomerdijk et al., 1994). 
Besides the generally established link between ribosomal (r)RNA synthesis and cancer (Drygin et al., 
2010), Taf1b has been implicated in the pathology of colorectal carcinoma as somatic frameshift 
mutations in Taf1b were identified in 82% of all analyzed mismatch repair-deficient tumors (Kim et 
al., 2002). In addition, a Taf1b truncating mutation has been associated with lung cancer risk. 
However, the germ line DNA of only one patient was analyzed in this study (Renieri et al., 2014). 
The importance of Taf1b for stem cell biology has just recently been demonstrated as the disruption 
of Taf1b by RNA interference, leading to decreased rRNA synthesis, resulted in reduced proliferation 
rates of ovarian germ line stem cells in Drosophila (Zhang et al., 2014). Therefore, Taf1b is an 
important component of the intrinsic transcription machinery that has the potential to modulate the 
cell fate, growth and proliferation of Drosophila stem cells. However, the role of Taf1b in the 
hematopoietic stem and progenitor compartment so far remains elusive. Therefore, we aimed at 
characterizing Taf1b in the context of HSC biology by summarizing different expression data of 
hematopoietic stem and progenitor cells. 
3.8.1.1 Taf1b expression levels under homeostatic conditions 
In order to get an initial idea about the relative expression levels of Taf1b in different tissues, we 
explored the BioGPS gene annotation portal (www.biogps.org), which provides a huge collection of 
gene expression data on a variety of biological samples. These data identified murine Taf1b to be 
highest expressed in testis and the mouse pro B cell line Baf3 (Figure 9). In addition, also the 
hematopoietic compartment seemed to express Taf1b. 
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Figure 9: Taf1b expression across different tissues and cell lines. Red arrows indicate pronounced 
expression in the mouse pro B cell line BaF3 cells and in testis. 
The role of Taf1b in the hematopoietic stem and progenitor compartment has not been characterized 
yet. In order to provide some insight into the relevance of Taf1b for HSC biology, we made use of a 
comprehensive gene expression dataset on the hematopoietic populations that was generated by high-
throughput RNA sequencing through the collaborative effort of the groups of Andreas Trumpp, 
Michael Milsom and Daniel Lipka at the German Cancer Research Center and the members of the 
group of Jerome Krijgsfeld at the European Molecular Biology Laboratories in Heidelberg (Cabezas-
Wallscheid et al., 2014). These data allowed assessing the Taf1b expression in HSC and MPP 
populations, which revealed that Taf1b was equally expressed across HSCs and a series of 
multipotent progenitor cells (Figure 10 A). 
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Figure 10: Taf1b expression levels and methylation pattern in HSC and progenitor populations. 
(A) Mean Taf1b expression levels in LT-HSCs and progenitor populations MPP1 – 4 as obtained by high-
throughput RNA sequencing. (B) Taf1b methylation pattern in LT-HSCs and MPP1 - 4 generated by 
tagmentation-based whole genome bisulfite sequencing. (C) Mean Taf1b expression levels in FA and WT LT-
HSCs under physiologic stress conditions as obtained by high-throughput RNA sequencing of IFN-α, Tpo-
and control-treated LT-HSCs. 
3.8.1.2 Epigenetic regulation of Taf1b expression 
Gene expression can be regulated through various mechanisms. One important mechanism involves 
the epigenetic regulation of chromatin structure through DNA and histone modifications. DNA 
methylation is a stable epigenetic mark, which in mammalian cells preferentially occurs at cytosine-
residues adjacent to guanine nucleotides, so called CpG-dinucleotides. CpG methylation is mediated 
by DNA methyltransferases. The genome-wide analysis of DNA methylation patterns provides an 
important measure of transcriptional regulation during differentiation (Cabezas-Wallscheid et al., 
2014; Lipka et al., 2014). Therefore we were interested in the analysis of the methylation patterns at 
the Taf1b locus, on the long arm of chromosome 12 in the sub band A1.3, across the individual 
hematopoietic stem and progenitor cell populations as it was addressed by a dataset that was 
generated by tagmentation-based whole genome bisulfite sequencing of these hematopoietic cells by 
Daniel Lipka and colleagues (Lipka et al., 2014). Using this data, we found a distinct differentially 
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methylated region among the LT-HSC and MPP3/4 populations, which was located in an intragenic 
region of Taf1b (Figure 10 B). This reveals a functional region, which may be involved in the 
epigenetic regulation of HSC biology during hematopoiesis. 
3.8.1.3 Taf1b expression under conditions of physiologic stress 
Since we could demonstrate that Taf1b was expressed in HSC and MPPs under steady state 
conditions, we also investigated the Taf1b expression under conditions of physiologic stress such as 
in response to bleeding, infections or inflammation. HSCs are rapidly activated in response to stress 
and proliferate in order to replenish the system (Cheshier et al., 2007; Wilson et al., 2008). Such an 
activation of the HSC compartment can also be induced experimentally with agonists that mimic a 
stress situation like interferons, lipopolysaccharide (LPS), G-CSF or Tpo (Baldridge et al., 2010; 
Essers et al., 2009; Takizawa et al., 2011; Wright et al., 2001; Yoshihara et al., 2007; Zhang et al., 
2008). Recently, we could show that treatment of HSCs with these agonists resulted in an increased 
production of intracellular reactive oxygen species and the accumulation of DNA damage, which 
may ultimately lead to cellular attrition (Walter et al., 2015). This demonstrates the extent of the 
stress the HSC has to cope with in order to maintain the integrity of the hematopoietic system. Here, 
IFN-α and Tpo were chosen to activate the HSCs on two consecutive days for the purpose of 
modeling HSC stress biology in vivo. In order to analyze the gene expression of highly purified LT-
HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-, CD34-) under stress conditions, Amelie Lier performed 
high-throughput RNA sequencing of Tpo- and IFN-α-treated LT-HSC populations and compared 
normal HSC biology as well as FA HSC biology to the respective stress conditions (Lier and Milsom, 
unpublished data). Under stress conditions Taf1b was slightly upregulated in both WT and FA 
HSCs, independent of whether Tpo or IFN-α treatment induced the stress (Figure 10 C). This 
suggests that Taf1b might be required for the maintenance of hematopoiesis in response to stress, 
both in WT and FA mice. 
3.8.1.4 Taf1b expression during development 
In order to reveal whether Taf1b could also play a role during embryonic development of the 
hematopoietic stem and progenitor cell compartment, we investigated the expression levels of Taf1b. 
For this purpose, we made use of a comprehensive gene expression dataset on HoxB4-yellow 
fluorescent protein (YFP)-positive embryonic stem (ES) reporter cell lines, which was generated by 
our colleague Paul Kaschutnig. These HoxB4-YFP-positive ES cells were isolated from the Hoxb4-
YFP reporter mouse model (Hills et al., 2011), in which the YFP-labeled HoxB4 expression is 
restricted to the definitive HSCs. During ES cell culture, YFP expression marks bona fide HSCs and 
therefore facilitates the purification and analysis of this population. In the microarray, three 
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populations from primitive (HoxB4- CD41- Flk1+ c-Kit+) to definitive/HSC-enriched (HoxB4+ 
CD41+ CD93+ c-Kit+) to more progenitor-like cells (HoxB4- CD41+ c-Kit+) were analyzed 
(Kaschutnig and Milsom, unpublished data) and revealed no significant differences in the mean 
expression levels of Taf1b expression (Figure 11) This indicates that differential Taf1b levels might 
not be relevant during these individual steps of specification. However, whether uniformly expressed 
Taf1b is required in these rapidly proliferating cell populations or does not play a role during 
developmental processes at all remains to be investigated. 
 
Figure 11: Taf1b expression during embryonic development. Mean expression levels of Taf1b in HoxB4-
YFP-expressing embryonic stem cells during developmental specification from (1) primitive (HoxB4- CD41- 
Flk1+ c-Kit+) to (2) definitive/HSC-enriched (HoxB4+ CD41+ CD93+ c-Kit+) to more (3) progenitor-like cells 
(HoxB4- CD41+ c-Kit+). 
3.8.2 Grainyhead-like 1 (Grhl1) 
We also found Grhl1 as a potential target of the vector integration in the dominant clone from 
mouse #A1, approximately 80 kb downstream of the retroviral integration on chromosome 12. The 
transcription start site of Grhl1 is separated from the vector integration by Taf1b. Despite the distant 
location of the transcription start site of Grhl1, it is still possible that the integration site has 
impacted upon Grhl1 expression due to the very strong enhancer elements of the SF91 vector, which 
may impact upon the gene expression of genes much further apart. Therefore, we aimed at 
characterizing Grhl1 in the context of HSC biology. 
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Grhl1 is one of three mammalian homologues of the drosophila transcription factor grainyhead 
(grh), which is expressed in ectoderm-derived tissues during drosophila development (Bray et al., 
1989; Bray and Kafatos, 1991). Mammalian Grhl1 shares high sequence homology with Grhl2 and -
3 functional domains and is expressed in the epidermis as well as in heart, lung and kidney of the 
developing mouse embryo (Auden et al., 2006). Mice lacking Grhl1 have demonstrated an important 
regulatory function of Grhl1 for desmosomal cadherin expression in the epidermis, which appears 
crucial for hair anchoring and epidermal differentiation (Wilanowski et al., 2008). Therefore, Grhl1 
knockout mice exhibit skin barrier defects and are more susceptible to the development of skin 
tumors such as squamous cell carcinoma (Mlacki et al., 2014). 
In neuroblastoma, Grhl1 was found to act as a tumor suppressor with high-level expression 
correlating with favorable patient survival. In addition, Grhl1 expression was induced upon HDAC 
inhibitor treatment in neuroblastoma cells, in which MYCN binding to the Grhl1 promoter had 
repressed its expression. This suggests a therapeutic benefit of HDAC inhibitor treatment provoking 
Grhl1 expression for neuroblastomagenesis at the molecular level (Fabian et al., 2014). 
A role for Grhl1 in HSC biology has not been demonstrated yet. Therefore, we aimed at 
summarizing comprehensive expression data on Grhl1 in different compartments of the 
hematopoietic system in order to investigate whether Grhl1 might play a role in hematopoiesis. 
3.8.2.1 Grhl1 expression levels under homeostatic conditions 
To elucidate the relative expression levels of Grhl1 among a variety of biological samples including 
cell lines and tissues, we explored the collection of gene expression data published by the BioGPS 
gene annotation portal (www.biogps.org).Grhl1 was found essentially expressed in tissue from 
epidermis and prostate, and to a somewhat lower extent in cornea and mammary gland (Figure 12). 
In contrast, Grhl1 expression was undetectable in bone marrow as well as in individual hematopoietic 
populations such as mature T-, B-, myeloid and progenitor cells. 
In order to investigate the Grhl1 expression levels in the hematopoietic stem and progenitor 
compartment we made use of high-throughput sequencing data that was generated by our colleagues 
and collaborators (Cabezas-Wallscheid et al., 2014). In general, the overall expression levels for Grhl1 
in the HSC and MPP compartment appeared to be below 1 read per kb of transcript per million 
reads mapped (RPKM), which might indicate that only very few transcripts of Grhl1 were present. 
Independent of this finding, Grhl1 expression was increased in MPP1 cells when compared to HSCs, 
and decreased upon hematopoiesis from MPP2 to MPP3 and MPP4 (Figure 13 A). However, 
whether this supports a regulatory role of Grhl1 during hematopoiesis remains to be clarified. 
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Figure 12: Grhl1 expression across different tissues and cell lines. Red arrows indicate pronounced 
expression of Grhl1 in epidermis and prostate. 
3.8.2.2 Epigenetic regulation of Grhl1 expression 
Next, we aimed at investigating the transcriptional regulation of Grhl1 during HSC differentiation 
and looked at the DNA methylation pattern of the Grhl1 locus as it was addressed by a dataset that 
was generated by tagmentation-based whole genome bisulfite sequencing by the collaborative effort 
of Daniel Lipka and members of our group (Cabezas-Wallscheid et al., 2014; Lipka et al., 2014). 
Using this data, we were able to assess the methylation status of the Grhl1 locus, on the long arm of 
chromosome 12 in the sub band qA1.3, which revealed no difference across the individual 
hematopoietic stem and progenitor cells (Figure 13 B). Therefore, Grhl1 expression during 
hematopoiesis seems to be independent of epigenetic regulation. However, the permissive 
methylation state for gene expression at the hypomethylated upstream promoter in HSCs and 
progenitors, led us to speculate that Grhl1 expression can be turned on under certain circumstances. 
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Figure 13: Grhl1 expression levels and methylation pattern in HSC and progenitor populations. 
(A) Mean Grhl1 expression levels in LT-HSCs and progenitor populations MPP1 – 4 as obtained by high-
throughput RNA sequencing. (B) Grhl1 methylation pattern in LT-HSCs and MPP1 - 4 generated by 
tagmentation-based whole genome bisulfite sequencing. (C) Mean Grhl1 expression levels in FA and WT LT-
HSCs under physiologic stress conditions as obtained by high-throughput RNA sequencing of IFN-α, Tpo-
and control-treated LT-HSCs. 
3.8.2.3 Grhl1 expression under conditions of physiologic stress 
As outlined in chapter X, conditions of physiologic stress such as in response to bleeding, infections 
or inflammation may result in the loss of mature blood cells and in the activation of HSCs. To 
investigate Grhl1 expression of highly purified LT-HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-, 
CD34-) in response to stress, we experimentally induced HSC activation in vivo using Tpo and IFN-
α treatment (Baldridge et al., 2010; Essers et al., 2009; Yoshihara et al., 2007) and performed high-
throughput RNA sequencing comparing normal HSC biology as well as FA HSC biology to the 
respective stress conditions (Lier and Milsom, unpublished data). 
This revealed that under conditions of physiologic stress as induced by Tpo- or IFN-α treatment, 
Grhl1 expression was slightly downregulated in WT and FA HSCs (Figure 13 C), which indicates a 
possible role for Grhl1 in the stress biology of normal as well as FA HSCs. In WT HSCs Tpo-
treatment induced a slightly stronger downregulation of Grhl1 expression than IFN-α treatment, 
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which might hint towards a different role for Grhl1 in response to Tpo-induced stress. However, this 
remains to be investigated. 
3.8.2.4 Grhl1 expression during development 
In order to investigate the Grhl1 expression levels during HSC development, we made use of 
HoxB4-YFP-positive ES reporter cell lines, which were derived from the Hoxb4-YFP reporter mouse 
model (Hills et al., 2011) and analyzed for their gene expression profiles using microarray (Kaschutnig 
and Milsom, unpublished data). As the YFP-labeled HoxB4 expression is restricted to the definitive 
HSCs in these mice, during ES cell culture YFP expression marks developing HSCs. As before, three 
populations corresponding to mesodermal precursors of hematopoietic stem and progenitor 
hemogenic endothelium, HOXB4+ hematopoietic stem and progenitor hemogenic endothelium and 
downstream hematopoietic progeny of HOXB4+ cells were analyzed in the microarray. All three 
populations revealed no major differences in the mean expression levels of Grhl1 (Figure 14), which 
could have two implications. It could either mean that Grhl1 does not play a role during 
developmental processes of hematopoietic populations or that hematopoietic development requires 
Grhl1 expression independent of differential expression levels.  
 
Figure 14: Grhl1 expression during embryonic development. Mean expression levels of Grhl1 in HoxB4-
YFP-expressing embryonic stem cells during developmental specification from (1) primitive (HoxB4- CD41- 
Flk1+ c-Kit+) to (2) definitive/HSC-enriched (HoxB4+ CD41+ CD93+ c-Kit+) to more (3) progenitor-like cells 
(HoxB4- CD41+ c-Kit+). 
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3.9 Identification and characterization of deregulated genes in mouse #G1 
In clone #G1, we have identified the retroviral vector integration within the MDS1-EVI1 complex 
(Mecom), which is located on chromosome 3. This genetic locus harbors two distinct transcription 
start sites located almost 500 kb apart giving rise to the two transcript variants EVI1 (downstream) 
and MDS1 (upstream) (Nucifora et al., 1994). 
To confirm that deregulated expression of one of the Mecom transcript variants was responsible for 
the emergence of the dominant stem cell clone #G1, we performed gene expression analysis in whole 
bone marrow samples from mouse #G1 using quantitative RT-PCR (Figure 15). In this respect, 
quantitative RT-PCR analysis confirmed the aberrant expression of the Mecom transcript variant I 
(EVI1) by 60-fold upregulation in comparison to unmodified Fancg-/- bone marrow as a result of the 
integration into the MDS1-EVI1 complex locus. Therefore, we have identified Evi1 as a potential 
driver of clonal dominance in the context of FA stem cell biology. 
 
Figure 15: Aberrant expression of Evi1 transcript variant I in the dominant stem cell clone #G1. 
Relative mRNA expression levels of Evi1 transcript variants I and II in bone marrow isolated from mouse 
#G1. Fancg-/- bone marrow served as control. 
3.9.1 The ecotropic virus integration site 1 (Evi1) 
EVI1, also known as the ecotropic virus integration site 1, is a transcriptional regulator that was 
initially identified as a site of proviral insertion in murine myeloid leukemias (Morishita et al., 1988) 
and is one of the most commonly identified drivers of clonal dominance, both in mouse experiments 
and in patients taking part in clinical gene therapy trials (Kustikova et al., 2005; Ott et al., 2006). 
Therefore, integration of the retroviral vector into this genetic locus can be interpreted as a positive 
control, which confirms the reliability of our study design. 
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Evi1 is a master regulator of hematopoiesis with a suggested function in myeloid differentiation, 
apoptosis, HSC quiescence and proliferation (Glass et al., 2014). However, the underlying molecular 
mechanisms still remain unclear and additional studies will be required. 
The oncogenic function of Evi1 is well established and chromosomal rearrangements involving the 
human gene on chromosome 3q26 that may activate Evi1 expression, have been associated with 
MDS, a slowly developing clonal disorder that can progress to hematopoietic cancer of poor 
prognosis (Groschel et al., 2010; Lugthart et al., 2010). The role of Evi1 in the pathogenesis of 
leukemia was mostly addressed using mouse models transplanted with retroviral-transduced Evi1-
expressing bone marrow cells. Overexpression of the gene product in murine models led to the 
development of MDS but was not sufficient to induce leukemia on its own (Buonamici et al., 2004; 
Cuenco and Ren, 2004) suggesting that additional cooperating hits are required for leukemic 
transformation (Haferlach et al., 2011; Maetzig et al., 2011; Modlich et al., 2005; Wolf et al., 2013). 
Since Evi1 was also frequently overexpressed in AMLs from FA patients, the genetic instability 
phenotype of FA patients may provide the necessary environment for leukemic transformation 
(Meyer et al., 2011; Meyer et al., 2007; Raynaud et al., 1996b). This suggests that EVI1 might 
confer a competitive advantage to FA cell clones. In addition, the pathologic functions of Evi1 are 
also relevant to the development of solid tumors as Evi1 expression was identified in epithelial 
cancers such as ovarian cancer, lung cancer and esophageal cancer (Brooks et al., 1996; Imoto et al., 
2001; Jazaeri et al., 2010; Yokoi et al., 2003) 
3.9.1.1 Evi1 expression levels under homeostatic conditions 
In order to look at the pattern of Evi1 expression across different tissues and cell lines, we consulted 
the BioGPS gene annotation portal (www.biogps.org), which provides a huge collection of gene 
expression data on a variety of biological samples. In this data, we saw highest expression in the 
pluripotent mouse embryonic fibroblast cell line C3H10T1/2 (Figure 16). In addition, Evi1 
expression was detectable in pancreas and bladder. 
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Figure 16: Evi1 expression across different tissues and cell lines. Red arrow indicates pronounced 
expression of Evi1 in the pluripotent mouse embryonic fibroblast cell line C3H10T1/2. 
In the hematopoietic system, Evi1 is differentially expressed between HSCs and downstream MPPs 
as identified in gene expression data of hematopoietic populations, which was generated by high-
throughput RNA sequencing through the collaborative effort of the groups of Andreas Trumpp, 
Michael Milsom and Daniel Lipka at the German Cancer Research Center and the members of the 
group of Jerome Krijgsfeld at the European Molecular Biology Laboratories in Heidelberg (Cabezas-
Wallscheid et al., 2014). As illustrated in Figure 17 A, Evi1 presented a comparably high expression 
in the HSC compartment at the RNA level when compared to the progenitor cell populations. This 
suggests a functional role for Evi1 in HSC biology. In comparison to HSCs, Evi1 expression is about 
2.1-fold decreased in the MPP1 population and about 4-fold in the in MPP2/3/4 populations. 
According to this expression pattern, Evi1 is likely to be involved in regulating HSC-specific 
processes such as HSC self-renewal, quiescence and differentiation. 
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Figure 17: Evi1 expression levels and methylation pattern in HSC and progenitor populations. 
(A) Mean Evi1 expression levels in LT-HSCs and progenitor populations MPP1 – 4 as obtained by high-
throughput RNA sequencing. (B) Evi1 methylation pattern in LT-HSCs and MPP1 - 4 generated by 
tagmentation-based whole genome bisulfite sequencing. Red box highlights the transcription start site of Evi1 
transcript variant I with differential methylation pattern across HSC and MPP populations (C) Mean Evi1 
expression levels in FA and WT LT-HSCs under physiologic stress conditions as obtained by high-throughput 
RNA sequencing of IFN-α, Tpo-and control-treated LT-HSCs. 
3.9.1.2 Epigenetic regulation of Evi1 expression 
In order to add further evidence for a role of Evi1 in regulating HSC differentiation, we investigated 
the epigenetic regulation of the chromatin structure at the Mecom locus, on the long arm of 
chromosome 3 in sub band A3, across the individual hematopoietic stem and progenitor cell 
populations. Therefore, we used a dataset on the methylation pattern of hematopoietic stem and 
progenitor cells, which was generated by Daniel Lipka using tagmentation-based whole genome 
bisulfite sequencing (Cabezas-Wallscheid et al., 2014; Lipka et al., 2014). This data revealed a 
relatively broad unmethylated region around the transcription start site of the Mecom transcript 
variant I (Figure 17 B), which might be relevant in regulating the transcription of Evi1 (highlighted 
by a red box). In addition, this area displayed several differentially methylated regions across the 
individual hematopoietic stem and progenitor cell populations (highlighted by a red box), which 
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strongly indicates that Evi1 undergoes changes in DNA methylation during the individual 
differentiation steps from HSCs to the MPP populations. Furthermore, we found several additional 
distinct differentially methylated regions distributed across the whole Mecom locus. 
3.9.1.3 Evi1 expression under conditions of physiologic stress 
We were also interested in the Evi1 expression under conditions of physiologic stress such as in 
response to bleeding, infections or inflammation, which rapidly activates HSCs in order to ensure the 
continued production of mature blood cells (Cheshier et al., 2007; Wilson et al., 2008). Here, we 
induced HSC activation experimentally with two agonists, IFN-α and Tpo, which mimic a stress 
situation (Essers et al., 2009; Yoshihara et al., 2007). In order to analyze the gene expression of 
highly purified LT-HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-, CD34-) under stress conditions, 
Amelie Lier performed high-throughput RNA sequencing of Tpo- and IFN-α-treated LT-HSC 
populations and compared normal HSC biology as well as FA HSC biology to the respective stress 
conditions (Lier and Milsom, unpublished data). This revealed two distinct findings for Tpo and IFN-
α. While Evi1 expression was upregulated in WT and FA HSCs in response to Tpo-treatment, IFN-
α treatment resulted in the opposite finding, e.g. a downregulation of Evi1 expression, in FA HSCs 
(Figure 17 C). In addition, IFN-α did not impact upon the expression levels of EVI1 in WT HSCs. 
With this data, we could show that Evi1 might be involved in the regulation of HSC maintenance in 
response to stress, in WT and FA mice since both demonstrated deregulated Evi1 expression levels in 
response to a physiologic stress stimulus. However, the underlying mechanisms may be different, 
depending on the type of stress the HSC has to face. 
3.9.1.4 Evi1 expression during development 
Next, we wanted to evaluate Evi1 expression levels during HSC development. Therefore, we explored 
a gene expression dataset on HoxB4-YFP-positive ES reporter cell lines generated by Paul Kaschutnig 
(Kaschutnig and Milsom, unpublished data). These HoxB4-YFP-positive ES cells were initially isolated 
from the Hoxb4-YFP reporter mouse model (Hills et al., 2011), therefore allowing for the 
identification of YFP-labeled HoxB4-expressing bona fide HSCs. In the microarray, three 
populations from primitive (HoxB4- CD41- Flk1+ c-Kit+) to HSC-enriched (HoxB4+ CD41+ CD93+ 
c-Kit+) to more progenitor-like cells (HoxB4- CD41+ c-Kit+) were analyzed (Figure 18). While Evi1 
expression levels were slightly increased in the primitive cell population, the HSC-enriched and the 
progenitor-like fraction remained comparable. This might indicate an importance for Evi1 during 
the early step of ES cell differentiation.  
  R E S U L T S  
47 
 
Figure 18: Evi1 expression during embryonic development. Mean expression levels of Evi1 in HoxB4-
YFP-expressing embryonic stem cells during developmental specification from (1) primitive (HoxB4- CD41- 
Flk1+ c-Kit+) to (2) definitive/HSC-enriched (HoxB4+ CD41+ CD93+ c-Kit+) to more (3) progenitor-like cells 
(HoxB4- CD41+ c-Kit+). 
3.9.2 Gene expression profiling of bone marrow sample #G1 
In addition to the genes that are located in close proximity to the retroviral integration site and 
within the defined 300 kb window, also genes outside this genomic location might have been 
deregulated by the strong enhancer activity of the retroviral LTRs. Indeed, it has been shown, that 
three-dimensional structures such as DNA supercoiling allow enhancer action over considerable 
genomic distances (Plank and Dean, 2014; Schoenfelder et al., 2010). One such example is the sonic 
hedgehog (Shh) enhancer, which displays with one megabase the so far greatest distance to its 
promoter (Lettice et al., 2003). Just recently, the c-myc locus was shown to be controlled by an even 
more distant hematopoietic stem and progenitor-specific enhancer region, which is located almost 
1.7 Mb away from its promoter region (von Paleske, doctoral thesis). Therefore, it is very likely that 
the retroviral vector integration might control gene expression of genes located at distal sites by a 
long-range chromosomal interaction and we have to take into consideration that the emergence of 
the dominant stem cell clone #G1, might not exclusively result from the insertionally upregulated 
expression of Evi1 transcript variant I. 
To address this aspect, we next aimed at investigating the global gene expression pattern in the bone 
marrow of mouse #G1 and performed comprehensive genome-wide expression analysis on RNA 
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isolated from total bone marrow cells of mouse #G1 using the Illumina Mouse Sentrix-6_v2_r3 
BeadChip Array. RNA isolated from total bone marrow of three individual Fancg-/- mice served as 
controls. Reverse transcription, as well as the expression analysis was performed by the Genomics and 
Proteomics Core Facility of the German Cancer Research Center. After normalization, which 
removes systematic variation from the data, we analyzed the gene expression pattern in #G1 and 
compared it to the Fancg_/_ control groups. This revealed 687 transcripts that were differentially 
expressed with a fold-change greater than 2 including 243 up-regulated transcripts and 484 down-
regulated transcripts. 
Using the differential gene expression data, we could confirm the transcriptional up-regulation of 
eGFP (2.5-fold up), which results from the expression of the fluorescent marker Venus in the 
retroviral vector (Table 3). In contrast to the quantitative RT-PCR analysis, which identified Evi 
transcript variant I, aberrant expression of Evi1 could not be confirmed with the differential gene 
expression data. This is most probably due to the fact that the Evi1 transcript variants are not 
distinguishable with the Illumina BeadChip array. 
In order to obtain a more comprehensive picture of the signaling networks that are changed in the 
dominant stem cell clone #G1, we performed a functional analysis of the 687 most variable genes 
(fold change > 2) using the integrated software suite MetaCore (Thomson Reuters). Gene ontology 
analysis of the upregulated genes highlighted the cellular response to stress as the most significantly 
changed pathway in stem cell clone #G1 (Figure 19 A). In addition, genes involved in the regulation 
of apoptosis, nucleosome organization and chromosome assembly were significantly enriched in the 
list of upregulated genes. These processes seem to play a role in the rescue of the inherent FA HSC 
defect. 
Under normal circumstances, the FA HSC defect would lead to cell depletion as a result of their 
inability to repair certain forms of DNA damage. As oxidative stress has recently been demonstrated 
as a source of DNA damage in HSCs, which ultimately leads to apoptosis in FA HSCs (Walter et al., 
2015) it might be possible that the dominant stem cell clone #G1 was able to overcome the defect by 
the upregulation of a mechanisms that protects the cell from oxidative DNA damage, for example by 
the upregulation of heat-shock proteins such as Hsbpa1a (13-fold up), Dusp1/MKP-1 (11.7-fold up) 
and Dnajc6 (2.8-fold) (Table 3). In addition, the cell might have found a mechanism to evade 
programmed cell death, for example by the upregulation of anti-apoptotic genes such as fosb/AP-1 
(20-fold), fos/c-fos (10-fold up) and Bcl-2 (2.2-fold up). In addition, Il-1β (5.3-fold up), which has 
been shown to activate HSCs into cell cycle and to induce HSC proliferation in vivo (Sujer, doctoral 
thesis), could have influenced the survival of the #G1 stem cell clone. 
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Gene sets that were significantly represented in the downregulated genes of stem cell clone #G1 were 





Figure 19: Most significantly changed gene ontology processes in stem cell clone #G1. (A) Gene 
ontology analysis of the upregulated genes in stem cell clone #G1. (B) Gene ontology analysis of the 
downregulated genes in stem cell clone #G1.  
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Table 3: Selection of differentially expressed genes in stem cell clone #G1 
Fold 
change 
Symbol Description Synonyms 
20,07 Fosb FBJ osteosarcoma oncogene B   
15,88 Eif2s3y eukar. transl. initiation factor 2, subunit 3, struct. gene Y-linked Tfy; Spy; Eif-2gy 
12,97 Hspa1a heat shock protein 1A Hsp70-3; Hsp72 
12,52 Egr1 early growth response 1 Zif268; NGFI-A 
12,46 Mylc2pl myosin light chain 2, prec. lymphocyte-specific, transcr. variant 2 PLRLC-A, -B, -C 
11,69 Dusp1 dual specificity phosphatase 1 erp; mkp-1; Ptpn16 
10,06 Fos FBJ osteosarcoma oncogene c-fos; D12Rfj1 
9,73 Tcrg-V4 T-cell receptor gamma, variable 4   
8,06 Gm525 gene model 525   
7,26 Ighg Immunogl. heavy chain (gamma polypeptide), transcript variant 1   
7,04 Plk3 Polo-like kinase 3   
6,90 Osm oncostatin M   
6,66 Cxcl2 chemokine (C-X-C motif) ligand 2 MIP-2a; Gro2 
5,99 Zfp36 zinc finger protein 36 Gos24; Nup475 
5,99 Bcl11b B-cell leukemia/lymphoma 11B, transcript variant 2 Rit1;  Ctip2 
5,92 Adam8 a disintegrin and metallopeptidase domain 8 MS2; CD156 
5,80 Rgs1 regulator of G-protein signaling 1 BL34 
5,78 Ybx3 Y box binding protein 3   
5,36 Junb Jun-B oncogene   
5,35 Jun Jun oncogene c-jun; Junc; AP-1 
5,26 Gm525 gene model 525   
5,26 Il1b Interleukin-1 beta catabolin 
⁞ ⁞ ⁞ ⁞ 
2,85 Dnajc6 DnaJ (Hsp40) homolog, subfamily C, member 6 mKIAA0473 
⁞ ⁞ ⁞ ⁞ 
2,50 eGFP enhanced green fluorescent protein   
⁞ ⁞ ⁞ ⁞ 
2,18 Bcl2  B-cell leukemia/lymphoma 2, transcript variant 2 Bcl-2 
⁞ ⁞ ⁞ ⁞ 
1,30 Evi1 ecotropic viral integration site 1 Evi-1;  Jbo 
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3.10 Identification and characterization of deregulated genes in mouse #A2 
In clone #A2, we have identified two retroviral vector integrations, one which was located on 
chromosome 8 and one on the X-chromosome. The genetic locus on chromosome 8 contained eight 
genes (Cdh13, Hsbp1, Mlycd, Osgin1, Necab2, Slc38a8, Mbtps1 and Hsdl1) whereas the 
X-chromosome revealed four additional genes (Gm8817, Tmsb4x, Tlr7 and Tlr8). 
To identify the genes that drive clonal dominance in mouse #A2 among the twelve potential 
candidates, we sought to investigate deregulated expression of genes upstream and downstream of the 
retroviral integrations in whole bone marrow samples from this particular mouse using quantitative 
RT-PCR (Figure 20). The results from this analysis revealed that the Oxidative Stress-induced 
Growth Inhibitor 1 (Osgin1) was about 3-fold upregulated and therefore the likely driver of clonal 
dominance in this mouse. 
 
Figure 20: Aberrant expression of Osgin1 in the dominant stem cell clone #A2. Relative mRNA 
expression levels of genes proximal to the retroviral integration site in bone marrow isolated from mouse #A2. 
Red bar indicates upregulated expression of Osgin1; grey bars represent expression levels of genes that were 
comparable to Fanca-/- control bone marrow. 
3.10.1 Oxidative stress-induced growth inhibitor 1 (Osgin-1) 
Osgin1, also referred to as OKL38 or bone marrow stromal cell-derived growth inhibitor (BDGI), 
was initially identified as a pregnancy-induced growth inhibitor with a major role in breast epithelial 
cell growth regulation and differentiation during pregnancy and tumorigenesis (Huynh et al., 2001). 
In addition, it was demonstrated to have an antiproliferative effect on human breast cancer cells by 
inducing cellular apoptosis and cell cycle arrest (Wang et al., 2005). These findings support Osgin1 
as a tumor suppressor gene, however the mechanisms underlying this effect remain largely elusive. 
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Furthermore, Osgin1 is an oxidative stress response protein with a pathophysiological role in chronic 
inflammatory diseases such as atherosclerosis. In this context, Osgin1 expression is induced by high 
superoxide levels and was suggested to protect cells against oxidative stress (Li R, 2007; Yan et al., 
2014). In response to oxidative stress or DNA damage, Osgin1 was shown to interact with p53 and 
translocate to the mitochondria in order to induce a cytochrome c release during apoptosis (Hu et al., 
2012; Yao et al., 2008). 
Loss or decreased levels of Osgin1 expression have been associated with the carcinogenesis of liver 
and kidney and could be correlated to an adverse outcome with shorter survival times of patients 
(Ong et al., 2007; Ong et al., 2004). Just recently, a nucleotide variation in the Osgin1 gene 
resulting in an amino acid substitution from arginine to histidine on codon 438, was identified in 
tumor tissue from patients with hepatocellular carcinoma. This Osgin1 variant was less effective in 
the translocation from nucleus and mitochondria, which reduced its apoptotic effect (Liu et al., 
2014). 
The role of Osgin1 in the hematopoietic system and in stem cell biology remains largely elusive. In 
addition, Osgin1 expression in the context of FA has not been studied yet. However, due to its 
suggested function as an oxidative stress response gene with a role in atherosclerosis, it may also be 
involved in the pathology of FA, in which oxidative stress signals can promote a collapse of the entire 
hematopoietic system leading to bone marrow failure. 
3.10.1.1 Osgin1 expression levels under homeostatic conditions 
For an overview on the relative expression levels of Osgin1, we explored the BioGPS gene annotation 
portal (www.biogps.org), which provides a huge collection of gene expression data on a variety of 
biological samples. Comparing different tissues, Osgin1 expression was found highest in liver, testis 
and adrenal gland (Figure 21). 
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Figure 21: Osgin1 expression across different tissues and cell lines. Red arrows indicate pronounced 
expression of Osgin1 in adrenal gland, liver and testis. 
As the role of Osgin1 in the hematopoietic stem and progenitor compartment has not been addressed 
to date, we were interested in the expression levels of Osgin1 in HSCs and MPPs. Therefore, we 
made use of a comprehensive gene expression dataset that was generated by high-throughput RNA 
sequencing through the collaborative effort of the groups of Andreas Trumpp, Michael Milsom and 
Daniel Lipka at the German Cancer Research Center and the members of the group of Jerome 
Krijgsfeld at the European Molecular Biology Laboratories in Heidelberg (Cabezas-Wallscheid et al., 
2014). These data revealed about 3-fold higher levels of Osgin1 in HSCs and MPP4 than in MPP2 
and MPP3 (Figure 22 A). 
3.10.1.2 Epigenetic regulation of Osgin1 expression 
Next, we investigated the methylation pattern of the Osgin1 locus, on the long arm of chromosome 
8 in the sub band E1, using the tagmentation-based whole genome bisulfite sequencing dataset on 
the hematopoietic stem and progenitor cells generated by Daniel Lipka (Cabezas-Wallscheid et al., 
2014; Lipka et al., 2014). This analysis identified a relatively broad hypomethylated region of 
approximately 10 kb upstream of the Osgin1 transcription start site, which was conserved 
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throughout from LT-HSCs to MPPs (Figure 22 B; highlighted by a grey box). In addition, the 
Osgin1 transcription start site also revealed a distinct differentially methylated region across the HSC 
and MPP3/4 populations (highlighted by a red box), which might indicate some relevance for 
Osgin1 in the regulation of HSC biology as HSCs seem to undergo changes in DNA methylation 
during differentiation towards multipotent progenitors. 
 
Figure 22: Osgin1 expression levels and methylation pattern in HSC and progenitor populations. 
(A) Mean Osgin1 expression levels in LT-HSCs and progenitor populations MPP1 – 4 as obtained by high-
throughput RNA sequencing. (B) Osgin1 methylation pattern in LT-HSCs and MPP1 - 4 generated by 
tagmentation-based whole genome bisulfite sequencing. Red box highlights the transcription start site of 
Osgin1 transcript variant I with differential methylation across HSC and MPP3/4 populations; grey box 
highlights a broad hypomethylated region, which was conserved throughout from LT-HSCs to MPPs 
(C) Mean Osgin1 expression levels in FA and WT LT-HSCs under physiologic stress conditions as obtained 
by high-throughput RNA sequencing of IFN-α, Tpo-and control-treated LT-HSCs. 
  R E S U L T S  
55 
3.10.1.3 Osgin1 expression under conditions of physiologic stress 
Next, we wanted to evaluate Osgin1 expression under conditions of physiologic stress such as in 
response to severe bleeding or infections, which rapidly activates HSCs in order to ensure the 
continued production of mature blood cells. Such a stress situation can be modeled using interferons 
or Tpo, which can induce HSC proliferation upon administration (Baldridge et al., 2010; Essers et 
al., 2009; Yoshihara et al., 2007). In order to analyze the gene expression of highly purified LT-
HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-, CD34-) under stress conditions, Amelie Lier performed 
high-throughput RNA sequencing of IFN-α- and Tpo-treated LT-HSC populations and compared 
normal HSC biology as well as FA HSC biology to the respective stress conditions (Lier and Milsom, 
unpublished data). This revealed that in response to both treatments, Osgin1 was down regulated 
both in WT and FA HSCs (Figure 22 C). This strongly suggests a role for Osgin1 in the stress 
biology of WT as well as FA HSCs. Although we observed comparable levels of downregulation in 
stressed FA and WT HSCs, the effect was much stronger in response to IFN-α when compared to 
Tpo treatment suggesting a more pronounced role for Osgin1 during the proinflammatory stress 
response. 
3.10.1.4 Osgin1 expression during development 
In order to investigate the Osgin1 expression levels during HSC development, we made use of 
HoxB4-YFP-positive ES reporter cell lines, which were derived from the Hoxb4-YFP reporter mouse 
model (Hills et al., 2011) and analyzed for their gene expression profiles using microarray by Paul 
Kaschutnig (Kaschutnig and Milsom, unpublished data). As the YFP-labeled HoxB4 expression is 
restricted to the definitive HSCs in these mice, during ES cell culture YFP expression marks bona 
fide HSCs. In the microarray, three populations were analyzed: A primitive population, which also 
contains mesodermal cells (HoxB4- CD41- Flk1+ c-Kit+), a more definitive population, which is 
enriched for HSCs (HoxB4+ CD41+ CD93+ c-Kit+) and a population of more progenitor-like cells 
(HoxB4- CD41+ c-Kit+). In this dataset, a major difference in the mean expression levels of Osgin1 
expression could be detected (Figure 23). While the expression levels of Osgin1 remain comparable 
in the primitive and in the progenitor-like cell population, Osgin1 is almost 4-fold upregulated in the 
HSC-enriched fraction. This suggests an HSC-specific role for Osgin1 during developmental 
processes. 
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Figure 23: Osgin1 expression during embryonic development. Mean expression levels of Osgin1 in 
HoxB4-YFP-expressing embryonic stem cells during developmental specification from (1) primitive (HoxB4- 
CD41- Flk1+ c-Kit+) to (2) definitive/HSC-enriched (HoxB4+ CD41+ CD93+ c-Kit+) to more (3) progenitor-
like cells (HoxB4- CD41+ c-Kit+). 
3.10.2 Gene expression profiling of bone marrow sample #A2 
As outlined in chapter 3.9.2, enhancer elements as contained in the LTRs of the retroviral SF91 
vector can elicit their effects over large genomic distances mediated by long-range chromosomal 
interactions. Therefore the emergence of the dominant stem cell clone #A2 might not exclusively 
result from the insertionally upregulated expression of Osgin1, but could also be the result of a 
change in gene expression of additional genes located at sites outside the 300 kb window that we 
have assessed. 
In order to address this aspect, we performed gene expression analysis on RNA isolated from total 
bone marrow cells of mouse #A2 was using the Illumina Mouse Sentrix-6_v2_r3 BeadChip Array. 
RNA isolates from total bone marrow of three individual Fanca-/- mice served as control samples. The 
Genomics and Proteomics Core Facility of the German Cancer Research Center performed reverse 
transcription, expression analysis as well as the removal of systematic variation in the microarray data 
by normalization. We analyzed the gene expression pattern in #A2 and compared it to the three 
Fanca-/- control groups in order to identify the differentially regulated genes. This revealed 1551 
transcripts that were differentially expressed with a fold-change greater than 2 including 706 up-
regulated transcripts and 851 down-regulated transcripts. 
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Using the differential gene expression data, we could confirm the transcriptional up-regulation of 
eGFP (28.2-fold up), which results from the expression of the fluorescent marker Venus in the 
retroviral vector (Table 4). In addition, also the 3-fold upregulated expression of Osgin1 as identified 
by quantitative RT-PCR could be confirmed with the differential gene expression data (2.9-fold up). 
Despite the slight difference in the level of the fold changes between the array and the quantitative 
RT-PCR data, this result reliably reflects the deregulated expression of Osgin1 in stem cell clone 
#A2. 
In order to identify the enriched biological processes in the dominant stem cell clone #A2, we 
performed a functional analysis on the 773 most variable genes with a fold change of more than 2.5 
using the MetaCore enrichment analysis tool (Thomson Reuters). For this analysis, we chose a more 
stringent threshold as opposed to the analysis of stem cell clone #G1 (refer to 3.9.2), where we used a 
threshold of 2.0, as many more differentially regulated genes were identified in stem cell clone #A1 
and we wanted to keep the overall number of genes comparable. Gene ontology analysis of the 382 
upregulated genes highlighted the response to stress as the most significantly changed process in stem 
cell clone #A2 (Figure 24 A), which together with the increased expression of Osgin1 (2.9-fold up; 
Table 4) indicates a defense mechanism towards oxidative stress. Since oxidative stress has recently 
been demonstrated to cause DNA damage and induce apoptosis in FA HSCs (Walter et al., 2015) 
the dominant stem cell clone might have upregulated a defense mechanism against oxidative DNA 
damage. Furthermore, we found increased levels of anti-stress genes such as Cxcl2 (14-fold up) and 
Dusp1 (4.2-fold up) as well as the heat-shock proteins Dnajb2 (4.2-fold up), Dusp1 (4.2-fold up) 
and Serpinh1 (3.8-fold up) among the top upregulated candidates (Table 4). In addition, cell cycle 
regulators such as Cdkn1a (8.2-fold up), Plk3 (7-fold up), Gas6 (5.7-fold up), Cdkn2a/p16 (3.9-fold 
up) and Il-1 beta (3.6-fold up) as well as anti-apoptotic genes such as fosb/AP-1 (7.2-fold up) might 
indicate a mechanism that promotes cell cycle progression and proliferation while suppressing 
programmed cell death. 
Gene sets that were significantly represented among the 393 downregulated genes of stem cell 
clone#G1 were associated with the regulation of the immune system (Figure 24 B). 
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Table 4 Selection of differentially expressed genes in stem cell clone #A2 
Fold 
change 
Symbol Description Synonyms 
28,20 eGFP enhanced green fluorescent protein   
24,51 Cfd complement factor D (adipsin) Adn; DF; factor D 
14,05 Cxcl2 chemokine (C-X-C motif) ligand 2 Mgsa-b; Scyb; MIP-2a; Gro2 
12,10 Xist inactive X specific transcripts on chromosome X. 
 
9,65 Adipoq adiponectin, C1Q and collagen domain containing adipo; Acrp30; GBP28 
8,96 Mmp13 matrix metallopeptidase 13 MMP-13; Mmp1; Clg 
8,76 Cma2 chymase 2, mast cell Mcp10 
8,23 Cma1 chymase 1, mast cell Mcpt5; MMCP-5; Mcp-5 
8,18 Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) p21Cip1; P21; Waf1; CDKI 
7,72 Rgs1 regulator of G-protein signaling 1  BL34 
7,68 Mcpt4 mast cell protease 4 Mcp-4; MMCP-4 
7,19 Fosb FBJ osteosarcoma oncogene B 
 
7,00 Plk3 polo-like kinase 3 (Drosophila) CNK, FNK, PRK 
6,45 Igfbp5 insulin-like growth factor binding protein 5 IGFBP-5 
6,44 Esm1 endothelial cell-specific molecule 1 ESM-1 
6,34 Igfbp7 insulin-like growth factor binding protein 7 Fstl2; mac25 
6,17 Mcpt6 mast cell protease 6 MMCP-6; Mcp-6 
6,07 Egr1 early growth response 1 Zif268; NGFI-A 
6,04 Bglap2 bone gamma-carboxyglutamate protein 2 OG2; mOC-B 
5,90 Ctsk cathepsin K MMS10-Q; catK; Ms10q 
5,66 Gas6 growth arrest specific 6 Gas-6 
5,57 Cox6b2 cytochrome c oxidase subunit VIb polypeptide 2 
 
5,56 Mgp matrix Gla protein Mglap 
5,53 Bgn biglycan 
 
5,28 Bglap1 bone gamma carboxyglut. protein 1, transcript variant 2 OC; mOC-A; Bglap; OG1 
5,28 Sparc secreted acidic cysteine rich glycoprotein Osteonectin, BM-40 
5,28 Ctla4 cytotoxic T-lymphocyte-associated protein 4 Ctla-4; Cd152; Ly-56 
4,60 Cxcl14 chemokine (C-X-C motif) ligand 14 
 
4,51 Tnfaip3 tumor necrosis factor, alpha-induced protein 3  A20; Tnfip3 
4,23 Dnajb2 DnaJ homolog, subfamily B, member 2, transcr. var. 2 
 
4,19 Dusp1 dual specificity phosphatase 1 erp; mkp-1; Ptpn16 
4,14 Ccl4 chemokine (C-C motif) ligand 4 
Scya4; Mip1b; Act-2; MIP-
1B 
3,93 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 Raldh1; E1; Ahd2; Aldh1 
3,85 Cdkn2a cyclin-dependent kinase inhibitor 2A, transcr. var. 1 p16; MTS1; Arf; Pctr1 
3,82 Serpinh1 serpin peptidase inhibitor, clade H, member 1 HSP47 
3,60 Il1b Interleukin-1 beta catabolin 
3,41 Bbc3 BCL2 binding component 3 PUMA; PUMA/JFY1 
2,90 Osgin1 oxidative stress induced growth inhibitor 1 Okl38 






Figure 24: Most significantly changed gene ontology processes in stem cell clone #A2. (A) Gene 
ontology analysis of the upregulated genes in stem cell clone #A2. (B) Gene ontology analysis of the 
downregulated genes in stem cell clone #A2.  
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3.11 Target gene validation studies 
To investigate whether the genes, which were identified in the retroviral insertional mutagenesis 
screen, were able to confer a selection advantage to FA HSCs upon transplantation, we next 
performed target gene validation studies. For this purpose lentiviral expression constructs were 
generated to be able to perform gain-of-function or loss-of-function studies by constitutive 
overexpression or knockdown of target genes in vivo. 
3.11.1 Generation of lentiviral vectors for target gene validation studies 
For the purpose of target gene validation, we decided to use lentiviral vectors as they provide several 
advantages over other types of viral vectors. In general, lentiviral vectors allow for functional gene 
analysis by stable long-term expression of the transgene as they integrate their genome into the host 
cell and are potent in transducing both actively proliferating and non-dividing cells (Naldini et al., 
1996; Weinberg et al., 1991) while for example γ-retroviruses only transduce cells that divide shortly 
after infection (Miller et al., 1990; Roe et al., 1993). Therefore, they are particularly useful for studies 
in primary hematopoietic stem and progenitor cells, which do not divide very frequently in vitro 
during short term culture. In addition, the design of the lentiviral vectors allows for integration of 
relatively large genetic sequences of up to 9 kb. However the major advantage of using lentiviruses is 
their safety profile. In comparison to retroviral vectors, which have been found to convey mutagenic 
side effects in several human gene therapy trials and animal models (Cavazzana-Calvo et al., 2000; 
Hacein-Bey-Abina et al., 2003a; Li et al., 2002; Modlich et al., 2005; Nienhuis et al., 2006) lentiviral 
vectors show a different integration profile not associated with insertional mutagenesis (Montini et 
al., 2006). Since we aimed at investigating a genetic effect that was identified in response to 
insertional mutagenesis, we wanted to get around the integrational upregulation of random genes and 
only look at the effects of the overexpressed transgenes of interest. For this reason, lentiviral vectors 
are very well suited for the purpose of target gene validation studies in this context. 
The lentiviral vectors used in this study are based on the lentiviral “gene ontology” (LeGO) vectors, 
which are human immunodeficiency (HIV)-1 derived third generation lentiviral vectors that allow 
for stable transgene expression under the control of the spleen focus-forming virus (SFFV) 
promoter/enhancer (Weber et al., 2008). LeGOiV2, the vector backbone for the lentiviral vectors 
generated in this study, contains an encephalomyocarditis virus internal ribosomal entry site (IRES) 
for expression of the fluorescent marker gene Venus and a multiple cloning site (MCS) with the five 
restriction sites BamHI, EcoRI, SbfI, StuI, NotI (Figure 25 A). 
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Figure 25: Generation of lentiviral vectors for target gene validation. (A) Schematic representation of the 
LeGOiV2 vector backbone with the SFFV promoter, the multiple cloning site (MCS) with detailed 
representation of the restriction sites, the internal ribosomal entry sequence (IRES) and the Venus fluorescent 
reporter protein (B) Schematic representation of the LeGO(EFS-MCS)iV2 after insertion of the elongation 
factor 1 (EFS) promoter and the optimized MCS containing five additional restriction sites (represented in 
red). (C) Schematic representation of the three final lentiviral vector constructs LeGO(EFS-MCS)iV/T/G2 
containing the different marker proteins Venus, tdTomato and eGFP respectively. 
To facilitate the cloning procedure when integrating transgenes and to ensure stable but non-
mutagenic expression levels, LeGOiV2 was modified in order to obtain the LeGO(EFS-MCS)iV2 
vector as follows (Figure 25 B). In a first step, the SFFV promoter in the original construct was 
replaced with the elongation factor 1 (EFS) promoter (Kim et al., 1990), which allows for stable 
transgene expression, especially in cells of the hematopoietic compartment. In contrast to the 
retroviral enhancer-promoter SFFV, which has been shown to have significantly greater potential of 
activating neighboring promoters, the cellular EFS promoter derived from a human gene reduces the 
genotoxic risk and does not get silenced (Zychlinski et al., 2008). The EFS promoter was amplified 
from the SRS11-EFS-MGMT(P140K)-IRES-Venus plasmid and subcloned into the LeGOiV2 
vector. 
Next, five unique restriction sites (PspXI, XhoI, PmeI, AsiSI and XbaI) were added to the MCS of 
the LeGOiV2 to generate an optimized MCS with a total of nine unique restriction sites of which 
four are eight-base-cutters, five are six-base-cutters and two are blunt-end-cutters. This provides some 
flexibility for the integration of the selected target genes in a later cloning step. 
Furthermore, we aimed at developing a panel of vectors, each expressing a different fluorescent 
marker gene as we wanted to have the option of using several vectors simultaneously as well as 
choosing the color of the vector according to the experimental conditions such as antibody 
combinations in stainings for flow cytometry. For this purpose, the newly generated EFS-MCS 
cassette was subcloned into the LeGOiT2 and LeGOiG2 vector backbones in order to generate two 
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additional versions of the vector, LeGO(EFS-MCS)iT2 with the fluorescent tdTomato-cassette and 
LeGO(EFS-MCS)iG2 with the fluorescent eGFP-cassette (Figure 25 C). This provides some 
flexibility in terms of colors as the expression of the inserted transgenes can be monitored by either 
Venus-, tdTomato- or eGFP expression according to the type of vector used in the experiment. 
3.11.1.1 Subcloning of Osgin1 
Out of the target genes, which were identified in the insertional mutagenesis screen, we decided to 
subclone Osgin1 as the most interesting candidate into the LeGO(EFS-MCS)iV/T/G2 vectors in 
order to obtain expression vectors for overexpression of Osgin1 in vivo. 
The full-length cDNA sequence for murine Osgin1 was purchased from the Mammalian Gene 
Collection (MGC). The MGC clone with the ID 37844 was obtained in the pCMV-SPORT6 
vector and correctness of the sequence was confirmed using sanger sequencing with the M13 forward 
and reverse primers. Blasting of the sequencing against the murine genome confirmed that this 
cDNA clone picked up all five splice variants of Osgin1. In order to subclone Osgin1 into the 
LeGO(EFS-MCS)iV/T/G2 vector, EcoRI and XhoI restriction enzymes were used to cut insert and 
vector (Figure 26 A). Presence of the insert resulting in the LeGO(EFS-Osgin1)iV/T/G2 vector was 
confirmed with a test digest using EcoRI and XhoI. Gel electrophoresis identified a 1.5 kb fragment 
corresponding to the Osgin1 insert and the LeGO(EFS-MCS)iV2/iT2 and iG2 vectors of 
approximately 7.7 and 8.4 kb respectively. 
 
Figure 26: Subcloning of Osgin1 and Taf1b into the lentiviral vector backbone LeGO(EFS-MCS)iV2. 
(A) The full-length cDNA for Osgin1 was subcloned into the LeGO(EFS-MCS)iV2 vector using XhoI and 
EcoRI restriction enzymes (B) The restriction digest for the generation of the LeGO(EFS-Taf1b)iV2 vector 
was set up using AleI and EcoRI restriction enzymes. 
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3.11.1.2 Subcloning of Taf1b 
In addition to Osgin1, we also generated a lentiviral overexpression construct for Taf1b. For this 
purpose, the group of Ingrid Grummt at the German Cancer Research Center provided the full-
length cDNA sequence for murine Taf1b, which was contained in the pTβ-FLAG-mTaf168 vector 
(ID 1059). The identity of the construct was verified by DNA sequencing using a set of customized 
primers that allow generation of a full-length sequencing product. In order to subclone Taf1b into 
the LeGO(EFS-MCS)iV/T/G2 vector backbone, a restriction digest was set up with AleI and EcoRI 
(Figure 26 B) to isolate the 2 kb fragment corresponding to Taf1b from the pTβ-FLAG-mTaf168. 
To linearize the LeGO(EFS-MCS)iV/T/G2 vectors, PmeI and EcoRI enzymes were used. However, 
so far we were not yet successful in generating the ligation product LeGO(EFS-Taf1b)iV/T/G2. 
3.11.2 Production of lentiviral Osgin1 overexpression vectors 
The generated replication-deficient HIV-derived lentiviral vectors, which contained the candidate 
target gene Osgin1 (LeGO(EFS-transgene)iV2) and the corresponding empty control vectors 
(LeGO(EFS-MCS)iT2) were produced by transient co-transfection of the vector plasmids, envelope 
and packaging constructs into human embryonic kidney 293T producer cells using calcium 
phosphate co-precipitation (Figure 27). Due to safety concerns, the viral components were delivered 
on three separate plasmids (Naldini et al., 1996): the lentiviral expression construct, the Gag/Pol 
packaging plasmid pSPAX2 and the envelope plasmid pMD2.G. The lentiviral expression plasmid 
encodes the LeGO(EFS-transgene)iV2 construct while the pSPAX2 expresses the structural genes Gag 
and Pol and the regulatory Tat and Rev components, which are necessary for the packaging and 
replication process of the lentiviral vectors respectively (Zufferey et al., 1997). To obtain a broad 
tropism as well as vector particle stability, the viral particles were pseudotyped with the ecotropic 
envelope plasmid pMD2.G, which is derived from the G-protein of the vesicular stomatitis virus 
(VSV-G) (Burns et al., 1993). All virus stocks were harvested, concentrated by ultracentrifugation 
and re-suspended in serum-free medium for long-term storage. 
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Figure 27: Production of lentiviral overexpression vectors. Lentiviral particles were produced by transient 
co-transfection of the human embryonic kidney producer cell line 293T with the desired expression construct 
(LeGo(EFS)iV2, the packaging plasmid (pSPAX2) and the envelope plasmid (pMD2.G). 
Since we found that the initial protocol, which was routinely used for the production of lentiviral 
vectors for in vitro applications in our laboratory, was not sufficient to generate high viral titers that 
efficiently transduce primary bone marrow cells in vivo, we aimed at optimizing the original protocol. 
In order to obtain high lentiviral titers, we first of all increased the overall virus yield by increasing 
the number of transduced human embryonic kidney 293T cells. For a better handling during 
transfection and also afterwards during medium changes and virus harvest we switched from 10 cm 
cell culture dishes to T175 cell culture flasks by scaling up the individual components used in the 
transfection protocol. In addition, the optimal ratio of the components in the transfection mixture 
was evaluated by adjusting the amounts of the lentiviral plasmid, the packaging plasmid and the 
envelope plasmid. LeGO(EFS-MCS)iT2 was used as a sample vector to investigate the potency of the 
pseudoviral particles generated according to the three different transfection protocols A, B and C 
(Figure 28). In contrast to the above mentioned standard protocol for lentiviral production, 
LeGO(EFS-MCS)iT2 pseudoviral particles, which were generated to test the efficiency of the 
different transduction mixtures, were not concentrated using ultracentrifugation and frozen 
immediately upon harvest on day three. The efficiency of the viral particles was evaluated following 
limiting dilution transduction of murine 3T3 cells using flow cytometry according to the percentage 
of transduced cells (Figure 29 A) 
As shown in Figure 28, the highest transduction efficiency was obtained with viral particles that were 
produced using transfection mixture B with a titer of 9.6 x 105 transducing units/ml. Therefore, the 
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production of all lentiviral overexpression vectors and corresponding control constructs was based on 
protocol B. 
 
Figure 28: Evaluation of transfection mixtures for the generation of lentiviral vectors. Murine 3T3 cells 
were transduced with a limiting dilution of the pseudoviral particles that were generated according to the 
transfection mixtures A, B and C and evaluated using flow cytometry. Viral particles generated according to 
transfection mixture B (shown in red) resulted in the highest transduction efficiency. 
 
 
Figure 29: Analysis of lentiviral vector titers. (A) Representative FACS plots of the limiting dilution 
transduction of murine 3T3 cells with LeGO(EFS-MCS)iT2. Each FACS plots depicts the transduction 
efficiency at the indicated dilution of the virus (B) Range of viral titers obtained using limiting dilution 
analysis. 
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Furthermore, the virus titers for all lentiviral vectors packaged with the G protein of VSV-G and 
generated according to protocol B were determined following limiting dilution transduction of 
murine 3T3 cells using flow cytometry (Figure 29 A). 
As shown in Figure 29 B, high titers were readily obtained for LeGO(EFS-MCS)iT2 and the 
corresponding overexpression construct for Osgin1, LeGO(EFS-Osgin)iV2, ranging from 5 x 107 to 
2.3 x 108 transducing units/ml. These titers were used to evaluate the relative amount of virus needed 
for a certain infection rate in order to be able to transduce primary bone marrow LSK cells at 
comparable levels. 
3.11.3 Lentiviral overexpression of Osgin1 in LSK cells 
In order to transduce primary bone marrow cells with the lentiviral vectors generated in this study, 
LSK cells were isolated from either FA or WT mice and cultured on retronectin-coated plates in the 
presence of serum-free medium supplemented with 50 ng/ml mSCF, mTpo and hFlt3-L. For an 
efficient transduction it is necessary to keep the cells to be transduced in a relatively small volume of 
medium to increase the likelihood of cells coming into contact with the pseudoviral particles. LSK 
cells were subsequently transduced with the Osgin1 overexpression construct or the vector control at 
a MOI ranging from 10 to 50 aiming for approximately 5 x 106 transducing units/well. In order to 
enhance the transduction efficiency of the lentiviral particles, 4 µg/ml polybrene (Sigma-Aldrich) was 
added to the culture for a maximum of 12 hours. 
To test whether the LeGO(EFS-MCS)iT2 vector and the LeGO(EFS-Osgin1)iV2 constructs allowed 
for efficient marking of transduced primary LSK cells, the transduction efficiency of lentiviral vectors 
was evaluated 36 – 48 hours post-transduction by flow cytometry. The results from this analysis are 
shown in Figure 30. We could confirm that the EFS promoter provided high expression levels of the 
marker gene, particularly in LSK cells independent of whether the Osgin1 transgene was 
incorporated in the vector or not. Empty vector controls LeGO(EFS-MCS)iT2 as well as LeGO(EFS-
Osgin1)iV2 overexpression constructs achieved comparable levels of transduction ranging from 32 –
 90% of transduced WT as well as FA cells. As expected, increasing MOIs also resulted in higher 
expression levels as a direct consequence of the number of vector integrations. However, above an 
MOI of 34 the transduction efficiency was not increased anymore and the high viral load was also 
found to be cytotoxic as more dead cells were observed in the well 36 – 48h post transduction. 
Therefore, we chose to keep the MOIs below 34 and aim for a transduction efficiency of 
approximately 70%. 
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Figure 30: Transduction of primary bone marrow cells. Purified and FACS-isolated bone marrow LSK 
cells were transduced with the lentiviral vector constructs and evaluated for their transduction efficiencies 36 –
 48 hours post transduction. Table depicts the transduced cell types (WT/FA), the multiplicity of infection 
(MOI), the infectious units per well (IU/well) as wells as the evaluated transduction efficiency for each 
lentiviral vector construct. Transduced cells were transplanted into myeloablated WT recipient mice.  
3.11.4 Evaluation of Osgin1 overexpression in a competitive transplantation setting 
In order to provide proof-of-principle for the potential of Osgin1 to confer an engraftment advantage 
to FA or WT HSCs in vivo, the lentiviral overexpression construct for Osgin1 was utilized to assess 
the biological consequences of Osgin1 expression in a competitive transplantation experiment (Figure 
31 A). For this purpose, CD45.1+ LSK bone marrow cells were isolated from either FA or WT mice 
and transduced in vitro with the overexpression construct for Osgin1 or the empty control vector 
respectively at a MOI ranging from 10 to 39. The details for the transduction are provided in Figure 
30. Afterwards, the transduction rates of the CD45.1+ progeny cells were evaluated using flow 
cytometry and the cells were mixed according to the schematic in Figure 31 B in order to obtain a 
1:1 ratio of Osgin1-overexpressing and control-transduced cells. To investigate the biological 
consequences of the transgene overexpression in vivo and to assess whether Osgin1 was able to confer 
a competitive advantage to HSCs, Osgin1-overexpressing and control-transduced cells were harvested 
from the cell culture plates and injected into the tail vein of lethally irradiated CD45.2+ WT mice 
according to the schematic in Figure 31 A. 
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Figure 31: Overexpression of Osgin1 in a competitive transplantation setting. (A) Lentiviral vector 
constructs LeGO(EFS-Osgin1)iV2 and LeGO(EFS-MCS)iT2 were used to transduce CD45.1+ LSK cells, 
which were then mixed in a 1:1 ratio and transplanted into myeloablated CD45.2+ WT recipient mice. 
(B) Schematic example of how the transduced cells were mixed in order to normalize for unequal transduction 
efficiencies. (C) Time scale of the analysis of transplanted mice. The peripheral blood chimerism was 
evaluated at 12 and 24 weeks post transplantation and whole bone marrow cells were transplanted into 
secondary CD45.2+ recipients. These were analyzed 12 weeks post transplant. 
Figure 31 C depicts the time scale of the analysis. At 12 weeks post transplant, mice were subjected to 
an intermediate bleed and the percentage contribution of FA and WT cells to the peripheral blood 
was determined by flow cytometric analysis, taking advantage of the differential expression of CD45 
subtypes on the surface of transplanted CD45.1+ donor FA and WT leukocytes in contrast to the 
CD45.2+ recipient WT leukocytes (Figure 32 A). This analysis revealed a high peripheral blood 
chimerism for WT (Figure 32 B) donor cells in all six transplanted mice. In contrast, FA donor cells 
had engrafted the recipients to a much lower extend and only one mouse revealed a donor-graft 
comparable to WT levels (Figure 32 C). However, since we initially transplanted a mixture of 
transduced and untransduced cells, we next analyzed the ratio of Venus-positive Osgin1-
overexpressing donor cells and tdTomato-positive control-transduced donor cells and compared it to 
the bulk of untransduced donor cells in these mice (Figure 32 D). This analysis revealed neither 
Venus- nor tdTomato-expressing donor cells in the peripheral blood of WT and FA mice at 12 weeks 
post transplant (Figure 32 E+F), which clearly indicated that the transduced cells had been 
outcompeted by non-transduced cells during the initial weeks after transplantation. This is likely the 
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result of a very low input number of transduced cells. However, we still wanted to analyze the mice at 
a later time point in order to check for the gene-marked chimerism in the bone marrow. 
 
Figure 32: Analysis of the peripheral blood chimerism of FA and WT mice transplanted with a mixture 
of Osgin1-overexpressing and control-transduced cells at 12 weeks post transplant. (A) Gating scheme 
for the distinction of CD45.1+ donor and CD45.2+ recipient cells in transplanted animals. (B) Relative 
contribution of CD45.1+ WT donor cells (red) to the peripheral blood chimerism in transplanted animals. 
(C) Relative contribution of CD45.1+ FA donor cells (red) to the peripheral blood chimerism in transplanted 
animals. (D) Gating scheme for the distinction of Osgin1-overexpressing (Venus+) and control-transduced 
(tdTomato+) CD45.1+ donor cells in transplanted animals. (E) Relative contribution of CD45.1+ WT donor 
cell populations to the peripheral blood chimerism in transplanted animals. (F) Relative contribution of 
CD45.1+ FA donor cell populations to the peripheral blood chimerism in transplanted animals. 
At 24 weeks post transplant the mice were sacrificed and bone marrow cells were harvested in order 
to analyze the donor chimerism (Figure 33). Similar to the analysis of the peripheral blood chimerism 
at 12 weeks post transplant, the analysis of the bone marrow at 24 weeks post transplant revealed 
different donor chimerism for WT and FA (Figure 33 A). While almost all WT mice exhibited a 
donor chimerism above 90% (Figure 33 B) with one exception, which showed a lower chimerism of 
around 40%, FA donor cells had only engrafted two individuals. However when we looked at the 
ratio of Venus-positive Osgin1-overexpressing donor cells and tdTomato-positive control-transduced 
donor cells in the bone marrow of the mice (Figure 33 D), we saw the same picture as in the analysis 
of the peripheral blood chimerism at 12 weeks post transplant, for both WT and FA cells (Figure 33 
E+F). 
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Figure 33: Analysis of the peripheral blood chimerism of FA and WT mice transplanted with a mixture 
of Osgin1-overexpressing and control-transduced cells at 24 weeks post transplant. (A) Gating scheme 
for the distinction of CD45.1+ donor and CD45.2+ recipient cells in transplanted animals. (B) Relative 
contribution of CD45.1+ WT donor cells (red) to the peripheral blood chimerism in transplanted animals. 
(C) Relative contribution of CD45.1+ FA donor cells (red) to the peripheral blood chimerism in transplanted 
animals. (D) Gating scheme for the distinction of Osgin1-overexpressing (Venus+) and control-transduced 
(tdTomato+) CD45.1+ donor cells in transplanted animals. (E) Relative contribution of CD45.1+ WT donor 
cell populations to the peripheral blood chimerism in transplanted animals. (F) Relative contribution of 
CD45.1+ FA donor cell populations to the peripheral blood chimerism in transplanted animals. 
In addition, 300.000 total bone marrow cells were transplanted into irradiated secondary CD45+ WT 
recipient mice in order to restrict the analysis to a stem cell readout. With these mice, we are still 
waiting for the final observation endpoints at 12 weeks post transplant. 
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3.12 FA HSC growth defect in vitro 
FA is a fatal hereditary disorder with hematologic abnormalities such as aplastic anemia and 
thrombocytopenia, which originate from severely defective HSCs at the top of the hierarchy of the 
hematopoietic system. This HSC defect has been studied intensively using the various FA knockout 
mouse models that are available to date (Geiselhart et al., 2012). HSCs isolated from these mouse 
knockout models are severely compromised in numbers and demonstrate a severe HSC engraftment 
defect, when transplanted into lethally irradiated recipient mice. However, very little is known about 
the mechanistic basis of this defect and the consequences on HSC fate decisions. 
In order to investigate the behavior of FA HSCs and their progeny in a more simplified system, we 
aimed at assessing the inherent FA HSC defect ex vivo. In this respect, we first sought to examine the 
growth properties of highly purified Fanca-/- HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-) in vitro 
over 7 days under conditions of minimal cytokine stimulation with mSCF and mTpo. Under 
physiologic conditions SCF is produced by niche cells, such as fibroblasts and endothelial cells and 
acts as the ligand for the receptor tyrosine kinase c-Kit, which is highly expressed on hematopoietic 
stem and progenitor cells (Ashman, 1999). Tpo, which is produced by the liver, is the primary 
regulator of platelet generation, but also plays and important role in controlling the HSC 
compartment (Hitchcock and Kaushansky, 2014). As both, SCF and Tpo, are crucial for the 
maintenance of HSCs in vivo (Kimura et al., 1998; McCarthy et al., 1977; Qian et al., 2007; Thoren 
et al., 2008), these two cytokines provide the basis for the survival and expansion of primitive 
hematopoietic cells in vitro (Broudy, 1997; Kaushansky, 2006). In addition, we kept the cells under 
serum-free culture conditions using StemSpan SFEM culture medium (Stem Cell Technologies), 
which is recommended for the culture and expansion of mouse hematopoietic cells. 
Immediately after sorting of Lin-, c-Kit+, Sca-1+, CD150+, CD48- from Fanca-/- as well as from WT 
bone marrow, HSCs were plated into 96-well plates with 100 cells per well. In order to be able to 
follow their proliferation rates in vitro over the time course of 7 days, the initial input number of cells 
as well as the output number was determined using a flow cytometry-based technology suited for low 
input cell numbers. Using a defined number of fluorescence-coupled beads, which was added to the 
test sample and analyzed along with the cells, we were able to enumerate the relative cell counts of 
each sample by relating the number of cells counted to the total number of fluorescent beads 
analyzed. This analysis revealed that the proliferation rates of FA HSCs (36.31-fold increase) were 
drastically reduced in comparison to WT HSCs (83.73-fold increase), demonstrating that FA HSCs 
have a profound growth defect under these culture conditions (Figure 34). 
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Figure 34: FA HSCs demonstrate a severe growth defect in vitro. (A) Schematic representation of the 
experimental procedure. FA or WT LT-HSCs were isolated and subjected to in vitro culture for 7 days. 
(B) Fold-change of FA (red) and WT HSC (grey) proliferation in vitro over 7 days. 
Based on this data and in collaboration with the group of Michael Rieger at the LOEWE Center for 
Cell and Gene Therapy in Frankfurt we then went on to analyze the basis for this growth defect 
using in vitro cell fate tracking as developed by the group of Tim Schroeder (Schroeder, 2008; 
Schroeder, 2011). This method has already demonstrated great value in analyzing cell fate decisions 
such as the balance between self-renewal and differentiation or the instructive function of cytokines 
during hematopoietic lineage choice as it allows for continuous long-term tracking of individual 
single cells and their progeny over several days in vitro (Rieger, 2009; Thalheimer et al., 2014). 
In order to look at the growth defect of individual FA HSCs and their progeny we have isolated 
Fanca-/- LT-HSCs (Lin-, c-Kit+, Sca-1+, CD150+, CD48-, CD34-) together with the FACS core 
facility of the German Cancer Research Center in Heidelberg. Immediately afterwards the cells were 
shipped to Frankfurt and Frederic Thalheimer put them into in vitro culture supplemented with SCF 
and Tpo in order to follow their cell fate outcome using time-lapse microscopy (cell observer). 
Looking at the cell fate and lineage decisions of individual FA HSCs and their progeny, we found 
some significant differences between WT and FA HSCs already during the first two days of culture 
(Figure 35 A). While WT cells were happily growing and divided after about 1.5 days (1d14h) in 
culture and divided even a second (2d1h) and third (2d2h) time, the FA LT-HSCs, divided only 
once. In comparison to WT, FA HSCs divided about 4 hours earlier (1d10h), but then underwent 
cell death about 10 hours after their first cell division. This striking difference is further depicted in 
the representative dendrogram plot (Figure 35 B), which demonstrated a single cell division event for 
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the FA HSCs while WT HSCs were still proliferating. Overall we have observed very high rates of 
cell death in FA LT-HSCs, after the first and after the second in vitro division (Figure 35 C+D), 
which again revealed some drastic aspects of the HSC defect. This data demonstrates that 
programmed cell death is a frequent cell fate decision for Fanca-/- LT-HSCs as they are induced into 
cycle and is likely a major component of the strong negative selective pressure we observed when 
Fanca-/- LT-HSCs are asked to reconstitute lethally irradiated recipient mice. This novel insight into 
the cell biology of stem cells deficient in the FA DNA repair pathway was recently published as part 
of a peer-reviewed manuscript, which identifies stress hematopoiesis as a major driver of bone 
marrow failure in this disease (Walter et al., 2015). 
 
Figure 35: Cell fate of FA and WT LT-HSCs in vitro. (A) Representative images of the time-lapse video 
microscopy analysis of FACS-isolated FA and WT LT-HSCs. X indicates cell death. (B) Representative 
dendrogram plot for a single cell division event comparing WT and FA LT-HSCs. X indicates cell death. 
(C) Cumulative incidence of LT-HSC death after the first in vitro division. n= 126 (WT) and 187 (FA) cells 
tracked. (D) Cumulative incidence of LT-HSC death after the second in vitro division. n= 218 (WT) and 
263 (FA) cells tracked. **P<0.01 
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3.12.1 Outlook of the FA HSC in vitro growth defect 
Altogether the in vitro cell culture assay that we have developed allowed us to perform some initial 
analyses on the processes underlying the FA HSC defect. Initially, we found that the FA HSCs had 
reduced proliferation rates in the in vitro culture system. However, using time-lapse video 
microscopy, we could demonstrate that they were not as actively proliferating as their WT 
counterparts but instead were more rapidly dying. These data provide the basis for further analyses, 
which are intended to decipher the processes underlying the FA HSC defect. In this respect, this 
technique could serve as a potential surrogate assay to very quickly and efficiently screen for factors 
that are able to rescue or change the inherent FA HSC cell fate choice. Therefore, future studies 
evolve around overexpressing the genes, which were identified in the insertional mutagenesis screen, 
in the respective murine FA knockout background in order to analyze them for their potential to 
rescue the FA HSC defect. In addition, this will eventually allow us to add some mechanistic data to 
the question on how the target genes can compensate for the FA HSC defect in the insertional 
mutagenesis setting. 
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4 Discussion 
4.1 Retroviral insertional mutagenesis screen in the FA HSC murine 
transplantation model 
Retroviral insertional mutagenesis has the potential to randomly deregulate gene expression within 
the genome of transduced HSCs, thereby promoting clonal outgrowth of genetically modified cells 
that have gained a proliferative advantage over non-transduced cells (Kustikova et al., 2005) and 
provides the basis for genetic screens aiming to identify candidates with the potential to impact upon 
certain cellular processes relevant for HSC maintenance (Geiger et al., 2012; Kustikova et al., 2007). 
In this respect, we were the first to successfully conduct such a forward genetic screen in the context 
of FA HSC biology.  
Although insertional mutagenesis can facilitate clonal dominance in WT HSCs, it was not clear 
whether it could impact upon the biology of FA knockout HSCs in a murine transplantation model. 
Nonetheless, we successfully transduced purified FA HSCs in vitro with the replication-deficient 
SF91 murine γ-retrovirus. In light of the findings that murine FA HSCs are prone to excessive 
apoptosis during in vitro culture conditions, which involve cytokine stimulation to induce HSC 
proliferation required for γ-retroviral transduction (Li et al., 2005; Walter et al., 2015), the 
generation of transplantable gene-modified cells was a first step towards conducting a successful 
insertional mutagenesis screen in the FA HSC transplant model.  
Although we were able to recover the retroviral integrations from the transplanted mice, we could not 
perform a bioinformatics analysis for clusters of insertion sites across all mice as it was carried out in 
previous studies (Akagi et al., 2004). Although we had set up the screen with a relatively large 
number of mice, not enough integration sites could be recovered to reveal areas of the same genomic 
locations with a selective advantage for the cell. This is in part due to the FA HSC defect, which 
works as an additional selection pressure towards the successful engraftment of FA HSCs.  
On the other hand, this engraftment defect allowed us to base our analysis on the selection of 
individual mice in which gene-modification with the virus had resulted in the outgrowth of 
dominant stem cell clones despite the severe FA HSC engraftment defect. We were thus able to 
demonstrate that retroviral insertional mutagenesis had impacted upon the FA HSC biology in the 
murine transplantation model. 
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4.2 Dominant FA HSC clones are able to overcome the inherent FA HSC defect 
upon retroviral insertional mutagenesis 
As observed in patients undergoing clinical gene therapy trials for other hematologic diseases, 
dominant FA HSC clones arose in individual mice and took over the hematopoietic system as a result 
of the retroviral integration. In these mice, the proviral integrant had impacted upon the FA HSC 
biology resulting in the outgrowth of the genetically modified cell.  
We were able to select twelve individual mice and evaluate the clonality of the bone marrow samples. 
We could demonstrate that over the course of serial transplantations, polyclonal hematopoiesis in the 
primary recipient was restricted towards oligo- or monoclonal hematopoiesis with the outgrowth of 
dominant clones. These dominant clones appear to have been able to compensate for the inherent FA 
HSC engraftment defect and gain a growth advantage despite their presumed genomic instability.  
Although FA patients are predisposed towards malignant transformation, we could not detect any 
signs of leukemogenesis in primary nor secondary transplants, which demonstrates the non-
malignant expansion of the dominant FA HSC clones in all selected mice. 
4.2.1 Identification of retroviral integration sites in the genome of dominant FA HSC 
clones 
The molecular analysis of the dominant clones using nrLAM-PCR helped us to identify the genomic 
location of the retroviral integration sites and revealed the genes that are located in the vicinity of the 
integrant with the potential to influence FA HSC biology. Moreover, this method provided 
additional proof for the mono- to oligoclonal hematopoietic reconstitution of these mice and 
revealed the relative contribution of each individual integration site to the genome in each mouse.  
Due to the high selection pressure that we have observed in Fanca-/- and Fancg-/-, we focused our 
subsequent analysis on the three mice with evidence of clonal dominance in these transplant groups 
(#A1, #A2 and #G1). In these mice, we could demonstrate retroviral vector integration into the 
region of transcriptionally active or epigenetically accessible genes, as it has been suggested in the 
literature already (Bushman et al., 2005; Mitchell et al., 2004; Wu et al., 2003). In all four 
integration sites recovered from mice #A1, #A2 and #G1, we identified the vector integrations in 
genomic regions that show lower methylation than the genome-wide average in all subpopulations 
from HSCs to MPPs (refer to 3.8.1.2, 3.8.2.2, 3.9.1.2, 0), which may facilitate vector integration 
due to the transcriptionally permissive chromatin state. It is likely that these sites might be prone to 
the integration of retroviral vectors. 
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4.2.2 Dominant FA HSC clones allow the identification of deregulated genes in the vicinity 
of the proviral integration site 
Using quantitative RT-PCR and gene expression profiling, we could demonstrate that the normal 
gene expression was disrupted in the vicinity of the proviral integration in mice #A2 and #G1. In this 
respect, we could identify Osgin1 and Evi1 as the likely drivers of clonal dominance in these mice.  
Although, quantitative RT-PCR was able to clearly confirm the aberrant expression of Evi1 using 
specific primers to distinguish transcript variant I and II, we could not recapitulate this finding with 
the global gene expression data, which was probably due to the fact that the analysis of the Mecom 
locus considered both Evi1 isoforms and might not reflect what was observed using specific primers. 
For mouse #A1, we were not able to confirm deregulated expression of Taf1b and/or Grhl1 due to 
the lack of backup cell pellets for RNA isolation, however we could still select both for further 
functional characterization. 
Dominant FA HSC clones have upregulated stress response genes to compensate the FA HSC 
engraftment defect 
Gene expression profiling on the bone marrow of mice #G1 and #A2 provided insight into the 
potential mechanism underlying the compensation of the FA HSC engraftment defect. To these 
ends, we were able to show that both dominant FA HSC clones had upregulated genes that were part 
of the cellular stress response. We hypothesize that these mechanisms provided the dominant FA 
HSCs with an advantage in order to proliferate and engraft in the face of genome instability. In light 
of the recent finding, that FA HSCs suffer DNA damage as a result of their inability to tolerate and 
impact upon the production of intracellular reactive oxygen species and undergo apoptosis (Walter et 
al., 2015), the oxidative stress response would be a possible explanation of how the dominant FA 
HSC clones were able to overcome the inherent defect. In addition, gene ontology analysis confirmed 
the regulation of processes such as apoptosis, cell cycle regulation and chromosome assembly in the 
dominant stem cell clones of mice #G1 and #A2. 
In this context, the analysis of more dominant FA HSC clones would be of interest in order to add 
additional evidence to our hypothesis. For this purpose, back-up cell pellets from the mice 
dominating in the insertional mutagenesis screen (e.g. mice #C1 – #C6) could be analyzed and 
compared to non-transduced bone marrow cells from FA knockout mice. Moreover, also the cellular 
mechanism that allowed normal HSC clones #WT1 - #WT3 to expand would be of interest in order 
to see whether this was distinct from the mechanism that dominant FA clones employed. 
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4.2.3 The dominant FA clones provide insight into disease-specific biology 
Dominant FA HSC clones are able to overcome the FA HSC selection pressure and allow the 
identification of genes that are likely drivers of clonal dominance. However, the question arises 
whether the observed effects are truly disease specific and can, therefore, provide insight into the 
pathology of FA HSCs rather than also contributing towards clonal expansion in an insertional 
mutagenesis screen using WT cells.  
If we evaluate the outcome of the screen globally and look at all mice that have received transduced 
FA HSCs, we could only identify a few mice with dominant clones due to the extremely strong 
selection pressure in the FA model. This clearly argues for a disease-specific outcome of the screen, as 
such a selection pressure has not been observed in any of the previously conducted insertional 
mutagenesis screens.  
However, what has been observed in many WT screens already was the fact that Evi1, which led to 
clonal expansion in the dominant stem cell clone #G1, reliably drives clonal dominance upon 
retroviral insertional mutagenesis. This might mean that the mechanism of acquisition of clonal 
dominance in FA cells is not that different from WT cells. However, Evi1 has been found to be 
frequently overexpressed in AMLs from FA patients harboring 3q amplifications, suggesting that 
Evi1 may promote the survival and transformation of the FA stem cells (Meyer et al., 2011; Meyer et 
al., 2007; Raynaud et al., 1996a; Raynaud et al., 1996b; White et al., 2013). This suggests that Evi1 
would indeed be able to confer a disease-specific advantage to FA HSCs despite its established role in 
WT hematopoiesis and might therefore be interesting to follow up on.  
Moreover, we identified 3 novel hits, Taf1b, Osgin1, Grhl1, which have not been demonstrated to 
come up as frequent hits in WT screens (Akagi et al., 2004) and, therefore, hold the potential to 
provide insight into the pathology of FA or even represent targets for therapeutic intervention. 
4.3 Candidate target genes with the potential to drive clonal dominance in the face 
of genomic instability 
The candidate targets, which were identified in the screen, have demonstrated the potential to drive 
clonal dominance in the face of genome instability. This might have implications for therapeutic 
intervention in FA, but may also contribute towards the understanding of normal versus leukemic 
HSC biology. Therefore, we characterized the candidate target genes in order to evaluate whether 
these genes are relevant for normal hematopoiesis. Along those lines we were able to summarize gene 
expression data on HSCs under homeostatic and stress conditions as well as during development and 
provide epigenetic information on HSC differentiation for all four candidate target genes Osgin1, 
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Evi1, Taf1b and Grhl1. To functionally address the biological impact of the target genes on 
hematopoietic reconstitution in vivo, we generated lentiviral vector constructs for overexpression of 
the target genes in FA and WT HSCs. These could be employed for the overexpression of Osgin1 in 
a competitive transplantation setting. 
4.3.1 Taf1b 
4.3.1.1 Relevance of Taf1b expression for normal and stress hematopoiesis as well as during 
development 
Taf1b, a component of the transcription machinery for RNA polymerase I, which was shown to 
contribute to promoter specificity and gene regulation in cells (Heix et al., 1997; Zomerdijk et al., 
1994), has not been characterized in the context of HSC biology before. For the first time, to our 
knowledge, we provide a summary of different expression data for Taf1b on hematopoietic stem and 
progenitor cells in normal and stress hematopoiesis as well as during development. 
The pronounced expression of Taf1b across all hematopoietic cell types, including HSCs, might 
suggest a general role for Taf1b in the maintenance of the hematopoietic compartment. However, 
this precludes a specific function during hematopoiesis with relevance for a certain hematopoietic 
population. In contrast, we could identify a functional region among LT-HSCs and MPP3/4, which 
might be involved in the epigenetic regulation of HSC biology during hematopoiesis as well as 
slightly upregulated expression levels of Taf1b in response to a stress stimulus, which might indicate 
some relevance for HSC stress biology, both in WT and FA HSCs. 
In summary, Taf1b appears to have a broad function among various types of tissues. Although, the 
gene expression data of HSCs during different conditions led us to speculate that Taf1b might be 
equally relevant for all components of the hematopoietic compartment, functional data on its role 
during hematopoietic reconstitution will be needed to further support this initial speculation, 
especially since we lack proof for its deregulated expression in the dominant stem cell clone #A1. 
4.3.2 Grhl1 
4.3.2.1 Relevance of Grhl1 expression for normal and stress hematopoiesis as well as during 
development 
Grhl1 expression, which is important for murine embryonic development as well as in the pathology 
of skin tumors and neuroblastoma, has not been addressed in the context of hematopoiesis yet. Here, 
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we provide a first summary of Grhl1 expression in hematopoietic stem and progenitor cells under 
normal and stress conditions as well as during development. 
Grhl1 expression is very specific to certain types of tissue such as epidermis and prostate whereas it 
seems absent in most other tissues. Although expressed at very low levels in the hematopoietic stem 
and progenitor compartment, we could demonstrate differential expression levels with a peak in 
MPP2 cells and a stepwise decrease along with differentiation. In addition, Grhl1 expression was 
downregulated under conditions that mimic physiologic stress. This suggests that Grhl1 might be 
relevant for HSC differentiation as well as during HSC stress. However, the very low expression 
levels have to be taken into consideration since the differential expression levels, which were detected 
with RNA sequencing, could also be a result of insensitivity when reaching the detection limit. 
Although essential for murine development, Grhl1 is not differentially expressed during 
hematopoietic specification.  
Taken together, we are hesitant to suggest a role for Grhl1 during hematopoiesis but consider 
generating some functional data on its role during hematopoietic reconstitution in order to further 
address this issue. 
4.3.3 Evi1 
4.3.3.1 Relevance of Evi1 expression for normal and stress hematopoiesis as well as during 
development 
In the only dominant stem cell clone of the Fancg-/- experimental group (#G1), we could identify 
Evi1. Evi1 is one of the most commonly identified drivers of clonal dominance in WT HSCs, which 
serves as a positive control for our screen. The importance of Evi1 for the regulation of hematopoiesis 
has already been demonstrated. Here we add additional evidence for the importance of Evi1 during 
hematopoiesis as we could demonstrate differential expression of Evi1 between HSCs and 
downstream progenitor populations as well as during development. In addition, several regulatory 
regions in the epigenome of the Mecom locus may have implications for the regulation of Evi1 
transcription during HSC differentiation.  
Furthermore, we could provide novel insight into the role of Evi1 in regulating the response towards 
physiologic stress in both WT and FA HSCs as Evi1 expression levels were differentially regulated 
upon treatment with IFN-α or Tpo. In this context, Evi1 seems to be crucial for the stress response 
in FA HSCs. While it is known that FA HSCs are hypersensitive towards the inhibitory action of 
proinflammatory cytokines (Haneline et al., 1998; Rathbun et al., 1997) and readily undergo 
apoptosis (Dufour et al., 2003; Rosselli et al., 1994; Wang et al., 1998), WT HSCs can tolerate the 
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inflammatory stress much better than FA HSCs. Under such conditions, Evi1 levels are decreased in 
comparison to homeostatic conditions whereas they remain stable in WT HSCs. This suggests, that 
Evi1 is integral to the inflammatory stress response in HSCs, however FA HSCs fail to maintain Evi1 
levels. Likewise, FA HSCs demonstrate a similar defect in response to Tpo-treatment. Although Evi1 
expression is increased with Tpo, FA HSCs do not reach comparable levels of Evi1 as WT HSCs. 
Moreover, since we could demonstrate that increased Evi1 levels could provide a clonal advantage for 
the dominant stem cell clone #G1 during transplantation, we conclude that Evi1 is an important 
player of the HSC response towards physiologic stress. 
4.3.3.2 Evi1 as a driver of clonal dominance in the face of genome instability 
The role of Evi1 in the pathogenesis of leukemia and MDS is well established. In addition, Evi1 has 
implications for FA HSC biology as it was frequently overexpressed in AMLs from FA patients 
(Meyer et al., 2011; Meyer et al., 2007; Raynaud et al., 1996a). Although we could verify Evi1 
overexpression in the bone marrow of mouse #G1, we could not detect any signs of leukemogenesis 
in this mouse. This is consistent with the finding that overexpression of Evi1 is not sufficient to 
induce leukemia in murine models (Buonamici et al., 2004; Cuenco and Ren, 2004) and requires a 
collaborating hit (Haferlach et al., 2011; Maetzig et al., 2011; Modlich et al., 2005; Wolf et al., 
2013). However, we were surprised that the genomic instability phenotype of the Fancg-/- HSC, 
which would provide a perfect environment for oncogenic transformation, did not result in 
leukemogenesis in this particular mouse. In this respect it is not surprising that Evi1 confers a 
competitive advantage to the FA HSC clone #G1 as also cancer cells seem to exploit this mechanistic 
route, however it might be interesting to investigate how non-malignant expansion has been possible 
and which factors make the difference towards the expansion of cancer cells as it is not really known 
how Evi1 contributes to the transformation of cells. This finding suggests that Evi1 may impact on 
cell survival as a contributing component of leukemic transformation. However this remains to be 
investigated and we therefore interested in overexpressing Evi1 in the context of FA HSC biology 
using lentiviral vectors. 
4.3.4 Osgin1 
4.3.4.1 Relevance of Osgin1 expression for normal and stress hematopoiesis as well as during 
development 
We could demonstrate that among all the genes located in the vicinity of the two retroviral 
integrations in mouse #A2, Osgin1 was the only one that was overexpressed. As Osgin1 has already 
been implicated in the protection of cells against oxidative stress (Li R, 2007; Yan et al., 2014), 
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which has been demonstrated to cause DNA damage and HSC attrition in FA (Walter et al., 2015), 
the upregulation of Osgin1 would provide a likely explanation for the growth advantage of the 
dominant FA HSC clone #A2. Here we provide novel insight into the role of Osgin1 in the 
hematopoietic system under homeostatic and stress conditions as well as during different 
developmental steps, which, to our knowledge, has not been addressed yet. 
We could demonstrate that Osgin1 is expressed in HSCs as well as in hemogenic 
endothelium/HSCPs during developmental specification from embryonic stem cells. This strongly 
indicates that Osgin1 is relevant for the HSC compartment during homeostasis as well as during 
development. Furthermore, Osgin1 is differentially regulated during the individual steps of HSC 
commitment, which correlates with the identification of a relatively broad and conserved regulatory 
region in the epigenome of the Osgin1 locus and a differentially methylated region between the HSC 
and MPP3/4 compartment. These findings strongly indicate that the Osgin1 expression in HSCs is 
regulated through DNA methylation and provides evidence for a role of Osgin1 in HSC 
maintenance and differentiation. Osgin1 is also expressed in FA HSCs, approximately to the same 
level as in WT HSCs. In response to stress, Osgin1 levels are downregulated to comparable levels in 
both WT and FA HSCs, indicating that Osgin1 is involved in the regulation of the stress response in 
both WT and FA HSCs. Altogether, we conclude that Osgin1 is an essential factor for hematopoiesis 
as it is involved in HSC maintenance, differentiation as well as during HSC development and stress. 
4.3.4.2 Biological impact of Osgin1 overexpression in WT and FA HSCs during hematopoietic 
reconstitution 
To functionally address the biological impact of target gene overexpression in WT and FA HSCs 
during hematopoietic reconstitution following transplantation, we have overexpressed Osgin1 in a 
competitive transplantation experiment. However, so far we were not successful in obtaining 
functional data on the role of Osgin1 during this process. Although, we were successful in generating 
lentiviral vectors, which allowed us to overexpress Osgin1 in murine LSK cells, transplantation of 
transduced LSK cells did not contribute to our understanding of Osgin1 function for HSC 
engraftment and expansion yet. This is due to several reasons, which all result from the inadequate 
experimental setup of the transplantation assay. First of all, the input transduction frequency of 
Osgin1 as well as control-transduced cells was very low. Although WT donor cells could be detected 
in transplanted animals at 12 weeks post transplant, we could not detect any transduced cells in the 
peripheral blood regardless of whether input cells were transduced with the Osgin1-overexpressing or 
the control vector.  The same held true for FA donor cells, which still contributed to the graft at 12 
weeks post transplant but were negative for Osgin1 or the control virus. This strongly implicates that 
the input frequency of transduced cells was indeed too low as these cells were overgrown and 
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depleted by the non-transduced cells in the graft. This is not surprising since in relation to the 
transduced cells, the unmodified cells were overrepresented, which demonstrates another reason of 
why this experiment failed to generate sufficient results. The competitive setting of the experiment 
certainly adds another layer of selection pressure, which in retrospect appears too harsh in this 
context. Therefore, we suggest repeating this experiment in a less-competitive manner and with 
higher input transduction efficiency. With this revised set-up, we would aim to analyze the effects of 
Osgin1 overexpression on the engraftment of transplanted LSK cells and hope to be able to obtain 
insight into the role of Osgin1 in this context. 
4.3.4.3 Osgin1 as a driver of clonal dominance in the face of genome instability 
Osgin1 has been implicated in the biology of human breast cancer (Wang et al., 2005) as well as in 
the carcinogenesis of liver and kidney cells (Ong et al., 2007; Ong et al., 2004). In this context, loss 
of Osgin1 or decreased levels was associated with an adverse outcome whereas high levels of Osgin1 
were beneficial as they had an antiproliferative effect on the cancer cells. In the case of the dominant 
stem cell clone #A1, increased levels of Osgin1 also seemed beneficial as the normally defective cell 
had been able to expand without any evidence of malignant transformation. It is surprising that 
Osgin1 has an apoptotic effect on cancer cells while conferring an engraftment advantage to the FA 
HSC, which would normally undergo apoptosis and fail to engraft. As nothing is known about the 
effect of supraphysiologic Osgin1 levels on the hematopoietic system of both WT and FA mice, the 
above suggested overexpression experiments would provide an insight to this aspect. Moreover, 
Osgin1 was implicated in the pathophysiology of chronic inflammatory diseases such as 
atherosclerosis, in which Osgin1 expression is induced in response to oxidative stress in order to 
protect the cells from the oxidative damage (Li R, 2007; Yan et al., 2014). This aspect could help 
explaining the survival of the dominant FA HSC clone #A1, which could survive in the face of 
genomic instability, although this was recently shown to predispose the cells towards oxidative DNA 
damage (Walter et al., 2015). In addition, the results from the gene ontology analysis of clone #A1, 
which demonstrate the upregulation of cellular stress response mechanisms, add further evidence to 
the hypothesis on how the FA HSC clone #A1 could survive. According to these findings, it is very 
likely that the regulation of oxidative stress can provide a potential mechanism towards the 
compensation of the FA HSC defect. However, in order to fully proof this hypothesis further insight 
into the mechanistic regulation as well as the identification of additional key regulators will be 
needed. 
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4.3.4.4 Future studies on Osgin1 
We are especially interested in the analysis of Osgin1 as our most promising candidate target gene, 
which seems to play a major role in the maintenance of the hematopoietic system and, in addition, 
indicates some relevance to FA HSC biology. The mechanistic insight obtained from previous studies 
on Osgin1, which demonstrate its potential as an oxidative stress response gene make us confident to 
further assess the role of Osgin1 in the pathology of FA. Therefore, in addition to the overexpression 
experiments suggested above, it would also be interesting to obtain a genetic model for Osgin1 in 
order to be able to analyze the hematopoietic compartment in Osgin1-overexpressing mice. 
However, such a mouse model is, to our knowledge, not available to date and would have to be 
generated in a time-consuming effort. Crossing of Osgin1-overexpressing mice with the FA knockout 
mouse model would generate a valuable research tool that would allow us to study the effect of 
Osgin1 overexpression in the context of FA HSC biology. Likewise, the effects of perturbed Osgin1 
expression would be of interest to us. In this respect, a nucleotide variation in the Osgin1 gene, 
which was recently identified in tumor tissue from patients with hepatocellular carcinoma (Liu et al., 
2014), would be of help. This less effective variant of Osgin1, which results in an amino acid 
substitution from arginine to histidine on codon 438, could be overexpressed in the context of WT 
HSC biology and analyzed for its effect on the cell fate using the in vitro assay that we have 
established. Alternatively, a short-hairpin (sh)RNA targeting Osgin1 could be cloned into the 
lentiviral vector construct in order to knock down Osgin1 expression in WT HSCs 
4.4 Development of an in vitro assay with the potential to assess the impact of 
candidate target genes on HSC biology 
We were successful in developing an in vitro assay, which not only allowed us to reveal the cell fate of 
FA HSCs in culture, but also provides the basis for assessing the impact of target gene overexpression 
on HSC fate decisions. 
The insights gained from the in vitro cell fate tracking experiments, which we have conducted in 
collaboration with the group of Michael Rieger at the LOEWE Center for Cell and Gene Therapy in 
Frankfurt, have contributed to our understanding of the cell biology of stem cells deficient in the 
Fanconi anemia DNA repair pathway as recently published in a peer-reviewed manuscript (Walter et 
al., 2015). We could show that FA HSCs demonstrate a proliferative disadvantage when compared to 
WT HSCs and readily undergo apoptosis already after one day in culture. This led us to conclude 
that programmed cell death is a frequent cell fate decision for FA HSCs and a major driver of bone 
marrow failure in this disease. Moreover, the increased rates of moribund FA HSCs account for the 
strong negative selection pressure in the transplant setting, which we have applied in the insertional 
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mutagenesis screen. In this respect, the dominant FA HSC clones must have gained the ability to 
overcome this selection pressure by choosing an alternate and more advantageous cell fate as opposed 
to apoptosis in order to expand and reconstitute the hematopoietic system of the transplanted host 
mice. Therefore, the identified candidate target genes promise to reveal insight into the underlying 
mechanisms of the apoptosis escape in combination with the ability to compensate for the inherent 
FA HSC defect. These processes are of great interest to regenerative medicine as well as for the 
general understanding of HSC biology, especially in the context of hematologic disorders and ageing. 
Therefore, we are very much interested in investigating the potential of the candidate target genes to 
rescue or change the inherent FA HSC cell fate choice. In this respect, the in vitro cell culture assay 
that we have developed serves as a potential surrogate assay to overexpress the candidate target genes, 
which were identified in the insertional mutagenesis screen, in the respective murine FA knockout 
background using the lentiviral vectors that we have developed. With this we aim at providing some 
mechanistic insight into the compensation of the FA HSC defect in the insertional mutagenesis 
setting. Future work includes the inhibition of apoptosis to see how this impacts on FA cell survival 
in order to formally demonstrate in vitro and in vivo that apoptosis is the major route via which FA 
deficient cells are lost. Some of the tools, which would allow us to interrogate this are already in 
place. Together with Julia Detzer, a bachelor student in our lab, we have validated retroviral 
overexpression constructs for the anti-apoptotic Bcl2 family members Bcl2, Bcl-XL and Mcl1. In 
addition, conditional Bak/Bax double knockout mice, which are resistant to cell-intrinsic and 
extrinsic apoptosis have been obtained (http://jaxmice.jax.org/strain/006329.html). 
4.5 Summary and outlook 
The data presented in this thesis contributes to the understanding of the severe FA HSC defect, 
which results in hematologic abnormalities and bone marrow failure in FA patients. Using a murine 
FA transplantation model, we have demonstrated the possibility to compensate for this severe 
engraftment defect, which would normally result in the death of the FA HSCs upon transplantation. 
This was, to our knowledge, the first proof that FA HSCs can be rescued as a result of genomic 
provirus integration. Furthermore, we suggest four candidate target genes (Taf1b, Grhl1, Evi1 and 
Osgin1) with the potential to rescue the defective FA HSCs in the murine FA transplant setting and 
provide data on their relevance for HSC biology. In addition, we propose a likely mechanistic 
explanation of how the rescue of stem cells that would normally undergo apoptosis might have 
happened and provide the basis for future experiments aiming at further elucidating the mechanistic 
basis of FA HSC survival. 
Taken together, these findings have allowed us to build a model of how the FA HSCs might have 
gained a growth advantage in the insertional mutagenesis screen despite the genomic instability 
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phenotype (Figure 36). As we have recently shown, during transplantation and reconstitution, stem 
cells suffer DNA damage as a result of the replicative stress. Normal HSCs can deal with the stress 
and repair the damage whereas it remains largely unresolved in FA HSCs leading to decreased HSC 
function and cellular depletion (Walter et al., 2015). Since we have been able to detect dominant 
stem cell clones in some of the retroviral-transduced FA HSCs, we hypothesize that we have rescued 
the FA HSC defect by deregulation of cellular genes that might play a role in the pathology of FA 
HSCs. According to their likely mechanism of action, we postulate that these target genes might fall 
into different categories depending on which mechanistic aspect of FA HSC depletion they impact 
upon. 
A candidate target gene rescuing the phenotype by acting at the upstream part of our model 
indicated as target gene A (Figure 36), would act by limiting the amount of DNA damage that the 
cell was exposed to. For example, if metabolic reactive oxygen species were driving DNA damage in 
this setting, then the upregulation of detoxifying enzymes that eliminate the metabolic reactive 
oxygen species would rescue the HSC depletion phenotype. 
 
Figure 36: Schematic model of how the potential candidate target genes might rescue the FA HSC 
during transplantation and reconstitution. Upon transplantation, the FA HSC suffers DNA damage, which 
remains unrepaired due to the inactive FA DNA repair. The likely consequences are cell depletion or 
transformation. A potential candidate target gene may either (A) inhibit the cause of the DNA damage, 
(B) compensate for the DNA damage or (C) block the mechanism through which the cell is lost. 
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Genes acting at position B would act by enhancing the mechanism through which the DNA damage 
is repaired in the absence of a functional FA pathway, for example by the upregulation of a 
component of an alternate DNA repair pathway. 
Finally candidates acting at position C would inhibit the mechanism through which the damaged cell 
is lost, for example by upregulation of anti-apoptotic genes such as Bcl-2 or inhibitors of p53. 
However, this mechanism has the likely consequence of cellular transformation as the DNA damage 
can be accumulated if the apoptotic escape mechanism is blocked. 
The identification of such candidate target genes might have broader implications for FA patients as 
they could impact upon the pathology of FA HSCs. In this respect, the first two classes of target 
genes (A+B) may be of interest in terms of preventing the genetic instability that can lead to cell 
depletion or transformation. In contrast, the third class of target genes (C) may be useful to inhibit 
genes that promote the survival of genetically unstable cells. In this context, this would provide a 
suitable model for the investigation of how and why HSCs are lost. 
Moreover, similar mechanisms may be in play in tumor cells, in which the FA pathway is inactivated. 
Indeed, in several tumor types of non-FA patients, the FA pathway has been found to be inactivated 
in somatic cells as opposed to the germ line loss of function seen in FA patients. This is the case in 
breast and ovarian cancer patients, which present with a loss of heterozygosity in the downstream 
pathway members like FANCD1/BRCA2, FANCN/PALB2 or FANCO/RAD51C. Therefore, the 
identified candidates might also have some relevance to cancer in general as the FA pathway is 
potentially a common tumor suppressor pathway suggesting that the tumor cells acquire genetic 
instability through the inactivation of the FA pathway. 
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5 Material and methods 
5.1 Animals and animal experiments 
All animal experiments were carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996) and the European Community guidelines for the use of experimental animals. All 
procedures involving animals were registered with and approved by the Animal Care and Use 
Committees of the German Regierungspräsidium Karlsruhe für Tierschutz und 
Arzneimittelüberwachung (TVA no. G-89/13). 
5.1.1 Mouse lines 
The mouse lines were bred and kept under specific pathogen-free conditions (SPF) in individually 
ventilated cages (IVC) at the German Cancer Research Center (DKFZ, Heidelberg) animal facility. 
C57Bl/6 J (CD45.2+ WT mice) 
C57Bl/6 J mice are referred to as CD45.2+ WT mice. These mice were either purchased from Harlan 
Laboratories or were bred at the DKFZ in-house facility. 
B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+ WT mice) 
B6.SJL-Ptprca Pepcb/BoyJ mice are referred to as CD45.1+ WT mice. These mice were purchased 
from Charles River Laboratories, Italy or were bred at the DKFZ in-house facility. 
FA knockout mouse lines 
FA knockout mice are on a C57Bl/6 background and carry a knockout allele, which was generated 
by homologous recombination of the respective FA locus in embryonic stem cells. Therefore, the 
expression of the respective FA protein is repressed. 
In the course of this work, knockout mice for the Fanca-/- (Cheng et al., 2000; Wong et al., 2003), 
Fancc-/- (Chen et al., 1996) and Fancg-/- (Yang et al., 2001) proteins were obtained by breeding of 
heterozygous individuals. Homozygous FA knockout mice in the litter were identified by genotyping 
of the littermates. Therefore, total DNA isolated from mouse tail biopsies (5.8.1.2) was amplified by 
PCR (5.8.2.1) and analyzed by gel electrophoresis (5.10) on a 1 - 2% agarose gel. 
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5.1.2 Collection of murine primary material 
5.1.2.1 Peripheral blood sample collection 
Peripheral blood was obtained by puncturing the craniofacial capillary bed of the mice. 
Approximately 100 µl of peripheral blood were collected into a tube containing EDTA for blood cell 
assessment (5.2.1, 5.4.3.2). Approximately 0.5 – 1 ml of peripheral blood was collected when a 
sample of the blood cells was snap frozen (5.2.4.1) for later isolation of DNA (5.8.1.1) and analysis 
of vector integrations (5.9). In this case, the mice were sacrificed by cervical dislocation immediately 
after they had been bled. 
5.1.2.2 Removal of hind legs, vertebrae and sternum 
Mice were sacrificed by cervical dislocation and hind legs (femora, tibiae and ilia), vertebrae and 
sternum were removed and collected in ice-cold Iscove’s Modified Dulbecco’s Medium (IMDM; Life 
Technologies). 
5.1.2.3 Removal of mouse lymphoid organs 
From each mouse that was sacrificed during the course of this work, lymphoid organs such as spleen 
and thymus were checked in order to exclude hematologic abnormalities. In case of abnormal organ 
size, lymphoid organs were removed and kept on ice-cold IMDM (Life Technologies) for further 
analysis of weight and histology (5.2.3). 
5.1.2.4 Collection of tail biopsies 
Tail biopsies were collected from the offspring of FA knockout animals and the genomic DNA was 
isolated (5.8.1.2) for the purpose of genotyping (5.8.2.1). 
5.1.3 Transplantation of myeloablated mice 
For the transplantation of purified murine bone marrow cells (5.4) modified by viral transduction 
(5.6.5), host mice were lethally irradiated by whole-body irradiation with 10 Gy (2 x 550 rad) using 
the irradiator from the DKFZ animal facility (Buchler GmbH, Braunschweig, Cesium source). The 
transplantation of the respective number of cells contained in 200 µl of PBS was performed by 
injection into the tail vein of the myeloablated mice. Mice were kept on antibiotic (trimethoprim/ 
sulfamethoxazole) containing water for 3 weeks post transplantation. In addition, the skin of the 
mouse was treated with biafine cream for three days to prevent burns. 
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5.2 Analysis and conservation of murine primary material  
5.2.1 Analysis of the peripheral blood 
The peripheral blood of mouse lines (5.1.1) and transplanted animals (5.1.3) was collected (5.1.2.1) 
and analyzed as described below. 
5.2.1.1 Evaluation of peripheral blood cell numbers 
Peripheral blood cell counts were obtained in order to detect hematologic abnormalities using a 
Hemavet 950 FS veterinary blood cell counting machine (Drew Scientific). Therefore, an aliquot of 
30 µl peripheral blood was analyzed. In case of abnormal white blood cell counts, peripheral blood 
smears (5.2.1.2) and bone marrow cytospins (5.3) were performed. 
5.2.1.2 Peripheral blood smear 
Peripheral blood smears were generated in order to evaluate the cellular composition as well as the 
morphology of the peripheral blood sample and identify abnormal cells such as blasts. Therefore, a 
drop of approximately 5 µl of blood was placed on the surface of a glass slide, and spread along the 
surface of the glass slide in order to obtain a thin layer of blood. Glass slides were air-dried, fixed in 
Methanol and histologically stained with Wright’s stain (Sigma-Aldrich) according to the 
manufacturer’s instructions. 
5.2.2 Purification and analysis of murine bone marrow cells 
In order to purify murine bone marrow cells, hind legs (femora, tibiae and iliac crests), vertebrae and 
sternum were dissected by cleaning the bones from adherent soft tissue using a scalpel (Feather Safety 
Razor) and by removing the spinal cord. Bones were either crushed (5.2.2.1) or flushed (5.2.2.2) and 
the bone marrow cells were kept in 2% FCS/PBS (PAA Laboratories/Sigma-Aldrich) on ice. Murine 
bone marrow cells were further processed (5.4) in order to be analyzed by flow cytometry (5.5) and 
for their cell morphology (5.3) or transplanted into myeloablated mice (5.1.3). 
5.2.2.1 Crushing of murine bone marrow cells 
When bone marrow cells were pooled from multiple mice, bones were crushed in a mortar with 
IMDM (Life Technologies) and the cell suspension was filtered through a 40 μm cell strainer 
(Becton Dickinson) and washed by spin down and resuspension in 2% FCS/PBS (PAA 
Laboratories/Sigma-Aldrich). 
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5.2.2.2 Flushing of murine bone marrow cells 
When only a small sample of bone marrow cells was analyzed from an individual mouse, bones were 
harvested from one or two femurs by flushing the cells out of the femur into 1 or 2 ml 2% FCS/PBS 
(PAA Laboratories/Sigma-Aldrich) respectively using a 1 ml syringe (Terumo). The cell suspension 
was filtered through a 40 µm cell strainer (Becton Dickinson). 
5.2.3 Analysis of lymphoid organs and isolation of spleenocytes 
5.2.3.1 Evaluation of spleen weight 
In case of abnormal size, PBS storage buffer was removed from the outside surface of the spleen by 
gentle dabbing on tissue paper and the weight was determined. A weight of over 200 mg, which 
corresponds to approximately twice its average weight, was considered as abnormal. In this case, 
detailed analysis of the tissue histology (5.2.3.2) was carried out and spleenocytes were isolated 
(5.2.3.3) for further analysis. 
5.2.3.2 Histology of thymus and spleen 
In case of abnormal thymus size and/or spleen weight, organs were embedded in paraffin and sections 
were histologically stained for analysis of tissue morphology using Wright’s stain (Sigma-Aldrich) 
according to the manufacturer’s instructions. 
5.2.3.3 Isolation of spleenocytes 
To isolate spleenocytes from murine spleens (5.1.2.3) and get rid of the capsule, a piece of tissue was 
put into a 40 µm cell strainer (Becton Dickinson) on top of a cell culture plate with PBS and meshed 
up with the back of a syringe (Terumo). The mesh was washed with 2% FCS/PBS (PAA 
Laboratories/Sigma-Aldrich) and the cell suspension was thoroughly resuspended and kept on ice for 
cell counts using a cell counting machine such as the Hemavet 950 FS (Drew Scientific), cell 
morphology (5.3) and flow cytometry (5.5.1). 
5.2.4 Freezing of peripheral blood and bone marrow cells 
5.2.4.1 Snap freezing of peripheral blood and bone marrow cells 
To freeze down blood cells for later molecular analysis, aliquots of peripheral blood (5.1.2.1) and 
purified murine bone marrow cells (5.2.2) were lysed with ACK lysis buffer (Lonza) for 5 min at 
room temperature, spun down at 450 x g 4°C and resuspended in 2% FCS/PBS (PAA 
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Laboratories/Sigma-Aldrich). After an additional spin, the supernatant was discarded and the cell 
pellets were snap frozen in liquid nitrogen in order to be stored at -80°C for further use. 
5.2.4.2 Freezing of viable bone marrow cells 
Viable bone marrow cells were purified from the bones (5.2.2) and frozen using dimethylsulfoxide 
(DMSO; Sigma-Aldrich) as a cryoprotective agent. Therefore, bone marrow cells were resuspended 
in 2% DMSO/FCS (Sigma-Aldrich) and aliquoted into cryotubes (Thermo Scientific). Cryotubes 
were placed into cryogenic freezing containers (Nalgene) with 250 ml isopropanol (Sigma-Aldrich), 
which provide a cooling rate of 1°C per min in order to freeze down the cells slowly and reduce ice 
crystal formation. Cryotubes were kept in the freezing containers for approximately 24 hours 
at -80°C and subsequently transferred to the vapor phase of liquid nitrogen for long-term storage. 
5.3 Analysis of cell morphology using cytospins 
To analyze the cell morphology of purified bone marrow cells (5.2.2) or spleenocytes (5.2.3.3), 
cytospins were performed to concentrate the cells on object slides. Therefore, cytospin columns 
(Thermo Scientific) were set up on object slides and the cell suspension was prepared with 1 x 105 
cells/ml in 10% FCS/PBS (PAA Laboratories/Sigma-Aldrich). For two final cell concentrations on 
the slide, 100 µl of cell suspension corresponding to 1 x 104 cells was applied to the upper column 
and 200 µl corresponding to 2 x 104 to the lower column. Cytospins were performed at 28 x g for 
5 min and low acceleration in a cytospin cytocentrifuge (Thermo Scientific). Coverslips were air-
dried, fixed in Methanol and histologically stained with Wright’s stain (Sigma-Aldrich) according to 
the manufacturer’s instructions. 
5.4 Identification and isolation of stem cell populations 
5.4.1 Isolation of low-density mononuclear cells (LDMNCs) 
The LDMNCs were isolated from the purified murine bone marrow cells (5.2.2) by two steps of 
density gradient centrifugation using Histopaque 1083 (Sigma-Aldrich). 
Therefore, an equal volume of the bone marrow cell suspension was layered onto the surface of an 
equal volume of the ficoll in a falcon (Greiner; Sarstedt) or polystyrene tube (Becton Dickinson). 
After centrifugation at room temperature and 450 x g for 20 min without break, the opaque 
interphase and the first parts of the ficoll containing the LDMNCs were harvested and washed with 
ice-cold PBS. 
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5.4.2 Lineage depletion of murine bone marrow cells 
To further enrich the isolated LDMNC fraction (5.4.1) for the lineage-negative cells, the mature 
lineage-positive cells were excluded by lineage-depletion as described below. 
The samples were stained with a panel of rat anti-mouse biotin-conjugated lineage markers (see table 
Table 5) for a maximum of 1 hour at 4°C. After two washing steps, the sample was incubated with 
magnetic Biotin Binder Dynabeads (Life Technologies) for 45 – 60 min at 4°C. Subsequently, the 
lineage-positive cells bound to these magnetic polystyrene beads, were depleted using a Dynamag-15 
magnet (Life Technologies). All centrifugation steps were conducted at 450 x g for 5 min at 4°C. All 
wash steps were performed with ice-cold PBS supplemented with 2% FCS (PAA Laboratories). 
Table 5: Antibodies for lineage depletion 
Antigen Label Clone Company 
CD5  biotin 53-7.3 BioLegend 
B220 biotin RA3-6B2 BioLegend 
CD11b biotin M1/70 BioLegend 
CD8a biotin 53-6.7 BioLegend 
Gr-1 biotin RB6-8C5 BioLegend 
TER-119 biotin TER-119 BioLegend 
5.4.3 Cell surface stainings 
In order to stain the cell surface of peripheral blood and bone marrow cells, specific monoclonal 
antibody stainings were performed. Therefore, the cells were incubated with the respective panel of 
antibodies in a 2% FCS/PBS (PAA Laboratories/Sigma-Aldrich) solution at 4°C for 1 hour. 
Subsequently, the cells were washed two times with 2% FCS/PBS (PAA Laboratories/Sigma-Aldrich) 
and incubated with the dead cell marker 7-amino actinomycin D (7AAD, Life Technologies) in 
order to be able to exclude the dead cells from the analysis using flow cytometry (5.5). 
5.4.3.1 Stainings for the identification of stem cell populations 
To prospectively isolate LSK (lin-, c-Kit+, Sca-1+), HSC (lin-, c-Kit+, Sca-1+, CD48-, CD150+) or LT-
HSC (lin-, c-Kit+, Sca-1+, CD48-, CD150+, CD34-) fractions by flow sorting (5.5.2), lineage-depleted 
bone marrow cells (5.4.2) were stained for the respective cell surface markers using the antibody 
combinations outlined in Table 6. 
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Table 6: Antibodies for flow cytometric cell sorting of stem cell populations 
Antigen Label Clone Company 
Streptavidin PE - BD Pharming 
Sca-1 APC-Cy7 D7 eBioscience 
CD117 (c-Kit) APC 2B8 eBioscience 
CD48 PB HM48-1 BioLegend 
CD150 PE-Cy5 TC15-12F12.2 BioLegend 
CD34 FITC RAM34 eBioscience 
Abbreviations: allophycocyanin (APC), allophycocyanin-Cyanine 7 (APC-Cy7), fluorescein isothiocyanate 
(FITC), pacific blue (PB), phycoerythrin (PE), phycoerythrin-Cyanine 5 (PE-Cy5) 
5.4.3.2 Stainings for the identification of mature cells 
For the assessment of mature peripheral blood and bone marrow cells using flow cytometric analysis 
(5.5.1), samples were stained for lineage markers (CD4, CD8a, CD11b and B220). In order to 
distinguish host from donor cells after bone marrow transplantation using flow cytometry (5.5), 
peripheral blood and bone marrow samples were stained for the CD45.1 and CD45.2 cell surface 
markers. Therefore, the combination of monoclonal antibodies as listed in Table 7 was used.  
Antibody-stained peripheral blood and bone marrow samples were treated with 1 ml ACK lysing 
buffer (Lonza) at room temperature for 10 min to lyse erythrocytes. Subsequently, samples were 
washed with ice-cold PBS (Sigma-Aldrich) supplemented with 2% FCS (PAA Laboratories) and 
analyzed by flow cytometry (5.5). 
Table 7: Antibodies for flow cytometric analysis of mature cells 
Antigen Label Clone Company 
CD45.1 APC-Cy7 A20.1 eBioscience 
CD45.2 PB 104 BioLegend 
CD11b APC M1/70 eBioscience 
B220 APC RA3-6B2 eBioscience 
CD4 PE GK1.5 eBioscience 
CD8a PE 53-6.7 eBioscience 
B220 PE RA3-6B2 eBioscience 
Abbreviations: allophycocyanin (APC), allophycocyanin-Cyanine 7 (APC-Cy7), pacific blue (PB), 
phycoerythrin (PE) 
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5.5 Flow cytometry and flow cytometric cell sorting 
5.5.1 Flow cytometric analysis of cells 
Cells were analyzed by flow cytometry after cell surface staining (5.4.3) and resuspension in 
2% FCS/PBS (PAA Laboratories/Sigma-Aldrich) on either a LSR II (Becton Dickinson) or 
LSR Fortessa (Becton Dickinson) cell analyzer equipped with 350 nm, 405 nm, 488 nm, 561 nm, 
and 640 nm excitation lasers. Prior to analysis of multicolor samples, compensation was manually 
adjusted according to signals from OneComp eBeads (eBioscience) stained with single antibodies. 
For all experiments, dead cells were excluded by using 7AAD (Life Technologies). The analysis of the 
flow cytometric data was performed as described in 5.5.3. 
5.5.2 Flow cytometric cell sorting 
All sorting experiments were performed using a BD FACS Aria I, II or III flow cytometer (BD 
Biosciences) at the DKFZ Flow Cytometry Service Unit according to the gating strategy shown in 
Figure 37. 
 
Figure 37: Schematic of the flow cytometric cell sorting to prospectively purify the respective stem cell 
populations from murine bone marrow. Cells were gated according to forward and side scatter 
characteristics and doublets were excluded in order to enrich for lineage negative (lin-), LSK (lin-, c-Kit+, Sca-
1+), HSC (lin-, c-Kit+, Sca-1+, CD48-, CD150+) ors long-term (LT)-HSC (lin-, c-Kit+, Sca-1+, CD48-, 
CD150+, CD34-) fractions by flow sorting. In addition, gates for multipotent progenitor cells (MPPs) and 
short-term (ST)-HSCs are displayed. 
5.5.3 Analysis of flow cytometric data 
Analysis of flow cytometric data as obtained in 5.5.1 and 5.5.2 was performed using the FlowJo 
software version X (TreeStar). Analysis was performed on live cells gated according to forward and 
side scatter characteristics. 
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5.6 Cultivation and manipulation of cells 
5.6.1 In vitro culture of sorted bone marrow cells 
LSK cells, HSCs or LT-HSCs were purified from murine bone marrow (5.4), resuspended in media 
containing 1% Pen/Strep (Sigma-Aldrich), 2% L-glutamine (Gibco) and cytokines (Peprotech) as 
described individually and cultivated in low attachment suspension culture plates (Cellstar) at 37°C 
and 5% CO2 in a standard cell culture incubator. 
5.6.2 In vitro culture of adherent cell lines 
The adherent human embryonic kidney cell line 293T stably expressing the SV40 T-antigen and the 
293T-derived phoenix-GP cell line (Nolan Laboratory) were used for virus production (5.6.3). For 
virus titration (5.6.4), the murine embryonic fibroblast cell line 3T3 was used. 
All cell lines were cultured in DMEM growth media (Sigma-Aldrich) supplemented with 10% FCS 
(PAA Laboratories), 1% Pen/Strep (Sigma-Aldrich) and 1% L-glutamine (Gibco) in a standard cell 
culture incubator at 37°C and 5% CO2. Confluent plates of cells were split using trypsin-EDTA 
(Life Technologies) and further expanded with fresh media. 293T and phoenix-GP cells were 
cultured on 0.1% gelatine-coated (Sigma-Aldrich) tissue culture dishes. 
5.6.3 Transient calcium phosphate transfection of cells for virus production 
Retroviral (5.6.3.1) and lentiviral (5.6.3.2) supernatant was generated by transient calcium phosphate 
transfection of the respective cell lines according to the manufacturer’s protocol of the Calcium 
Phosphate kit (Life Technologies). Therefore, the respective cell lines were cultured as described 
(5.6.2). On the day before transfection, confluent plates of cells were split and the cells were seeded 
on plates in order to reach 70 – 80% confluency on the day of transfection. The respective 
transfection mixtures were prepared as individually described (5.6.3.1; 5.6.3.2). To obtain a fine 
precipitate of the transfection components, hepes buffered saline (contained in the kit) was 
thoroughly mixed with the transfection mixture and incubated for 45 min at room temperature. 
Meanwhile, the culture media was replaced with fresh media supplemented with 25 µM chloroquine 
(AppliChem) to improve the transfection efficiency. The transfection mixture was added dropwise to 
the cells and the transduced cells were incubated at 37°C and 5% CO2. In the morning of the next 
day, the culture media was changed to fresh culture media by carefully aspirating the transfection mix 
and adding fresh media. In the evening, the culture media was changed to collection media, which in 
addition to the components of the growth media contained 1% HEPES buffer (Life Technologies) 
and was adjusted to pH 7.8 – 7.9. From the morning of the next day onwards, the viral supernatant 
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of each plate was collected and filtered using a 0.45 µm filter (Merck Millipore). Viral particles were 
concentrated by ultracentrifugation, resuspended in the respective media and stored at -80°C. One 
aliquot was used for virus titration (5.6.4) 
5.6.3.1 Production of retroviral particles 
Retroviral supernatant was generated by transient calcium phosphate transfection of the phoenix-GP 
cell line (Nolan Laboratory) with the retroviral transfection mixture for each 10 cm diameter plate of 
cells receiving 8 µg SF91 γ-retroviral plasmid, 10 µg Gag/Pol packaging plasmid (M57DAW), 3 µg 
envelope plasmid (Eco) and 2M CaCl2. For details see 5.6.3. 
In the morning after the transfection, the retroviral supernatant of each plate was collected, stored at 
4°C and fresh collection media was gently added to the cells in order to be collected again in the 
evening. The morning as well as the evening harvests were combined, filtered using a 0.45 µm filter 
(Merck Millipore) and viral particles were concentrated by ultracentrifugation at 17.000 x g at 4°C 
overnight. In the morning of the next day, the supernatant was aspirated and the virus pellet was 
resuspended in IMDM (Life Technologies). 
5.6.3.2 Production of lentiviral particles 
Lentiviral supernatant was generated by transient calcium phosphate transfection of the 293T cells 
(5.6.3) with the transfection mixture containing 50 µg SF91 lentiviral plasmid, 37.5 µg Gag/Pol 
packaging plasmid (pSPAX2), 5 µg envelope plasmid (pMD2.G) and 2M CaCl2. For details see 
5.6.3. 
In the morning after the transfection, the lentiviral supernatant of each plate was collected, 
centrifuged for 10 min at 450 x g and 4°C to get rid of the cell debris and filtered with the 0.45 µm 
filter (Merck Millipore). Lentiviral particles were concentrated by ultracentrifugation at 
7.520.000 x g for 2 hours at 4°C and subsequently resuspended in StemSpan SFEM (Stem Cell 
Technologies) for long-term storage at -80°C. 
5.6.4 Viral limiting dilution transduction of murine 3T3 cells 
To evaluate the efficiency of the viral particles as generated in 5.6.3, a limiting dilution transduction 
of murine 3T3 cells was performed. 3T3 cells were cultured as described (5.6.2) and seeded on 6-well 
plates (Corning) with 100.000 cells per well. On the next day, the cells of two wells were harvested, 
combined and counted in order to note the average number of cells to be transduced. A limiting 
dilution of the virus to be tested was prepared with culture media and 8 µg/ml polybrene (Sigma-
Aldrich) and each virus dilution was added to the corresponding well. In the morning of the next 
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day, the media of the transfected cells was changed to fresh growth media without polybrene (Sigma-
Aldrich). Approximately 36 – 48 hours later, cells were harvested and resuspended in 2% FCS/PBS 
(PAA Laboratories/Sigma-Aldrich) in order to be analyzed using flow cytometry (5.5.1). The 
infectious units (IU) of the virus were calculated according to the dilution factor, the frequency of 
transduced cells, the count noted on the day of transduction and the total volume: 
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5.6.5 Viral transduction of LSK cells 
For the transduction of LSK cells with retroviral or lentiviral vectors as generated in 5.6.3.1 and 
5.6.3.2 respectively, low-density mononuclear cells were isolated from the bone marrow (5.4.1) and 
sorted for the LSK fraction as described (5.5.2). The efficiency of transduced cells was assessed using 
flow cytometry (5.5.1) at 36 – 72 hours post transduction. In this respect, untransduced control cells 
were used to adjust the flow cytometry settings. 
5.6.5.1 Transduction of LSK cells with retroviral vectors 
For the insertional mutagenesis screen murine LSK cells were transduced with the SF91 retroviral 
vector. Therefore, LSK cells isolated as described (5.5.2) were pre-stimulated by in vitro culture in 
IMDM (Life Technologies) culture medium containing 1% Pen/Strep (Sigma-Aldrich), 1% L-
glutamine (Gibco), 10% FCS (PAA Laboratories), 100 ng/ml recombinant murine SCF (Peprotech), 
100 ng/ml recombinant murine Tpo (Peprotech) and 100 ng/ml G-CSF (Amgen), for at least 
36 hours on low attachment suspension culture plates (Cellstar) at 37°C and 5% CO2. On day 3, 
cells were counted using the Neubauer chamber (Braun) and 300.000 cells were transduced with the 
retroviral vector at a MOI in the range of 1 - 15. Transduction of the indicated cell numbers was 
performed in 12-well cell culture plates (Corning) pre-coated with 4 µg/cm2 retronectin (TaKaRa) 
and with the addition of fresh cytokine-supplemented media. In detail, the virus was immobilized on 
the retronectin-coated plates by spin-down for 45 min at 880 x g and 24°C and the appropriate 
volume of thoroughly resuspended cells was added onto each well of the virus-coated plate. In 
addition, one well of cells was kept untransduced as a control. About 8 hours later, the same amount 
of virus was added to each well, except for the control well, in order to perform a second infection of 
LSK cells. Transduced cells were incubated until the next day at 37°C and 5% CO2. On day 4, the 
cells were harvested. 
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5.6.5.2 Transduction of LSK cells with lentiviral vectors 
For the transduction of murine LSK cells with lentiviral LeGO vectors, sorted LSK cells (5.5.2) were 
plated on Retronectin-coated low attachment suspension culture plates (Cellstar) and cultured with 
StemSpan SFEM (Stem Cell Technologies) culture medium containing 1% Pen/Strep (Sigma-
Aldrich), 1% L-glutamine (Gibco) and 50 ng/ml of each recombinant murine SCF (Peprotech), 
recombinant murine Tpo (Peprotech) and recombinant human Flt3-L (Peprotech). Subsequently, 
LSK cells were transduced by adding the virus solution to each well aiming at 5 x 106 IU/ml. In 
addition 4 µg/ml polybrene (Sigma-Aldrich) was added to each well in order to enhance transduction 
and the cells were incubated at 37°C and 5% CO2. In the morning of day 2 the culture medium was 
changed by replacing about half the volume of polybrene-containing medium, which is toxic to the 
cells, with fresh cytokine-supplemented media. In the afternoon of day 3, approximately 36 –
 48 hours post transduction the cells were harvested. 
5.7 In vitro assays 
5.7.1 In vitro proliferation of HSCs 
For the analysis of the HSC proliferation rates, FACS-isolated HSCs (5.5.2) were resuspended in 
StemSpan SFEM (Stem Cell Technologies) medium supplemented with 1% Pen/Strep (Sigma-
Aldrich), 2% L-glutamine (Gibco) and 100 ng/ml SCF (Peprotech) and TPO (Peprotech) and 
counted using Greiner Terasaki plates (Sigma-Aldrich). The cell suspension was set up in triplicates 
with 100 cells per 96-well and 100 µl medium and the cells were cultured for 7 days at 37°C. 
To determine the proliferation rates of the cells in culture over 7 days, the input number of cultured 
cells was compared to the output cell number using a bead-based method that allows counting of low 
cell numbers. Therefore, a known volume of cell suspension was analyzed along with a known 
concentration of beads using flow cytometry (5.5.1). By relating the number of cells counted to the 
total number of beads analyzed, the number of cells/µl could be determined for each sample.  
5.7.2 In vitro cell fate tracking of LT-HSCs 
For the in vitro cell fate tracking experiments, FACS-isolated LT-HSCs (5.5.2) were resuspended in 
StemSpan SFEM (Stem Cell Technologies) containing 100 ng/ml SCF (Peprotech) and TPO 
(Peprotech) and seeded in 24-well plates (Corning) equipped with silicon culture inserts (IBIDI). 
Plates were gas-tight sealed with adhesive tape (Baiersdorf) after 5% CO2 saturation by pre-
incubation in a standard cell culture incubator for 2 hours. Time-lapse microscopy was performed 
using a CellObserver (Zeiss) at 37°C. Phase contrast images were acquired every 2-3 min using a 10x 
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phase contrast objective (Zeiss) and an AxioCamHRm camera (at 1388x1040 pixel resolution) with a 
self-written VBA module remote controlling Zeiss AxioVision 4.8 software. Movies were assembled 
using QuickTime 7.1.6 software. Cell tracking was performed using a self-written computer program 
(TTT) (Rieger, 2009). Individual cells were observed and tracked manually until the fate of all 
progeny in the third generation was determined. 
5.8 Molecular cell biology methods 
5.8.1 DNA and RNA isolation 
DNA and RNA were extracted and purified as specified below and the concentration and purity was 
assessed using the NanoDrop spectrophotometer (Peqlab Biotechnologie). To assess the purity of 
DNA and RNA, the ratio of absorbance at 260 nm and 280 nm was used. A ratio of 1.8 is generally 
accepted for pure DNA and a ratio of 2.0 for pure RNA. Lower ratios in either case may indicate 
contaminations. 
5.8.1.1 DNA isolation from primary cells 
DNA from snap frozen mouse peripheral blood or bone marrow cells (5.2.4.1) was isolated using the 
DNeasy blood & tissue kit (Qiagen) according to the manufacturer’s guidelines. 
5.8.1.2 DNA isolation from mouse tail biopsies 
DNA from mouse tail biopsies (5.1.2.4) was isolated by digestion of the tail tissue in 500 µl 50 nM 
NaOH (Sigma-Aldrich) at 95°C for 1 hour. Afterwards, 100 µl 1M Tris (Sigma-Aldrich) was added 
and DNA samples were stored at 4°C. 
5.8.1.3 DNA isolation from bacterial cultures 
DNA from bacterial cultures (5.11.9) was isolated using the mini or maxi plasmid purification kit 
(Qiagen) according to the manufacturer’s guidelines. 
5.8.1.4 DNA isolation from agarose gels 
To isolate DNA from agarose gels, which were run using gel electrophoresis (5.10), the respective gel 
band was cut using a scalpel (Feather Safety Razor) and extracted and purified using the QIAquick 
gel extraction kit (Qiagen) according to the manufacturer’s guidelines. 
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5.8.1.5 RNA isolation from primary cells 
The extraction and purification of total RNA from freshly isolated (5.2.2) or frozen bone marrow 
samples (5.2.4.1) was performed using the Arcturus PicoPure RNA Isolation Kit (Applied 
Biosystems) combined with RNase-Free DNase (Quiagen) treatment according to the manufacturer's 
protocol. Samples were stored at -80°C for further use. 
5.8.2 PCR 
PCR was used to amplify specific fragments of DNA to determine the genotype of FA knockout 
mice (5.1.1) or for molecular cloning purposes (5.11) as well as for the analysis of vector integrations 
in murine blood and bone marrow cells (5.9). For the reaction, the template DNA, a product-
specific oligonucleotide pair, dNTPs (Qiagen), polymerase buffer and the polymerase were mixed 
and placed into a standard thermal cycler to denature, anneal primers to and elongate the respective 
DNA fragments using the indicated PCR conditions as described (5.8.2.1 and 5.11.1). The PCR 
products were analyzed on agarose gels using gel electrophoresis (5.10) or purified from the gels 
(5.8.1.4) for further use. 
5.8.2.1 Genotyping PCRs of FA knockout mice 
In order to determine the genotype of the respective FA knockout mice, genotyping PCRs were 
performed on genomic DNA isolated from tail biopsies (5.8.1.2) using specific primers (Table 8). 
PCR reactions were set up in a final volume of 20 μl using the polymerases Apex taq (Sigma-Aldrich) 
for the amplification of Fanca-/- and Fancc-/- specific products and Red taq (Sigma-Aldrich) for Fancg-/- 
according to the manufacturer’s guidelines. Genotyping of Fancg-/- animals involved two separate 
PCRs, one for the knockout and one for the WT gene product. All PCRs were performed at an 
initial denaturation of 95°C for 5 min and 30 cycles of 95°C for 45 sec, 55°C for 40 sec, 72°C for 
40 sec and a final extension at 72°C for 7 min in a standard thermal cycler. Amplified PCR products 
were analyzed by agarose gel electrophoresis (5.10). 
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Table 8: Oligonucleotides for genotyping of FA knockout mouse lines (5’ to 3’) 
primer sequence (5'-3') Amplicon 
Fanca-I AGCCGATGTTCCAGACGCTATGC 
KO = 320bp 









KO = 227bp 
Fancg-KO_rev TCGTGCACGCGGATTTCGGCTCCAACAATG 
Fancg-WT_fwd CTTGTAGAGTGAGGAGGAGTTCCCTAAGCC 
WT = 400bp 
Fancg-WT_rev GGCGACAATGTCCAGCCAGGTCATTCCAGC 
5.9 Retroviral integration site analysis 
5.9.1 LM-PCR 
LM-PCR was used to assess the clonality of SF91-transduced murine peripheral blood and bone 
marrow cells and was performed essentially as described (Schmidt et al., 2001). Figure 38 depicts a 
schematic outline of the procedure. 
200 ng of genomic DNA isolated from murine peripheral blood and bone marrow cell pellets 
(5.8.1.1) were digested in two separate restriction digests with 4 U of restriction enzymes Tsp509I 
(New England Biolabs) or MseI (New England Biolabs) for 2 hours at 37°C and purified by standard 
ethanol precipitation. For primer extension the restriction-digested DNA was added to the reaction 
mixture containing 2U of native Pfu polymerase (Stratagene), 10X native Pfu reaction buffer 
(Strategene), 200 mM dNTPs (Qiagen) and 0.25 pmol of biotinylated retroviral primer LTR I 
(Table 9) and the reaction was run at 95°C for 5 min, 64°C for 30 min and 72°C for 15 min in a 
standard PCR machine. The extension product was diluted in 450 ml H2O and concentrated in a 
Microcon30 centrifugal filter device (Millipore) according to the manufacturer’s guidelines. The 
concentrated sample was mixed with 200 µg of streptavidin-coated magnetic beads, which were 
prepared according to the manufacturer’s instructions of the Dynabeads kilobase binder kit (Dynal) 
and incubated shaking at room temperature overnight. The captured DNA was retrieved using a 
magnetic particle concentrator, washed with H2O, resuspended in 100 µl H2O and ligated to the 
oligo linker cassette, which was generated by annealing of the denatured OC1 and OC2 (Table 9) as 
described (5.11.4). The ligation was performed in the presence of 2U T4 DNA ligase using the fast-
link ligation kit (Cambio) for 15 min at room temperature. The sample was washed with H2O and 
denatured in O.1M NaOH for 10 min shaking at room temperature to recover the ligation product 
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and get rid of the biotinylation. The DNA was stored at -20°C or immediately processed in two 
exponential PCRs. In the first exponential PCR, 2 µl of the ligation product was amplified in a total 
volume of 50 µl using the Taq PCR kit (Qiagen) and 25 pmol of the retroviral primer LTRII and the 
linker-specific primer OCI (Table 9) at an initial denaturation of 95°C for 5 min and 30 cycles of 
95°C for 1 min, 58°C for 45 sec, 72°C for 90 sec and a final extension at 72°C for 10 min. A second 
exponential PCR was performed to amplify 1 µl of the amplified product from the first PCR using 
25 pmol of LTRIII and OCII nested primers under the reaction and cycling conditions described 
above. The PCR products were isolated from a 2% agarose gels (5.8.1.4) after electrophoresis (5.10) 
and sequenced (5.11.7) using the LTRIII and OCII primers (Table 9). 
 
Figure 38: Schematic outline of LM-PCR to amplify SF91 vector flanking sequences in genomic DNA 
isolated from murine peripheral blood and bone marrow cells. After restriction digest with MseI or 
Tsp509I, primer extension is performed with biotinylated LTR-specific primers (B). The fragments are 
immobilized on paramagnetic beads that can be captured with a magnet (solid phase) and a oligonucleotide 
linker cassette (OC) is ligated to the unknown end of the fragments. Denaturation recovers the free 
nonbiotinylated DNA strand, which is exponentially amplified using LTR-specific primers (LTR-II and LTR-
III) and oligo cassette primers (OC-I and OC-II) for the two exponential PCRs. (Based on Schmidt, 2001) 
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Table 9: Retroviral LTR oligo sequences and oligo cassette (5’ to 3’) 
primer name sequence (5'-3') 








nrLAM-PCR to identify SF91 vector flanking genomic sequences in genomic DNA isolated from 
murine bone marrow cell pellets (5.8.1.1) was conducted in collaboration with the group of Manfred 
Schmidt at the German Cancer Research Center as previously described (Paruzynski et al., 2010). 
Figure 39 depicts a schematic outline of the procedure. 
Briefly, 1000 ng of genomic DNA were used to amplify the vector flanking sequences by two 50-
cycles linear PCR amplification steps with a biotinylated primer LTR SFFV (Table 10) hybridizing 
to the 5-prime region of the LTRs of the vector. Subsequent steps involved magnetic capture of the 
biotinylated PCR-products and ligation of the single stranded linker cassette (LC). 2 µl of the eluate 
was used as template in an exponential PCR using a biotinylated vector- (LTRII SFFV) and adaptor-
specific primer (LCI) (Table 10). Magnetic capture of the biotinylated PCR-products was performed 
and 1/5 of the eluate was used for a re-amplification by a second exponential PCR step with nested 
vector- and adaptor-specific primers. The PCR products were prepared for 454 pyrosequencing 
(Roche) as previously described (Paruzynski et al., 2010). An additional PCR with special fusion-
primers carrying 454 sequencing adaptors was performed for both nrLAM-PCR products, which 
were pooled afterwards for the individual samples. DNA barcoding was used to allow parallel 
sequencing of multiple samples in a single sequencing run and the obtained data was analyzed using 
the semi-automated bioinformatical data mining pipeline as described (Arens et al., 2012). Sequences 
were trimmed by removing vector- and linker cassette-specific parts and aligned to the mouse 
genome using UCSC BLAT (mm10), while nearby genes and other integrating features were 
annotated as previously described (Cartier et al., 2009; Paruzynski et al., 2010). 
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Figure 39: Schematic outline of nrLAM-PCR to amplify SF91 vector flanking sequences in genomic 
DNA isolated from murine bone marrow cells. After linear amplification of the vector-genome junctions 
with biotinylated primers (B), the fragments are immobilized on paramagnetic beads that can be captured with 
a magnet (solid phase) and a single-stranded linker cassette (LC) is ligated to the unknown end of the 
fragments. The fragments are exponentially amplified using LTR primers (LTR-II and LTR-III) and linker 
cassette primers (LC-I and LC-II) for the two exponential PCRs. (Based on (Gabriel et al., 2009) 
Table 10: Retroviral LTR oligo sequences and linker cassette (5’ to 3’) 
primer name sequence (5'-3') 
LTR (bio) GTTTGGCCCAACGTTAGCTATT 
LTRII (bio)  GCCCTTGATCTGAACTTCTC 
LTRIII  TTCCATGCCTTGCAAAATGGC 
LC P-CCTAACTGCTGTGCCACTGAATTCAGATCTCCCGGGTddC 
LCI  GACCCGGGAGATCTGAATTC 
LCII  GATCTGAATTCAGTGGCACAG 
5.10 Agarose gel electrophoresis 
PCR products were analyzed for their molecular weights on agarose gels by separation of the DNA 
fragments in an electric field. The gels were composed of 1 - 2% agarose (Roth) diluted in 1X TAE 
buffer (AppliChem) and contained ethidiumbromide (Roth). The PCR products were mixed with 
loading buffer containing bromphenol blue and separated at 130 V in a chamber containing TAE 
buffer. DNA fragments were visualized using an UV transilluminator and compared to a DNA 
ladder control (Invitrogen) with a band pattern of known size. 
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5.11 Molecular cloning procedures 
Molecular cloning includes all the procedures used to produce recombinant DNA molecules and 
involves reactions comprising of the DNA fragment of interest as well as of a vector/plasmid 
backbone that allows replication in bacteria. In detail, the gene of interest was copied using PCR 
(5.11.1), excised out of the source DNA using restriction digest (5.11.3) or assembled from 
individual oligonucleotides (5.11.4). This so-called insert was ligated (5.11.6) into the linearized 
form of the plasmid vector and transformed into competent bacteria (5.11.8), which were grown in 
mini and maxi cultures (5.11.9) in order to amplify the cloned DNA. The amplified DNA was 
isolated from bacterial cultures (5.8.1.3) for further use. Molecular cloning requires several 
intermediate steps of DNA analysis on agarose gels (5.10), gel purification of the desired DNA 
fragment (5.8.1.4) as well as sequencing (5.11.7). 
5.11.1 Cloning PCRs 
PCR (5.8.2) was used to amplify a specific gene out of plasmid DNA isolated from bacterial cultures 
(5.8.1.3) adding specific restriction sites to the 3’ and 5’ ends of the DNA fragments compatible to 
the restriction sites in the target vector. Therefor, 25 pmol of each specific primer pair (Table 11) 
that was designed complementary to the respective genes was used in the reaction mix, which was set 
up in a final volume of 100 µl using 0.2 mM dNTPs, 1X reaction buffer and 1U taq polymerase of 
the Taq PCR core kit (Qiagen). All PCRs were performed at an initial denaturation of 94°C for 
5 min and 25 cycles of 94°C for 1 min, 60°C for 1 min, 70°C for 1 min in a standard thermal cycler. 
Amplified PCR products were analyzed by agarose gel electrophoresis (5.10), gel-purified (5.8.1.4) 
and TA cloned (5.11.2). 
Table 11: Oligonucleotides for amplification of the EFS promoter 
primer name primer sequence (5'-3') 
EFS + NheI fwd AAGCTAGCATCGATTGGCTCCGGTG 
EFS + BamHI rev GGATCCCGCGTCACGACAC 
5.11.2 TOPO TA cloning 
TOPO TA cloning was used to quickly and efficiently clone the gel-purified (5.8.1.4) PCR-
amplified (5.11.1) products into the PCR2.1-TOPO backbone vector using the TOPO TA 
subcloning kit (Life Technologies). The reaction was set up according to the manufacturer’s 
guidelines with 3 µl of the PCR product, 1 µl of the TOPO vector, 1 µl salt solution and 1 µl H2O. 
All components were mixed and incubated for 30 min at room temperature. Subsequently, 5 µl of 
the cloning reaction mix was transformed into competent E.coli bacteria as described (5.11.8) and 
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plated on pre-warmed selective plates containing 0.8 mg X-Gal and 0.8 mg IPTG required for 
blue/white screening of bacterial colonies. In this respect, white colonies contained plasmids with 
successful insertion of the PCR-amplified product and were picked for inoculation of bacterial mini 
cultures (5.11.9). The amplified DNA was isolated from bacterial cultures (5.8.1.3) and sent for 
sequencing analysis (5.11.7) in order to be able to decide for a perfect clone from which the desired 
DNA fragment could be excised (5.11.3). 
5.11.3 Restriction digest 
Restriction digests were performed to excise the genes of interest from the source DNA and linearize 
the self-replicating DNA plasmids prior to ligation (5.11.6) as well as for the analysis of newly ligated 
DNA fragments. The enzymatic digestion of the DNA fragments was performed using specific 
restriction endonucleases (New England Biolabs) that flank the DNA sequence and are present at the 
site of insertion. To prepare vector and insert for ligation, the digest was set up with 1 µg of DNA in 
a total volume of 100 µl. For analytical purposes 10 – 20 ng of DNA were digested in a total volume 
of 20 µl. In addition to the DNA, the mix containing the desired restriction enzymes (New England 
Biolabs) and the respective buffer (diluted to 1x) was set up according to the manufacturer’s 
guidelines. Digestion was carried out overnight or for at least 1h for analytical purposes at the 
enzyme-specific reaction temperature in a heating block. Agarose gel-electrophoresis was used to 
analyze the products of the restriction digest (5.11.3) and desired products were isolated by gel 
purification (5.8.1.4). 
5.11.4 Assembly of oligonucleotides 
To assemble two oligonucleotides (Table 12), an equimolar mixture of both was denatured in the 
presence of MgCl2 and Tris HCl for 5 min in a hot block at 95°C followed by a slow cool-down 
phase to room temperature and subsequent concentration using the Microcon30 centrifugal filter 
device (Millipore) according to the manufacturer’s guidelines. 
Table 12: Oligonucleotides for manufacture of the multiple cloning site (MCS) 
name sequence (5'-3') 
MCS 1 GATCCTCGAGGTTTAAACGCGATCGCTCTAGAG 
MCS 2 AATTCTCTAGAGCGATCGCGTTTAAACCTCGAG 
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5.11.5 Dephosphorylation of linearized vector DNA 
To prevent self-ligation of the linearized vector in the ligation reaction (5.11.6), the vector DNA was 
de-phosphorylated using calf-intestinal alkaline phosphatase (Roche) treatment at 37°C for 30 min 
directly after the restriction digest of the vector DNA (5.11.3). To inactivate the phosphatase, the 
DNA was load straight onto an agarose gel and gel purified (5.8.1.4). 
5.11.6 Ligation 
To join the phosphodiester bonds of two DNA fragments with specific complementary end 
sequences as generated by restriction digest (5.11.3), a ligation reaction using T4 DNA ligase 
(Roche) was performed. Therefore, DNA insert and vector were mixed in an approximate 3:1 ratio 
and the 10X ligation buffer (Roche) was diluted to 1X with H2O. The reaction was incubated in a 
PCR thermal cycler, which provides stable temperatures at 16°C for 16 hours. To amplify the 
ligation product, it was transformed into competent bacteria (5.11.8). 
5.11.7 Sequencing of DNA fragments 
Newly PCR-cloned DNA fragments (5.11.1) subcloned into the TOPO-TA vector (5.11.2) as well 
as LM-PCR products (5.9.1) were analyzed by sanger sequencing to confirm the correctness of the 
sequence and exclude errors, which may have been mistakenly introduced by the polymerase. For this 
purpose, 20 µl of DNA at 100 ng/µl were sent to GATC Biotech in Konstanz, who performed the 
sequencing reactions. 
5.11.8 Transformation of competent E.coli bacteria 
To amplify DNA plasmids, chemically competent E.coli bacteria, either One Shot TOP10 (Life 
Technologies) or Stbl3 (Life Technologies), which were specifically used for lentiviral vector 
backbones, were transformed by heat-shock. Therefore, competent bacteria were defrosted on ice for 
approximately 3 min, mixed with a small volume of DNA and incubated for 30 – 40 min on ice. 
The heat-shock was performed in a water bath at 42°C for 45 sec and the bacteria were put on ice for 
2 min immediately afterwards. After adding 200 µl of S.O.C medium (Life Technologies), the 
bacteria were incubated shaking for 1 hour at 37°C and subsequently spread on pre-warmed LB-agar 
(Merck) plates to obtain bacterial colonies at 37°C overnight. Due to the antibiotic resistance of the 
plasmid, the respective antibiotic in the LB agar plate allows for the selection of plasmid-containing 
bacteria whereas non-transformed bacteria won’t grow. 
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5.11.9 Bacterial mini and maxi cultures 
Bacterial mini cultures were obtained by inoculation of 2 ml LB medium (Merck) with a single 
colony picked from the LB agar plate that was obtained after bacterial transformation (5.11.8). The 
bacterial culture was grown in the presence of the respective antibiotic shaking at 37°C for a 
maximum of 16 hours. To further expand the bacteria, the mini culture was transferred to an 
Erlenmeyer containing 200 ml of LB medium (Merck) and the respective antibiotic and grown 
overnight for a maximum of 16 hours at 37°C. 
5.12 mRNA expression analysis 
5.12.1 Quantitative real-time PCR 
For quantitative real-time PCR, RNA extracted and purified from frozen murine bone marrow cell 
pellets (5.8.1.5) was reverse transcribed into cDNA according to the manufacturer's protocol of the 
SuperScript VILO cDNA Synthesis Kit (Life Technologies). cDNA was diluted in RNase-free water 
and stored at -20°C or immediately used to set up the quantitative PCR reactions.  
PCR reactions were set up with 2.5 ng of cDNA in 384-well plates using primers (Table 13) at 
concentrations of 0.5 µM. qRT-PCR was performed and analyzed on the ViiA7 Real-Time PCR 
System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) and 
amplification conditions of an initial denaturation step of 95°C for 10 min and 40 cycles of 15 sec at 
95°C and 60 sec at 60°C. Expression values for each target gene were normalized against both Oaz1 
and Sdha and the relative gene expression was analyzed applying relative quantification methods. 
5.12.2 Gene expression profiling (MicroArray) 
For gene expression profiling, frozen RNA samples (5.8.1.5) were submitted to the DKFZ Genomics 
and Proteomics Service Unit and their personnel further processed the samples. Quality control of 
the RNA was performed using an Agilent Bioanalyzer 2100 in order to exclude samples with a RIN 
score below 7 from the analysis. Sample amplification was performed using the Ovation PicoSL 
WTA system and labeled with the BiotinIL Module from NuGEN. For expression analysis the 
samples were hybridized to the Illumina Mouse Sentrix-6_v2_r3 BeadChip Array. 
The gene expression raw data was normalized by the core facility personnel and further analyzed 
using Microsoft OfficeTM Excel. The deregulated genes were listed according to their fold-changes 
and genes with a fold-change above a certain threshold were analyzed using the integrated software 
suite MetaCore (Thomson Reuters) to assess gene ontology. 
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Table 13: qRT-PCR primer 

























Gm8817 fwd AAGGCGGACAGGAACATCAG 










Evi1 variant I 
fwd CTTTGAATCCAAGGCAGAGC 
rev GACAGCATGTGCTTCTCCAA 
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